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ABSTRACT 
Detailed within this thesis are the production of diasteromerically enriched α-aryl 
carbonyl compounds prepared by a new and mild method based on the Truce-Smiles 
rearrangement; the synthesis of 1,3-dicarbonyl compounds utilising a Baker-
Venkataraman rearrangement; and the synthesis of salicylic acid derivatives and amides 
by a novel Baker-Venkataraman-retro-Claisen cascade. In addition, the in vitro 
screening of the cyclooxygenase inhibitory activity of some of the diarylethers of the 
acetamide based substrates prepared, has been undertaken. 
 
O
Aux*
O
OH
Aux*
O
Aux*= known chiral auxiliaries
R= aryl (asymmetric Truce-Smiles rearrangement)
R= acyl (asymmetric Baker-Venkataraman rearrangement)
R
R
base
 
A generic scheme highlighting the transformation pursued in this thesis towards 
constructing new chiral centres. 
 
The introduction summarises the significance and use of both the Truce-Smiles and 
Baker-Venkataraman rearrangement reactions in the synthesis of α-aryl and α-acyl 
carbonyl compounds, respectively. Additionally, a detailed review on some currently 
available chiral auxiliaries along with their applications is also mentioned. The 
discussion begins with the application of phase transfer catalysts, based on cinchona 
alkaloids, for the induction of chirality in ketone-based precursors. Further discussion 
continues with the synthesis of amide-based substrates from lactones and amines, and 
the use of C2-symmetric chiral auxiliaries to induce chirality during aryl migration.  
Using such an approach, a new and mild method for the production of diasteromerically 
enriched α-aryl carbonyl compounds has been achieved. It was found that propanamide-
based substrates did not rearrange whilst acetamide-based substrates did, favouring a 
five-membered transition state during aryl migration. In these initial efforts, only 
modest diastereoselectivies (dr= max. 1.7:1) were observed. 
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The amide-based substrates did not undergo the Baker-Venkataraman rearrangement, 
but instead suffered from facile hydrolysis. Thereafter, the section focuses on the 
investigation of a serendipitously discovered, novel Baker-Venkataraman-retro-Claisen 
cascade and its subsequent applications in the synthesis of important amides, in which, 
unusually, the ketone appears to act as an alkyl donor and the carbamoyl moiety as an 
alkyl acceptor.  
A separate chapter is given to the cyclooxygenase activity of some of the diarylethers 
prepared, wherein the diarylethers of certain acetamides were screened for their 
activities against cyclooxygenase enzymes, COX I and COX II. The preliminary results 
showed that the best compound was a pyrrolidyl-acetamide based precursor which 
showed good to modest inhibitory activity against both COX  I and COX II (25-37% 
and 44-70%, respectively) in the in vitro screening assay. 
The thesis concludes with the experimental section encompassing the experimental 
details, spectroscopic and analytical analysis of all the compounds prepared and 
described. 
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CHAPTER ONE - INTRODUCTION 
1.1 Rearrangements 
Rearrangement reactions are powerful tools in organic synthesis because simple, readily 
obtained precursors frequently produce molecules of much higher complexity.
1
 To be 
more specific, the Truce-Smiles rearrangement and Baker-Venkataraman rearrangement 
are reactions which have perceived application in organic chemistry, especially for the 
selective formation of carbon–carbon (C–C) bonds. The Truce–Smiles rearrangement is 
well established as part of the synthetic chemists toolbox for the synthesis of substituted 
arylsulfinic acids,
2
 while the Baker–Venkataraman rearrangement is often used to 
synthesize chromones and flavones.
3
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
O
R1
OH R1
R1= aryl (Truce-Smiles rearrangement)
R1= acyl (Baker-Venkataraman rearrangement)
O O
 
Scheme 1. An example of the Truce-Smiles and Baker-Venkataraman rearrangements. 
Both rearrangement reactions (Scheme 1) proceed via enolate formation followed by 
group transfer. A base abstracts the hydrogen atom alpha to the ketone, forming an 
enolate. Then, the enolate attacks the electrophilic carbon to form a cyclic intermediate. 
The cyclic intermediate is opened up to form a more stable phenolate, which is 
protonated during acidic workup to give the desired product. 
 
1.1.1 The Smiles and Truce-Smiles Rearrangements 
Smiles rearrangements of activated aromatic substrates are representative intramolecular 
SNAr reactions.
4–8
 The reaction begins by virtue of nucleophilic attack of the heteroatom 
on the ipso carbon (atom attached to the side chain connecting X and Y) (Scheme 2), 
which may be saturated or part of an aromatic system, but compelled to contain an atom 
with a lone pair of electrons (a nucleophile). X and Y represent diverse combinations of 
heteroatoms (O, S, and NR). In most cases the presence of a strong base is required as 
the displacement is by Y
-
 rather than by YH, but, when YH is an amino group (NH2 or 
NHR), a base may or may not be necessary for reaction to start. 
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X
Y
X
Y
XH
EWG EWG
EWG
YH
 
Scheme 2. The Smiles rearrangement. 
Substituents on the ring will cause both electronic and steric effects, and the influence 
of these effects on the rearrangement will vary according to which ring they are placed 
on and also the position these groups occupy.
6
 
 
X
YH
3
5
2 4
A B
X
YH
3
5
2
4
A B
6 6
 
Figure 1. Positions of importance in the Smiles rearrangement. 
In the common depiction, Figure 1, an electron-withdrawing substituent in the 2- or 4-
position of ring B will enhance the reaction whereas an electron donating group will 
hamper the nucleophilic attack of Y
-
 at the 1-position. For this reason, many 
rearrangements have been seen in components which have a 2- or 4-nitro substituent in 
ring B.
9
 
Electron withdrawing groups in the 4- and 6-position of ring B will accelerate the 
acceptance of a negative charge by X and so assist the displacement reaction. Also, by 
the inductive effects of these groups, proton removal from YH may be facilitated and 
this will also help rearrangement. In the same vein, electron withdrawing groups in the 
3- and 5-position of ring A will facilitate proton removal from YH and may also aid in 
electron withdrawal from the C-X bond. However, the displacement reaction will not 
work when EWG groups are present in the 3- or 5-position of ring A, because Y
-
 
becomes too weakly nucleophilic to be able to attack ring B. For example, the 
rearrangement of compound 1 (Scheme 3)  does not take place even on boiling with 
aqueous sodium hydroxide, while compound 3 rearranges easily to compound 4 at room 
temperature.
10
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O O
O
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N.R
r.t.
 
Scheme 3. Illustrative example showing EWG effect on the Smiles rearrangement. 
During the rearrangement the planes of the two rings are at right angles to one another, 
therefore, steric effects can also come to play during the Smiles rearrangement of an 
aromatic molecule, Figure 1, where YH is, say, OH or NH2. This can be seen in the 
reaction of sulfones, where a substituent in the 6-position of ring A speeds up the 
rearrangement in comparison with similar sulfones having a hydrogen atom in that 
position. This is  due to the influences on the rearrangement first by the relative 
orientations that the two rings may adopt, and secondly by the control which the two 
oxygen atoms of the sulfone group can exercise over the positions of the rings, Scheme 
4.
11
 
O2
S
R
H2C
5
O2
S
CH2
R
6
Li
+
Li
+
 
Scheme 4. The effect of conformation on the Smiles rearrangement. 
In one particular modification of the Smiles rearrangement—the Truce–Smiles 
rearrangement—as the incoming nucleophile is a stronger carbanion the arene does not 
require the additional activation group. In 1958, Truce exemplified this reaction by the 
conversion of an aryl sulfone 7 into sulfinic acid 10 by action of the strong 
organolithium base n-butyllithium, Scheme 5.
12
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1.1.1.1 S to C Migration 
Truce developed this variant within diaryl sulfone compounds (such as 7), and proved it 
to be a reliable method for the synthesis of a variety of substituted aromatic sulfinic 
acids 10, Scheme 5. 
12
 
SO2
n-BuLi
Et2O, reflux
SO2
LiH2C
SO2Li
H+/H2O
SO2H
7 8 9 10, 98%  
Scheme 5. Truce's attempt towards the synthesis of a substituted aromatic sulfinic acid. 
In this example the base (n-BuLi) deprotonates a methyl group resulting in the 
formation of anion 8. This reactive nucleophile in turn attacks the ipso-carbon atom 
which is electron deficient (that bearing the sulfur atom), after which, substitution of the 
sulfur moiety (RSO2
-
) provides in the rearranged product 10, after acid workup.
13
 
Different circumstances, which have an effect on the orientation and reactivity in the 
Truce–Smiles rearrangement, have been studied. Within a variety of metalated sulfones 
the rate of the rearrangement has been measured and it was demonstrated to be first 
order with respect to the metalated sulfone when the rate of initial metalation was very 
high.
14
 Sulfones with a 6-methyl group substituent on the ring containing the lithiated 
alkyl group were found to react nearly one order of magnitude more rapidly than those 
with no 6-position substituent. This effect can be illustrated by consideration that the 
metalated sulfone 5 exists in a conformational equilibrium whereby conformer  5 reacts 
to give the Truce–Smiles product (Scheme 4). Consequently, factors which push the 
equilibrium toward this favourable conformer should facilitate the rearrangement. Based 
on this, when R= H, conformer 6 becomes sterically more favoured and this will slow 
down the reaction.
9,15,16
 
From the late fifties to the seventies, Truce reported the rearrangement of various O-
methyl-diaryl sulfones into arylsulfinic acids in high yield.
12,15,17,18
 It was demonstrated 
that only compounds with ortho-methyl groups rearrange, when treated with potassium 
tert-butoxide in DMSO.
18
 
Additionally, the naphthalene nucleus has been subjected to the rearrangement, Scheme 
6, whereby compound 11 and the related compound 13 were deprotonated resulting in 
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phenyl and naphthalene migration from sulfur to carbon to give benzyl naphthalene 
sulfinic acid 12 in 89% yield and product 14 in 84% yield, respectively.
13
 Conversely, 
in the second case a different reaction takes place, the migrating group itself is 
naphthalene and this begins with an intramolecular nucleophilic addition across the 1,2-
bond of naphthalene then followed by β-elimination to generate 14, Scheme 6.18  
SO2
i) t-BuOK
ii) H+
13 14, 84%
SO2H
-H2C
SO2
SO2
H
SO2
H
H
-elim.
i) n-BuLi
ii) H+
SO2H
11 12, 89%
SO2
 
Scheme 6. The naphthalene nucleus subjected to the Truce-Smiles rearrangement. 
Furthermore, rearrangements within heteroaromatic systems have also been 
demonstrated by Truce and his co-workers. It has been shown that substituted thienyl 
sulfones 15 (when R= Me) undergo the Truce–Smiles rearrangement via an addition–
elimination sequence to generate sulfinic acids 16, Scheme 7. Herein, the reaction does 
not begin through formation of a spiro-cyclic intermediate, as usual, but proceeds via 
addition of the anion to the position C-3 at the thiophene ring followed by β-elimination 
from the cyclised intermediate.
17
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15
SO2H
S
O2
S S
2
5
i) n-BuLi or KOt-Bu, DMSO
ii) H+
2
5
16
3
B:-
SO2
-
S
2
5
3
Li
O2
S
S
SO2
S
 
Scheme 7. Thienyl migration within the Truce-Smiles rearrangement. 
Unlike the previously mentioned naphthyl and substituted phenyl groups, the thienyl 
unit migrates with a change in orientation regardless of the base/solvent system used. In 
1978, Truce et al. showed the first example of the rearrangement (Scheme 7) 
proceeding with a change in aryl orientation in aprotic media. In this case, when the 
thiophene ring is unsubstituted two equivalents of base are needed because with one 
equivalent of base, the ring is deprotonated at C-5 and the resulting mono-metalated 
product decomposes.
17
 
Prior to 1979, the Truce-Smiles rearrangement had only been observed in diaryl sulfone 
substrates,  then after, when Truce investigated several reactions of metalated o-tolyl 
tert-butyl sulfone, it was found that refluxing the lithiated species 18 in THF for several 
hours led to the formation of o-neopentylbenzenesulfinic acid 19 in 75–80% yield, 
Scheme 8. This case was reported as the first example in which an alkyl group migrates 
rather than aryl group.
19
  
17
O2
S n-BuLi
THF, -78 C
18
O2
S
CH2
-
Li+
i) reflux
ii) H+
19
SO2H
 
Scheme 8. Formation of o-neopentylbenzenesulfinic acid 19. 
Truce et al. rationalised this novel rearrangement in terms of an electron-transfer 
radical-anion pathway, Scheme 9, contrary to the mechanism described in Scheme 5. 
They believed that the transfer of an electron from the benzylic carbanion 20, 
accelerated by the close proximity of the -SO- group, forms a stable benzylic radical 
and the sulfonyl radical anion 21. After which homolytic cleavage of the sulfur tert-
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butyl bond would generate the sulfinate anion and tert-butyl radical 22. Finally the 
desired product 23 will come from immediate radical combination, within the solvent 
cage.
17
 
20
O2
S
CH2
-
21
O2
.-
S
.
22
SO2
-
.
19
SO2
-
.
 
Scheme 9. Plausible radical-based mechanism for the formation of 19. 
After eight years, the same group showed that lithiation of appropriate methylaryl alkyl 
sulfones is followed by migration of the alkyl group from sulfur to the benzylic carbon. 
Product studies, relative reactivities and cross-over experiments are consistent with a 
radical–radical anion chain process for this rearrangement, consistent with that viewed 
in Scheme 9. They have also demonstrated that, with the use of amide bases, p-methyl 
groups (such as 23 in Scheme 10) can undergo metalation then rearrangement in the 
same vein to 20.
20
 
O2S
CH2Li
O2S
LDA
THF
reflux, 4h
then H+
SO2H
23  
Scheme 10. Migration of a quaternary centre in the Truce-Smiles rearrangement. 
 
1.1.1.1.1 S to C Migration under alternative reaction conditions 
Crowther and Hauser (1968) found that using sodium amide as base the deprotonation 
products of phenyl o-tolyl sulfones underwent the Truce–Smiles rearrangement when 
the solvent (ammonia) was replaced by tetrahydrofuran and the resulting mixture was 
refluxed. This alternate reaction condition gave a good yield for benzylbenzenesulfinic 
acid 26 (~70%), Scheme 11.
21
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24
O2
S
Ph NaNH2
liq NH3
25
O2
S
CH2
-Na+
Ph i) THF, reflux
ii) H+
26
SO2H
Ph
 
Scheme 11. Alternative conditions for the Truce-Smiles rearrangement. 
Additionally, the sodium salt 25 could be trapped by various intermolecular 
electrophiles, therefore, the yields would be better than those obtained using Truce’s 
developed conditions. They found that these condensation products (e.g. 27) could also 
undergo the Truce–Smiles rearrangement, Scheme 12.21 
27
O2
S
Ph
28
SO2H
Ph
n-BuLi
Ph
Ph
BnX
25
 
Scheme 12. "A double Truce-Smiles": Phenyl migration in a Truce-Smiles product. 
 
1.1.1.2 N to C migration 
The synthesis of 1,5-methano[10]annulene addressed by Itô et al. during their studies 
towards crystallographic analysis and they discovered a distinctive Truce–Smiles 
rearrangement of N-methylanilide intermediate 29 after subjecting it to LDA, Scheme 
13. On exposure to an oxidative process (LDA, THF, O2, -70 
○
C) the rearranged product 
30 was formed in 75% yield rather than the desired oxidation product.
22
 
O
N Ph
Me
Ph
29 30, 75%
LDA, O2
-70 C
O
N
Me
Li+
Proposed geometry of
the transition-state
O
Me(H)N
31
 
Scheme 13. N to C aryl migration in an N-methylanilide. 
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It was believed that this rearrangement was the outcome of a Truce–Smiles 
rearrangement which happens through the intramolecular nucleophilic attack of a bulky 
carbanion on the ipso position of the anilide 31, followed by extrusion of the amide 
nitrogen to give the product in good yield.
22
 
 
1.1.1.3 O to C migration 
The Truce-Smiles rearrangement has also been observed with O to C migration, when it 
was unexpectedly observed by Erickson and McKennon (2000), during their work on 
the synthesis of some anti-fungal compounds. When they attempted to apply a straight-
forward protocol for the formylation of an ester enolate followed by O-methylation, 
Scheme 14, formylated products were not produced when compounds such as 32 were 
exposed to the literature conditions. Rather, products were produced in which the 
pyridine ring was attacked by the enolate.
23
 They justified the results as a Truce–Smiles 
rearrangement product and initially they stated it as an undesired transformation, but, 
also as a new method to make 3-pyridyl-2-benzofuranones 34. When a number of esters 
(for example 32) were exposed to either NaH or KH at temperatures above 0 
○
C, the 
rearrangement was induced by producing an intermediate phenoxide (ArO
-
M
+
, 33) 
which immediately cyclised to the lactone (benzofuranone) 34. In certain cases, the 
benzofuranone tautomerised resulting in the isomeric products 35 if X=H, Scheme 14.
23
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Y
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NX
Z
Y
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NX
Z
Y
OH
NaH or KH
X= H, Cl or CF3; Y= H or Cl; Z= H or CF3
32
33 34 35
 
Scheme 14. A method to make 3-pyridyl-2-benzofuranones. 
To achieve a generic rearrangement method, other activated aromatic systems were 
studied by the authors, for example treating 36 with NaH in THF at 0 
○
C offers the 
lactone 37, Scheme 15. Moreover, the transformation of 38 smoothly gave 
hydroxybenzofuran 39 too.
23
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NaH
THF, 0 C O
O
NO2
O2N
O
N
N
O
O O
OH
N
N
36 37
38 39  
Scheme 15. Ester substrates undergoing the Truce-Smiles rearrangement. 
Later, when Mitchell and Barvian (2004) attempted the synthesis of a series of diphenyl 
ethers by the SNAr reaction of activated aryl fluorides with phenols, they noticed an 
aberration with 2’-hydroxyacetophenone, Scheme 16. They analysed the unexpected 
products obtained from the reaction of 2’-hydroxyacetophenone and both 2- and 4-
fluoronitrobenzene, then they documented that this deviation is due to the involvement 
of Truce–Smiles rearrangement in their preparations.24 The story came after they treated 
three isomers of hydroxyacetophenone (2’-, 3’- and 4’-hydroxyacetophenone) 
separately with 4-fluoronitrobenzene (K2CO3, DMF, 120 
○C) and found that 2’-
hydroxyacetophenone did not give required diphenyl ethers analogous to 40 and 42 but 
instead gave product 41 (Scheme 16). The unexpected product from the reaction 
showed a phenolic signal in the 
1
H NMR and was deprived of the signal correlating to 
the methyl group of the methyl ketone; alternatively, a two proton singlet at 4.64 ppm 
was seen, which justified that the product was indeed isomeric compound 41 (C-
arylated rather than O-arylated), Schemes 16 and 17. 
The authors considered that the C-arylated product 41 was not formed directly because 
no C-arylated product was identified in the case of the isomeric acetophenones. 
Moreover, a similar reaction with 2’-methoxyacetophenone gave only unreacted starting 
materials. Consequently, there was no doubt that the product came from a Truce–Smiles 
rearrangement. Thus, this unexpected transformation provided a method for carbon–
carbon bond formation under mild conditions. 
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O2N
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Scheme 16. Synthesis of α-aryl ketones. 
OH O
+
NO2
F
K2CO3
DMF, 60 C
O O
O2N
K2CO3
DMF
120 C
O
O-
O2N
H+
OH O
NO2
41
43
44  
Scheme 17. Conversion of diarylether 43 to the C-arylated product. 
In fact, Mitchell and Barvian observed that the intermediate (diarylether 43) in the 
Truce–Smiles rearrangement could be isolated (in 21% yield) after lowering the 
reaction temperature to 60 
○
C, Scheme 17.
24
 More evidence for the rearrangement was 
obtained by subjecting the diarylether 43 to the previously used reaction conditions 
(K2CO3, DMF, 120 
○
C) and quantitative conversion to the C-arylated product 41 was 
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demonstrated. A few remarkable traits of the reaction have been analysed by the 
authors: (a) the exact conditions essential for the rearrangement to take place are 
substrate dependent, (b) this first example of a homologous enolate Truce–Smiles 
rearrangement involves a six-membered transition state, and (c) the same conditions are 
responsible for producing the diarylether intermediate 43 and forcing it to undergo the 
rearrangement to give the C-arylated product 41. Thus, this is a novel one-pot two-step 
reaction.
24
  
 
1.1.1.4 C to S migration: (an unusual Truce–Smiles type rearrangement) 
An unusual Truce–Smiles type rearrangement was discovered by Varvounis and co-
workers in 2004,
25
 while attempting the synthesis of the pyrrolo[1,2-
a][3.1.6]benzothiadiazocine ring system, Scheme 18. As an illustration, compound 45, 
when treated with hot aqueous ethanolic sodium hydroxide, gave a mixture of two 
unexpected compounds 46 and 47 in 43% and 48% yield, respectively. A conjectural 
mechanism was postulated for the synthesis of 47 where the hydroxide anion can act as 
a base and as well as nucleophile, Scheme 18; the carbanion 48 can intramolecularly 
attack the benzene ring to give the Meisenheimer type intermediate 49 that would suffer 
from ring-opening pre- or post- addition of the hydroxide anion to the acetyl group to 
offer the pyrrolyl dianion 50, after losing an acetate anion. 
In a second proposed mechanism, after addition of hydroxide to the acetyl group of 45, 
the intermediate 51 would form and in turn would lose the acetate anion giving the 
products 52 and 53. Because compound 47 has been formed, therefore, it is regarded as 
an uncommon case of a Truce–Smiles rearrangement. Generally, it is convincing that 
wherever an electron deficient arene takes part in the rearrangement the reaction would 
occur via an intermediate anionic spiro adduct in a similar fashion to that represented by 
49.
26
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51 52 53  
Reaction conditions: (a) Zn, NaOH, H2O, EtOH, reflux; (b) NaOH, H2O, EtOH, reflux. 
Scheme 18. Plausible mechanism for the unusual Truce–Smiles type rearrangement. 
Similarly, the comparable sulfoxide 54 was tested under similar conditions (NaOH, 
H2O, EtOH, reflux) and it was shown to give the product 55 in 72% yield, presumably 
as a result of a Truce–Smiles type rearrangement, Scheme 19. The sulfoxide analogue 
of carbanion 50 was formed, because the sulfoxide analogue is less stabilised in 
comparison to sulfone intermediate 50, Scheme 18.
25
 
N
NO2
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S
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Reaction conditions: Zn, NaOH, H2O, EtOH, reflux; or NaOH, H2O, EtOH, reflux. 
Scheme 19. Sulfoxide containing substrates undergoiog an unusual Truce–Smiles type 
rearrangement. 
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1.1.1.5 Fragmented Truce–Smiles rearrangement 
This variant of the Truce–Smiles rearrangement was first demonstrated by Tennant and 
co-workers (1975) to make 2-acyl-3-hydroxyquinolines from 2-(2’-nitrobenzoyl) 
derivatives of certain 1,3-diketones by base-catalysed cyclisation; products that were 
previously unreachable, Scheme 20.
27
 The postulated mechanism for this transformation 
(56 to 58) would involve the intramolecular nucleophilic attack of the enolate at the ipso 
carbon generating spirocyclic intermediate 57. In contrast to the usual species in the 
Truce–Smiles rearrangement (see 56, CO replaces SO2), 58 cannot achieve stabilisation 
by ejection of the sulfonyl leaving group. As a consequence, the carbonyl group could 
be attacked by hydroxide to undergo ring scission and subsequent reduction of the nitro 
group to nitroso, Scheme 20.
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Scheme 20. Fragmented Truce–Smiles rearrangement. 
 
1.1.1.6 The importance of the Truce-Smiles rearrangement 
The synthetic utility of the Truce–Smiles rearrangement was first recognised by 
Mitchell and Barvian in their summary where they projected that the rearrangement 
provides a method for carbon–carbon bond formation under mild conditions, and may 
also prove useful if the acetyl, or a substituted acetyl was coupled after diphenyl ether 
formation, or if alternative diaryl ether formations were used. For example, they 
suggested reversing the sense of the coupling such that an ortho-fluoroacetophenone 
was the electrophilic partner. Additionally, they considered that it would be interesting 
to contemplate whether this reaction could be used successfully for ring-expansion or 
contraction in cases where the two aryl rings were linked.
24
  
α-Arylated carbonyl compounds are commonly occurring motifs in biologically 
interesting molecules
28
 and important classes of medication such as typical 
antipsychotics
29
 and opioids,
30
 however, the synthesis of such compounds is 
synthetically challenging and are therefore of high interest to the pharmaceutical 
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industry. Therefore, in 2008 Snape extended the scope of the Truce–Smiles 
rearrangement (O to C aryl migration) and established the conditions to allow 
synthetically useful substituted α-arylated aryl ketones (7 entries have been examined, 
62) to be prepared under very mild conditions (K2CO3, DMSO, room temperature). 
Furthermore, the synthetic utility of these compounds has been demonstrated with the 
facile conversion of the Truce–Smiles rearrangement product 62 into substituted indole 
2-(1H-indol-2-yl)phenol 63 in good yield (72%), Scheme 21.
31
 
R1
R2
OH O
R3
+
R4
NO2
K2CO3
DMSO R1
R2
O O
R3
R5
F
NO2
R5
R4
Truce-Smiles
rearrangement
R1
R2
OH O
R3
R4
R5
NO2
59 60 61
62
Pd/C, H2, MeOH
HNOH
when R1-R5= H63  
Scheme 21. The synthetic utility of the Truce–Smiles rearrangement to offer substituted 
indoles. 
As the indole motif is prevalent in a large number of target molecules, there is an 
extensive demand for finding efficient large-scale synthetic routes towards these 
compounds.
32
 To find a practical, scalable, and high-yielding synthesis of target indole 
68, the approach outlined in Scheme 21
31
 has been optimised by the researches of 
Merck, Sharp and Dohme toward a novel synthesis of a 2-substituted indole using a 
Truce−Smiles rearrangement as a key step (Scheme 22).33. 
The synthetic scheme for this approach is shown in Scheme 22. An SNAr reaction to 66 
and its rearrangement to 67 proved to be both selective and high yielding under the 
published DMF/ potassium carbonate conditions. Investigations therefore focused on 
the synthesis of the phenolic ketone fragment 67 and its final hydrogenation/ring 
closure to afford >50 kg of the target indole 68.
33
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CO2Me
NO2
64 65 66
67
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Scheme 22. Multi-kilo synthesis of a 2-substituted indole using Snape's Truce−Smiles 
rearrangement as a key step. 
A wide range of substituted α-arylated ketones were synthesized in moderate to 
excellent yields via a Truce-Smiles rearrangement. The main scaffold has various 
applications in medical and biochemical fields. This process also provides a facile and 
direct method for the C–C bond formation. 
Like indole motifs, α-arylated ketones are important components of many natural 
products, synthetic intermediates, and precursors of natural analogues such as 
coumestan 69,
34
 isoflavones 70, 
35
 and  the intermediates to phenylbenzofurans 71, 
Figure 2.
36
 Therefore, many synthetic approaches have been reported to construct these 
scaffolds; however, most of the procedures use metal catalysts or Grignard reagents, 
which are not eco-friendly or are sensitive to air and moisture. As such, the Truce-
Smiles rearrangement has been investigated for the synthesis of these scaffolds.
31
   
O
O
O
69
O
O
R
70
O
R
71
 
Figure 2. Natural products: coumestan 69, isoflavones 70, and  phenylbenzofurans 71. 
Recently, through expanding the Truce-Smiles rearrangement conditions,  an efficient 
metal free C–C bond formation reaction under mild condition has been reported by 
Yanli et al.. They generated an efficient method for the synthesis of a variety of 
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functionalized and substituted α-arylated ketones (74) using readily available 2-
hydroxyacetophenone (72) and substituted benzenes or pyridines (73), Scheme 23.
37
 
Y= F, Cl, NO2; X= NO2, F, Cl; Z
1-Z3= CH, N
OH O
+ Z3
Z1
Z2
Y
X
K2CO3, DMSO, r.t.
or Cs2CO3,CH3CN, reflux
OH O
Z3
Z2Z1
Y
747372  
Scheme 23. The synthesis of heterocyclic α-arylated ketones. 
In 1996 Okuda et al. began a  research programme on the synthesis of polycyclic N-
heterocyclic compounds (for example: 5-aminocycloalkeno[1,2-d]furo[2,3-b]pyridines 
76, Scheme 24) for medicinal applications and this started by developing  a general one 
step preparation of aromatic ring-fused furo[2,3-b]pyridines 76 from aryl-1-carbonitriles 
having a 3-cyanopropoxy group adjacent to the cyano (carbonitrile) group 75.
38–41
 A 
Truce–Smiles rearrangement was the key step (75→76) by the action of potassium tert-
butoxide and followed by an intramolecular cyclisation, Scheme 24.
42
  
CN
O CN
Ar base
N
75 76
Ar
O
NH2
Ar= aromatic ring  
Scheme 24. The synthesis of polycyclic N-heterocyclic compounds. 
They further explored the reaction sequence of 2-(3-cyanopropoxy)cycloalkene-1-
carbonitriles 77, and found that it followed the same mechanism to that seen previously 
for the synthesis of 76; the general mechanism is shown in Scheme 25.
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Scheme 25. Proposed mechanism for the synthesis of compound 78. 
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Again, Okuda et al. have expanded the method to include the synthesis of 5-amino-1,2-
dihydrofuro[2,3-c]isoquinoline derivatives (eg. 79) based on the Truce–Smiles 
rearrangement, Scheme 26.
43
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Scheme 26. The synthesis of 5-amino-1,2-dihydrofuro[2,3-c]isoquinoline derivatives. 
In the same vein, the same authors developed a method for the synthesis of benzo-fused 
5-aminocycloalkeno[1,2-d]furo[2,3-b]pyridines 81, in which the 5-amino group was 
transformed to the bromo derivative 82, which was allowed to react with cyclic amines 
(such as imidazole) to give amino-substituted derivatives (eg. 83) which has showed 
bronchodilator activity, Scheme 27.
44
 
Similarly, using the same protocol, further polycyclic N-heterocyclic compounds have 
been prepared by this group for example: 5-amino-1,2-dihydro[1]benzofuro[3,2-
d]furo[2,3-b]pyridines 85b,
45
 5-substituted 1,2-dihydrofuro[3,2-f][1,7]naphthyridines 
79a (X= N) which revealed bronchodilator effects
46
 5-amino-1,2-dihydrofuro[2,3-
b]pyrido[3’,2’:4,5]thieno[3,2-d]pyridines 85a,47 and 5‐substituted 
1,2‐dihydrofuro[2,3‐c]isoquinolines 79a (X= CH) 48 both as inducers of lipoprotein 
lipase mRNA expression, Scheme 28. 
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Scheme 27. The synthesis of the bronchodilator agent 83. 
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N Y
N
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NH2
84 85a: Y= S
85b: Y= O  
Scheme 28. The synthesis of polycyclic N-heterocyclic compounds as inducers of 
lipoprotein lipase mRNA expression and as bronchodilator agents. 
Further exploitation of the Truce-Smiles rearrangement has seen the synthesis of 3,3-
disubstituted aza-oxindoles being addressed; the aza-oxindole structural motif is 
prevalent in compounds exhibiting interesting biological properties such as oral anti-
inflammatory activity, and potent neurotrophic kinase receptor type-1 (TrkA) and Janus 
kinase (JAK-3) inhibition.
49–51
 Kündig et al. found a novel, efficient, inexpensive 
strategy for the synthesis of 3,3-disubstituted aza-oxindoles 87 (13 different derivatives 
and up to 99% yield) via a NaOt-Bu-mediated Truce–Smiles rearrangement–cyclisation 
pathway, Scheme 29. 
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Scheme 29. The synthesis of 3,3-disubstituted aza-oxindoles. 
Alongside, the Truce-Smiles rearrangement was also utilised to make diarylmethanol 
motifs. The diarylmethanol framework is considered to be a privileged structure in 
important intermediates and precursors for the synthesis of pharmacologically and 
biologically active compounds such as: antihistaminic pheniramines, methyl phenidates, 
clemastine and pipradrols, 1,4-dihydropyridine derivatives (with potent and long-lasting 
hypotensive effect) and cizolirtine (a novel non-opioid analgesic).
52–59
 At the same time, 
chiral diarylmethanols are important motifs in drug discovery, and developing novel 
routes to such compounds will help with their continued exploitation in medicinal 
chemistry.
60
 Therefore, the Truce-Smiles rearrangement  has been utilised as a method 
to obtain enantiopure diarylmethanols where aryl migration from N to C in lithiated 
carbamates afforded a secondary or a tertiary alcohol (example 88), Scheme 30.
61
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Scheme 30. The synthesis of chiral diarylmethanols (invertive aryl migration). 
Although the yield of the chiral tertiary alcohol (up to 50%) and the ee (up to 77%) was 
not as good as expected in 2010, Clayden et al. applied the same methodology to the 
first enantioselective synthesis of the antihistamine agent (−)-(S,S)-clemastine 91. To 
achieve this target, an ether was formed between a proline-derived 
chloroethylpyrrolidine 89 and an enantiomerically enriched tertiary alcohol 90. The 
tertiary alcohol 90 was formed from the corresponding carbamate 92 by invertive aryl 
migration on lithiation (i.e. Truce-Smiles rearrangement) , Scheme 31. 
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Scheme 31. Retrosynthesis of clemastine 91. 
In conclusion, the Truce-Smiles rearrangement has been shown to be a powerful 
reaction to generate new C-C bonds under mild conditions, and has been useful for the 
synthesis of α-arylated ketones, indoles, polycyclic N-heteroaromatic compounds, 3,3-
disubstituted aza-oxindoles, and diarylmethanols. However, to date, no examples have 
been reported which attempt to develop an enantioselective Truce-Smiles rearrangement 
and thus make compounds containing new chiral centres in an asymmetric manner. 
 
1.1.2 The Baker-Venkataraman rearrangement 
The Baker-Venkataraman rearrangement is an extremely reliable reaction in organic 
synthesis allowing the rapid construction of ß-diketones in high yield. ß-Diketones are 
important synthetic intermediates, and they are widely used for synthesis of chromones, 
flavones, isoflavones, and coumarins. As mentioned, the Baker-Venkataraman 
rearrangement is regarded as an analogue of the Truce-Smiles rearrangement in terms of 
mechanism of the reaction, however,  the difference is the migrating group; acyl group 
and aryl group for the Baker-Venkataraman and  Truce-Smiles rearrangements 
respectively. 
 
1.1.2.1 Historical perspective and the mechanism 
In 1910, it was observed by Auwers that esters  of 2-chloro-2'-hydroxyacetophenone 91, 
reacted with potassium carbonate to form 2-substituted coumaran-3-ones 93 and it was 
suggested that the reaction probably proceeded through a 1,3-diketone 92, Scheme 32.
63
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Scheme 32. The first example of the Baker-Venakataraman rearrangement by Auwers. 
Later in 1933, Harbhajan Mahal and Krishnasami Venkataraman
64
 and independently, 
Wilson Baker,
65
 reported the isolation of 1,3-diketone 98 after the rearrangement of o-
aroyloxyacetophenone 94, Scheme 33. Since then, the reaction, now known as the 
Baker-Venkataraman rearrangement, has been shown to be of prime importance in 
flavone synthesis.
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Scheme 33. The mechanism of the Baker-Venkataraman rearrangement. 
This rearrangement reaction proceeds via enolate formation (95) followed by acyl 
transfer, Scheme 33. A base abstracts the hydrogen atom alpha to the aromatic ketone 
94, forming an enolate (95). The enolate 95 attacks the ester carbonyl to form a cyclic 
alkoxide 96. The cyclic intermediate 96 is opened up to form a more stable phenolate 
97, which is protonated during acidic work-up to give the desired product 98. 
Additionally the 1,3-diketone 98 can cyclise to flavones 99, Scheme 33. 
Baker attempted the preparation of the benzyl ether of 4-O-benzoylresacetophenone 100 
(4-O-benzoylresacetophenone was heated in benzene with benzyl chloride (1 mol.) and 
anhydrous potassium carbonate), however, the product obtained was 2,4-
dibenzoylresacetephenone (20% yield) 101. Cold concentrated sulfuric acid converted 
101 smoothly into 7-hydroxy-flavone 102, Scheme 34.
65
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Scheme 34. Baker's attempt at the synthesis of 7-hydroxy-flavone 102.  
Later was found that 4-O-benzoylresacetophenone 100, when heated with benzene or 
toluene and potassium carbonate, underwent intramolecular rearrangement, giving 2,4-
dibenzoylresacetophenone 101, Scheme 34. 
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Figure 3. Early examples studied in the Baker-Venkataraman rearrangement. 
The same author tried to declare the generality of this new rearrangement by evidencing 
a variety of examples (O-benzoyloxyacetophenone (103), resacetophenone diveratrate 
(104), gallacetophenone tribenzoate (105), cinnamoylresacetophenone (106) and 2,4- 
dibenzyloxyphenyl  benzyl ketone (107), Figure 3).  Thus, it was proved that the 
migration involves solely the ortho- and meta-aryloxy group, since it occurs neither in 
4-O-benzoylresacetophenone (108) nor in 4-O-benzoyloxyacetophenone (109), Figure 
3.
65
  
In the same year (1933), continued attempts made by Venkataraman et al. to effect the 
dehydration of 2-acetyl-1-naphthyl benzoate 110 to 1,4-α-naphthapyrones, found that 
Introduction 
24 
 
the action of sodamide on an ethereal solution of 2-acetyl-1-naphthyl benzoate 110 at 
room temperature, followed by decomposition of the precipitate with acid, gave the 
diketone 111, Figure 4.
67
 The diketone 111 and its 3,4,5-trimethoxy-derivative were 
convertible into the corresponding α-naphthaflavones (112,  in the case of the O-
methoxy-analogue) in the usual manner by means of sulfuric acid, Figure 4.
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Figure 4. Preparation of α-naphthaflavones by Venkataraman et al. 
Furthermore, the rearrangement of O-aroyloxyacetophenones 113 to O-
hydroxydibenzoylmethane 114 by basic reagents such as sodium amide, was reported in 
the review on the chemistry of the alkali amides (part II and III).
68,69
 The rearrangement 
has been studied and extended by a number of workers
70,71,71–76
 and the rearrangement 
of O-aroyloxyacetophenones 113 to O-hydroxydibenzoylmethanes 114 in the presence 
of basic reagents is typical, Scheme 35.
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Scheme 35. The rearrangement of O-aroyloxyacetophenones 113 to O-
hydroxydibenzoylmethane 114 under basic conditions. 
During this period of time, the mechanism of these rearrangements has been studied.
77
 
These transformations, by which β-diketones are formed, have been regarded as 
intramolecular Claisen acylations. While in ordinary Claisen acylations the ketone and 
ester functions are not present in the same molecule, both of these functions are present 
in the ortho position to one another in compounds undergoing the Baker-Venkataraman 
transformation.
77
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Until the 1950s, there were scant reports of the Baker–Venkataraman rearrangement 
used in synthesis. To this end, the approach mentioned in Scheme 36 sees the O-
benzoyl ester of C-glycoside 115 undergoing rearrangement into the 1,3-dicarbonyl 
compound 116 formed as a keto–enol mixture in 48% yield.78 
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Scheme 36. O-Benzoyl ester of C-glycoside 115 undergoing rearrangement. 
In another approach, the para-anisoyl ester of C-glycoside 118, was treated with lithium 
diisopropylamide (LDA) to give the enol dibenzoylmethane 119, Scheme 37.
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Scheme 37. Lithiated para-anisoyl ester of C-glycoside 118 undergoing the 
rearrangement. 
For a few decades (1933 to 1950) the conditions of the Baker–Venkataraman 
rearrangement were investigated, Scheme 38.
79
 It was found that sodium ethoxide in 
benzene was the best reagent for this reaction. It was also shown that this rearrangement 
failed in the case of the ester 120 due to the deprotonation of the acidic proton (the 
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enolate will abort the migration) as well as the steric clash with the newly incorporated 
diphenyl rings, Scheme 39. 
O
O
O
R
39-41%
OH O O
R
O
O
R
conc. H2SO4
R= 2-Me, 3-Me, 4-Me
 
Scheme 38. The Baker–Venkataraman rearrangement using sodium ethoxide in 
benzene. 
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Ph
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OH O O
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Scheme 39. Ester 120  does not undergo the rearrangement. 
The Baker–Venkataraman rearrangement has also been used as a key step in syntheses 
of trihydroxyflavanones 121
80
  as well as isoflavones 122
81
, Scheme 40. An interesting 
example of the Baker–Venkataraman rearrangement was reported for 
periacyloxyketones 123
82
, Scheme 40. 
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Scheme 40. The Baker–Venkataraman rearrangement as a key step in the synthesis of 
trihydroxyflavanones 121,  isoflavones 122 and periacyloxyketones 123. 
 
1.1.2.2 Modified Baker-Venkataraman rearrangement 
The first modified Baker-Venkataraman rearrangement (offering directly the rearranged 
product: 1,3-diketones) was declared by Seshadri et al. (1957) in which o-
hydroxyacetophenones 124 and aroyl chlorides were refluxed in acetone containing 
anhydrous potassium carbonate, to give directly the o-hydroxydibenzoylmethanes 125, 
required for cyclisation to flavones, Scheme 41.
83
 However, this simplified procedure 
was reported to have its limitations. Thus, 2-hydroxy-4,6-dimethoxy- and 2-hydroxy-3'-
methyl-4,6-dimethyoxyacetophones 126 failed to undergo conversion into the 
corresponding dibenzoylmethanes, Scheme 41.
84
 The lack of activity of these 
acetophenones was attributed to the resonance effect of the methoxy groups.
31
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OOOOH OHaroyl chloride, acetone, 
K2CO3, reflux
OOOOH OH
MeO OMe MeO OMe
OOH
OMeMeO
R RR
124 125
126
R= H, Me
 
Scheme 41. The first example of a modified Baker-Venkataraman rearrangement. 
Later, in 1982 Makrandi et al. presented an extremely facile procedure for the synthesis 
of flavones depicted by 129. The o-hydroxyacetophenone 127, containing methoxy or 
methyl groups at various positions (Scheme 42), was treated with an aroyl chloride 128 
and aqueous potassium carbonate or potassium hydroxide solution in benzene under 
phase transfer-catalysed conditions, using n-tetrabutylammonium hydrogen sulphate, 
resulting in the formation of the corresponding o-hydroxydibenzoylmethanes, Scheme 
42.
84
 The benzene solution, on treatment with p-toluenesulphonic acid afforded the 
flavones 129 in excellent yields. The method was of general applicability; even 2-
hydroxy-4,6-dimethoxy- and 2-hydroxy-3-methyl-4,6-dimethyoxyacetophones (126) 
were found to undergo smooth conversion under their conditions.
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Scheme 42. The synthesis of flavones by a modified Baker-Venkataraman 
rearrangement. 
In the same vein, the same authors were able to synthesise a variety of hydroxyflavones 
130 (Scheme 43) using their modified phase transfer-catalysed Baker-Venkataraman 
transformations.
85
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Scheme 43. The synthesis of hydroxyflavones. 
While attempting to a find the most convenient route for the synthesis of 131 (when R
1
= 
5-OMe), Scheme 44, Jeffery et al. found that the conventional Baker-Venkataraman 
approach
65,67
 was not suitable for synthesizing large amounts of 131, since low yields 
and product isolation complications were encountered in the benzoylation and Claisen 
condensation steps, respectively, Scheme 44.
86
 In addition, newer methods for directly 
converting hydroxyacetophenones into the required diketones, such as potassium 
carbonate,
87
 organolithium reagents,
88,89
 or phase-transfer catalysis
84
 proved to be 
ineffective or impractical for large-scale use. Therefore, a convenient large-scale 
preparation of 5-methoxyflavone has been developed using a KOt-Bu-mediated 
diketone synthesis (modified Baker-Venkataraman rearrangement) as the key step.
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Scheme 44. Preparation of 5-methoxyflavones. 
The method has been successfully applied to the convenient synthesis of a number of 
flavone analogues (monosubstituted flavones substituted in either aromatic ring, as well 
as flavones substituted in both rings). It has also been combined with a phenolic 
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alkylation step, thereby providing a short and efficient means of transforming 
dihydroxyacetophenones into A-ring alkoxyflavones. Moreover, the same method was 
adapted for the synthesis of certain A-ring alkoxyflavones from 
dihydroxyacetophenones, Scheme 45.
86
 
However, the products' overall isolated yields are slightly lower than that of the 
conventional Baker-Venkataraman sequence, but the method is simple practically, 
scalable and takes far less time to operate.
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Scheme 45. Synthesis of hydroxyflavone 133, an intermediate for flavodilol 134. 
In the approach for the synthesis of a novel class of antihypertensive agents with 
catecholamine depleting properties (flavodilol 134 and its analogues 135, Scheme 45), 
Wu et al. demonstrated that the modified Seshadri protocol
83
 (potassium carbonate in 
refluxing acetone) would offer directly the diketone 132 then cyclisation to 7-
hydroxyflavone 133 in a good yield, Scheme 45.
87
  
 
1.1.2.3 Retro-Baker-Venkataraman rearrangement  
In 1979, Donnelly and Maloney reported that when 2-bromo-1,3-diketone 136 reacted 
with a base it forms 2,3-diphenylchromone epoxide 138.
90
 They rationalised this 
transposition to occur through the intermediate, 2-hydroxyflavanone conjugate base 
137, and also considered that without a nucleophile (eg. bromide ion) fragmentation 
might occur to offer an o-aroyloxyacetopheneone 139, Scheme 46.
90
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Scheme 46. The first example of a retro-Baker-Venkataraman rearrangement. 
The unbrominated analogue 140 of the 1,3-diketone 136 has also been well documented 
that on reaction with potassium carbonate at 0 
○
C in chloroform, afforded the 
deoxybenzoin ester 141, via a retro-Baker-Venkataraman rearrangement, Scheme 47.
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Scheme 47. The unbrominated analogue 140 undergoing the retro-Baker-Venkataraman 
rearrangement. 
When the 2-phenyl substituent of the 1,3-diketone 140  is exchanged for a methyl group 
(ie. 143) a retro-Baker-Venkataraman rearrangement also occurs, though very slowly. 
Refluxing under the same reaction conditions for several days gave 2’-
benzoyloxypropiophenone 144 in 54% yield. Treating the 1,3-diketone 140 with 
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potassium hydroxide at room temperature afforded the decomposed products: 2’-
hydroxypropiophenone and propiophenone.
91
 
Moreover, different conditions failed to force the diketone 145 to undergo the reverse 
rearrangement, Scheme 48. Therefore, the rate of retro-Baker-Venkataraman 
rearrangement depends on the 2-substituent of the 1,3-diketone. A rapid decrease in rate 
has been seen in the order of Ph> Me> H.
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Scheme 48. Diketone 145 does not undergo the reverse rearrangement. 
As mentioned, efforts by Dunne et al. were unsuccessful in demonstrating the Baker-
Venkataraman rearrangement of the ester 144 to the 2-methyl-1,3-diketone 143, Scheme 
47.
92
 Though, the same ester 144 treated with potassium hydroxide in pyridine at -8 
○
C 
gave the diketone 143 in 53% yield as well as 1-(2-benzyloxyphenyl)-2-methyl-3-
phenyl-1,3-propanedione 146 and 2’-hydroxypropiophenone, Figure 4. The trans-
esterification of the initially formed hydroxy-1,3-diketone 143 with 2’-
benzyloxypropiophenone is the possible explanation for the formation of the benzyloxy-
1,3-diketone 146 and 2’-hydroxypropiophenone, Figure 5. At 0 ○C the same Baker-
Venkataraman rearrangement product has been formed in a yield of 41%. Despite 
increasing the reaction temperature to 50 
○
C, the yield was lowered to 18%, and only 
when the reaction was carried out for few minutes were the 2’-hydroxypropiophenone 
and propiophenone elucidated. However, 3-methylflavone 147  was formed after 
cyclisation of the diketone 143 by acetic acid, Figure 5.
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Figure 5. Structure of benzyloxy-1,3-diketone 146, and 3-methylflavone 147. 
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Occupying the 2-position of a 1-(-hydroxyphenyl)-1,3-propanedione with a hydroxyl 
group gave rise to retro-Baker-Venkataraman failure, Scheme 49. Instead, an alternative 
ester forming transformation was demonstrated.
93
 Reaction of 2-hydroxyl-1-(2-
hydroxyphenyl)-3-phenyl-1,3-propanedione 148 with potassium carbonate offered 2-
benzyloxy-2’-hydroxyacetophenone 150. The proximal carbonyl group in the dianion 
149 was deactivated by the phenoxide, thus, aborting the formation of alternative 
intermediate 151, Scheme 49.
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Scheme 49. Occupying the 2-position of 148 with a hydroxyl group causes the retro-
Baker-Venkataraman to fail. 
 
1.1.2.4 A carbamoyl variant of the Baker-Venkataraman rearrangement 
The first major variant (the carbamoyl version) of the Baker-Venkataraman 
rearrangement (Scheme 50) was reported by Victor Snieckus,
94
 in which the requisite 
ortho-acyl arylcarbamates 152 were rapidly and efficiently converted into substituted 4-
hydroxycoumarins 154 in 79-95% yields: a large and highly diverse class of natural 
products exhibiting a broad spectrum of bioactivity.
95–97
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Scheme 50. A carbamoyl variant of the Baker-Venkataraman rearrangement. 
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Furthermore, the authors demonstrated the application of the carbamoyl Baker-
Venkataraman strategy to the construction of a putative coumarin natural product and 
provide its structural revision.
94
 
In their prototype study of the Baker-Venkataraman rearrangement on 152 (R
2
= H), 
Scheme 51, exploration of conditions gave varying results: (LDA/THF/0 
○
C (complex 
mixture); LDA/PhMe/r.t. (54% yield); BrMgN(i-Pr)2/PhMe/r.t.-70 
○
C (62% yield); 
K2CO3/l8-crown-6/PhMe/reflux (no reaction) led to NaH in several solvents (2.5 equiv 
NaH, THF or PhMe or Xylene 0.2 M, reflux/~2h) as the optimal conditions affording 
the 2-hydroxyarylacetamide 153 (R
2
= H) in high yield, whose conversion into 154 (R
2
= 
H) was effected smoothly with trifluoroacetic acid (3 equiv) in refluxing toluene (0.25 
M), Scheme 51.
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Scheme 51. Snieckus's protocol for the synthesis of coumarins exemplified by 154. 
Due to the absence of side products in the carbamoyl migration reaction, even at 
relatively high (0.2 M) concentrations, suggests; as demonstrated in the ester Baker-
Venkataraman equivalent,
98
 an intramolecular mechanism is taking place. For this 
reason, this route is regarded as a convenient, efficient method which offers 4-
hydroxycoumarins 154, and with particular preparative advantages that 3-substituted 
(alkyl and aryl) coumarins are obtained directly, Scheme 51.
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Figure 6. Sturcture of 4,6-dimethoxy-3,7-dimethylcoumarin (155), isoeugenetin (156a), 
and its methyl ether 156b. 
Using the same strategy, the authors demonstrated the total synthesis of 4,6-dimethoxy-
3,7-dimethylcoumarin (155), the putative natural product isolated from Colchicum 
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decaisnei, and isoeugenetin methyl ether (156b), a synthetic derivative of the 
isoeugenetin (156a), isolated from Eugenia carvophyllata, Figure 6.
99
 
 
1.1.2.5 A microwave assisted Baker-Venkataraman rearrangement 
As part of their continuing work on the synthesis and antioxidant evaluation of 
polyhydroxy-2-styrylchromones,
100
 Silva et al. have considered the synthesis of 
polyhydroxy-3-aroylflavones 162, which are new chromone-type compounds with 
essential features of good antioxidant and anti-inflammatory agents, Scheme 52.
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Reaction conditions: (i) DCC, 4-pyrrolidinopyridine, HO2CC6H3R
2
R
3
, CH2Cl2, r.t.; (ii) 
classical heating conditions: K2CO3, anhydrous pyridine, 120 
○
C, under nitrogen, 2 h; 
microwave conditions: K2CO3, anhydrous pyridine, 400 W, 10 min; (iii) BBr3, 
anhydrous  CH2Cl2, r.t.. 
Scheme 52. The synthesis of polyhydroxy-2-styrylchromones. 
Introduction 
36 
 
A new and successful methodology has been established, in which microwave 
irradiation selectively induces the Baker–Venkataraman rearrangement of 2’,6’-
diaroyloxyacetophenones to give the corresponding 3-aroyl-5-hydroxyflavones 160 and 
161, in very short reaction times (10 min) and in good yields (68–72%). Under classical 
thermal conditions these reactions afforded 5-hydroxyflavones 160 and 161 as by-
products, Scheme 52.
101
 
The scope of the reaction and its utility as a new synthetic methodology to obtain 3-
aroyl-5-hydroxyflavones 160 and 161 via the Baker–Venkataraman rearrangement of 
2’,6’-diaroyloxyacetophenones, was determined and extended to include other 
derivatives, for example; the use of 2’,6’-diaroyloxyacetophenones with strong electron-
withdrawing substituents in the aromatic ring of the aroyl groups. The Baker–
Venkataraman rearrangement of 2’,6’-diaroyloxyacetophenones 158 and 159 under 
their preferred microwave experimental conditions allowed for the synthesis of 3-aroyl-
5-hydroxyflavones 160 and 161 in good yields (68–72%), Scheme 52.101 
In addition, a practical and economical method has been developed by Brown et al. for 
the synthesis of eleven flavonoid derivatives 165 from 2-hydroxyacetophenones 163 
using a modified Baker–Venkataraman rearrangement, followed by microwave-assisted 
condensation of the diones 164 to close the heterocyclic ring (simply using EtOH 
containing a small amount of concentrated H2SO4 (100:1 by volume), Scheme 53.
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Scheme 53. The synthesis of flavonoid derivatives. 
All of the synthetic flavonoids 165 displayed antifungal activity against Aspergillus 
niger and Fusarium oxysporium, and two of the analogues 165 (when R
2
= cyclohexyl) 
exhibited significant activity against methicillin-resistant Staphylococcus aureus.
102
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1.1.2.6 Applications of the Baker-Venkataraman rearrangement 
The use of the Baker-Venkataraman rearrangement in the context of total synthesis has 
become increasingly more important, particularly as 1,3-diketone starting materials are 
becoming more widely utilised. As such, this rearrangement is regarded as one of the 
most common methods for synthesising xanthones 166, chromones 167, flavones 168, 
and coumarins 169, Figure 7. 
O
O
OO
O
R
167 R= H
168 R= Ph
169166
O
 
Figure 7. General structures of xanthones 166, chromones 167, flavones 168, and 
coumarins 169. 
 
1.1.2.6.1 Synthesis of xanthones 
Xanthones (9H-xanthen-9-one 166, Figure 8) are a class of oxygenated heterocyclic 
compounds widely occurring as secondary metabolites in some higher plant families, 
such as Gentianaceae, Guttiferae, fungi and lichens.
103
 These natural derivatives are 
found with numerous substitutions at different positions of their skeleton: methoxy, 
hydroxyl and glycosyl groups being the most frequently occurring ones.
104,105
 
O
O
166  
Figure 8. General structure of xanthones 166. 
The pharmacological properties of both natural and synthetic xanthone derivatives have 
been extensively reported in the literature;
106
 they include antiallergic,
107
 antifungal,
108
 
anti-inflammatory,
109
 antimalarial
110
  and antitumour activities
111
  and this reveals the 
growing interest in this type of compounds. Furthermore, xanthones have been widely 
applied as antioxidant agents.
112
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Additionally, there are already two formulations on the market containing oxygenated 
and prenylated xanthones, as antioxidants.
113
 The aromatic character and the presence of 
hydroxyl groups and/ or catechol moieties at certain positions of the xanthone core are 
crucial requirements for a strong antioxidant activity.
109
 
Silva et al. found an efficient and general route toward the synthesis of hydroxylated 
2,3-diarylxanthones 174, in which the key intermediate of this synthesis (3-bromo-2-
styryl-chromone 172), is obtained by a Baker–Venkataraman rearrangement of the 
appropriate 2’-cinnamoyloxyacetophenone 170, Scheme 54.3  
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174 R1, R2= H, OH  
Reaction conditions: i) (a) X = Cl, anhydrous pyridine, r.t., 2 h; (b) X = OH, POCl3, 
anhydrous pyridine, 60 
○
C, 2 h; ii) DMSO, KOH, r.t., 2 h; iii) PTT, THF, r.t., 12 h; iv) 
NMP, Et3N, PPh3, Pd(PPh3)4; v) anhydrous CH2Cl2, BBr3,  –78 
○
C to r.t. 
Scheme 54. The synthesis of hydroxylated 2,3-diarylxanthones 174. 
The key step consisted of the cinnamoyl group transposition from the 2’- position to the 
2-position of the acetophenone moiety 170→171. It was performed by treatment of 170 
with potassium hydroxide in DMSO to afford 5-aryl-3-hydroxy-1- (2-hydroxyphenyl)-
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2,4-pentadiene-1-ones 171, in good yields (73–95%) and cyclisation to the desired 3-
bromo-2-styrylchromones 172 (53–67%). After two more steps the hydroxylated 2,3-
diarylxanthones 174 were obtained in good yields (70– 94%), Scheme 54.3 
The growing interest in the synthesis of biologically active compounds, especially 
polyhydroxy-2-styrylchromones, built up a simple and successful programme by Pinto 
et al. towards the synthesis of (E,E)-3-cinnamoyl-5-hydroxy-2-styrylchromones 176, 
Scheme 55.
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Scheme 55. The synthesis of (E,E)-3-cinnamoyl-5-hydroxy-2-styrylchromones 176. 
In their programme, to use the less expensive reagents and shorter reaction times, they 
applied two-step approach (double esterification of the appropriate 2’-
hydroxyacetophenone with cinnamoyl chloride derivatives followed by the Baker–
Venkataraman rearrangement of the formed diester (E,E)-2-acetyl-1,3-phenylene bis(3-
phenylacrylates)) 175.
115
 Additionally, a great improvement in yield was achieved by 
using microwave irradiation (at constant power of 400 W for 17 min), Scheme 55.
101
 
Another beneficial effect of using microwave irradiation was the shortening of the 
reaction time from 1 hour to 17 minutes. This methodology was successfully employed 
for the rearrangement of (E,E)-2-acetyl-1,3-phenylene bis(3-phenylacrylate) (175) 
leading to (E,E)-3-cinnamoyl-5-hydroxy-2-styrylchromone (176) in good yield (86%, 
Scheme 55).
114
 
 
 
Introduction 
40 
 
1.1.2.6.2 Synthesis of chromones 
Chromones (4H-1-benzopyran-4-one, 167) are one of the most abundant classes of 
naturally occurring oxygen-heterocycles, Figure 9.
116
 Chromone motifs are found in a 
wide variety of naturally occurring and synthetic products. The significance of these 
compounds is due not only to the important biological functions they play in nature, but 
also because certain derivatives have shown considerable pharmacological, biocidal, 
antioxidant,
116
 anticancer,
117–119
 anti-inflammatory activities,
120
 and for the treatment of 
some cardiovascular disorders.
121
 Some of the more successful candidates are also 
marketed as drugs (such as cromolyn).
122
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Figure 9. General structure of chromone. 
Nishinaga et al. attempted the synthesis of ten different chromone derivatives through a 
Baker-Venkataraman rearrangement.
123
 In their approach, the starting compounds 179 
(54-89%) were prepared conveniently by the potassium tert-butoxide induced Baker-
Venkataraman rearrangement of O-acyloxyacetophenones (178) in dimethylformamide 
(DMF) at room temperature. The 1-(O-hydroxyaryl)-1,3-diketones (179) were then 
cyclised in methanol or trifluoroethanol containing Co
III
(salpr)(OH)
124
 at 60 ᵒC to offer 
the chromones 180 in 70-100% yield, Scheme 56.
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Scheme 56. The synthesis of chromones such as 180. 
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Other classes of chromones, which are less widely-occurring in nature, have also 
exhibited important biological activities. For example, within the newly-discovered 
group of 2-styrylchromones, only two natural derivatives have been found, but they 
have shown potent in vitro cytotoxicity against human leukaemia cells.
125,126
 Prior to the 
isolation of these natural 2-styrylchromones, studies had already been carried out on 
numerous synthetic derivatives,
127
 which also showed promising antitumour and anti-
allergic activities.
128
 More recently, it has been demonstrated that certain synthetic 
derivatives are inhibitors of the replication of the human anti-rhinovirus,
129
 while the 
authors have found that 3’-allyl-5,7,4’-trimethoxy-2-styrylchromone inhibits oxidative 
phosphorylation,
130
 and that some hydroxy-2-styrylchromones act as potent xanthine 
oxidase inhibitors.
100
 
Silva et al. prepared several hydroxy-2-styrylchromones 184 by the 
Baker−Venkataraman method, Scheme 57. In which, transformation of compounds 181 
into 5-aryl-3-hydroxy-1-(2-hydroxyaryl)-2,4-pentadien-1-ones 182 was carried out by 
their treatment with an excess of potassium hydroxide in DMSO, Scheme 57. 
Compounds 182 were subjected to cyclodehydration to offer the corresponding 
benzyloxy-2-styrylchromones 183. Subsequent debenzylation of the benzyloxy-2-
styrylchromones 183 was achieved by their treatment with a solution of hydrogen 
bromide in acetic acid at reflux, to give the corresponding hydroxy-2-styrylchromones 
184 in moderate yields, Scheme 57. 
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Reaction conditions: i) X=Cl, dry pyridine or X=OH, POCl3 in dry pyridine; ii) KOH, 
DMSO; iii) p-Toluenesulfonic acid or I2, iv) DMSO; HBr/AcOH. 
Scheme 57. Preparation of hydroxy-2-styrylchromones 184. 
Moreover, the Baker–Venkataraman rearrangement,131 in combination with oxidative or 
acidic catalytic cyclisation,
132,133
 has been revealed as an efficient method for chromone 
formation, Scheme 58.
134
 
For example, in their search for potent anticancer molecules, Bu et al. found an efficient 
one-pot synthesis of multi-functionalized chromeno[2,3-c]pyrrol-9(2H)-ones.
134
 
Acylation of o-hydroxylated diaryl 1,3-diketones followed by a Baker–Venkataraman 
rearrangement would accomplish the achievement of increasing substrate diversity. For 
example, the synthesis of 1,3-diaryl-1,3-diketones from 186 (after esterification (86-
90%) and Baker–Venkataraman rearrangement) was achieved. In this method, o-
acylated phenol esters 185 underwent Baker–Venkataraman rearrangement (K2CO3 (1 
eq.) in pyridine at 75 
○
C) to afford 186 in 70–83% yields, Scheme 58.134 
The β-diketone intermediates 186 were then esterified with various protected amino 
acids (lysine, aspartic acid, alanine, leucine, phenylalanine, tyrosine, and methionine), 
using 4-(dimethylamino)-pyridine (DMAP) as a catalyst in pyridine at 25 
○
C, to offer 
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the final product, 1,3-substituted chromeno[2,3-c]pyrrol-9(2H)-ones 187 in 44–89% 
yields, Scheme 58.
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Scheme 58. The synthesis of 1,3-substituted chromeno[2,3-c]pyrrol-9(2H)-ones 187. 
The proposed mechanism for the formation of the 1,3-substituted chromeno[2,3-
c]pyrrol-9(2H)-ones 187 involves two steps. Firstly, DMAP-catalysed Baker–
Venkataraman rearrangement occurs immediately after the esterification of 186, giving 
the chromone intermediate 188, Scheme 59. Secondly, the 9-
fluorenylmethyloxycarbonyl (Fmoc) group can be removed by DMAP under the same 
conditions.
135
 Subsequently, the liberated amino group of 188 undergoes intramolecular 
carbonyl addition and is followed by elimination to afford the final products 187, 
Scheme 59.
134
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Scheme 59. The proposed mechanism for the formation of the 1,3-substituted 
chromeno[2,3-c]pyrrol-9(2H)-ones 187. 
 
1.1.2.6.3 Synthesis of flavones 
The flavone nucleus (2-phenylchromones (168), Figure 10) seems to be an important 
scaffold to prepare pharmaceutical agents, since both natural and synthetic derivatives 
are responsible for a great variety of biological and pharmacological activities, 
including antitumour, anti-inflammatory, antiviral, and antioxidant properties.
136
 The 
presence of hydroxyl groups in the flavone skeleton is very important for their capacity 
to act as antioxidants,
137
 as exemplified by quercetin (3,3’,4’,5,7-pentahydroxyflavone), 
a well-known antioxidant agent and a very important compound with numerous 
biological activities, such as an inhibitory effect on tumour growth.
138
 Another 
important structural feature of flavones is the presence of a 3-aroyl group; in fact it has 
been reported that flavones bearing this substituent possess antibacterial, antifungal, and 
antimalarial activities.
139–141
 More recently, it was also reported that some 3-
aroylflavones present antitubulin activity.
142
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Figure 10. General structure of flavone 168. 
The initial application of the, now called, Baker-Venkataraman rearrangement was by 
Venkataraman himself, when he attempted the synthesis of α-naphthaflavone 112 from 
2-acetyl-1-naphthyl benzoate, Figure 4 (vide supra).
67
 
Thereafter, a variety of flavones have been synthesised via the Baker-Venkataraman 
rearrangement, for example, a modified Baker-Venkataraman transformation was the 
key step in the preparation of fourteen flavone derivatives 129, Scheme 42 (vide 
supra).
84
 Furthermore, aroyl-5-hydroxyflavones (nine analogues 160 and 161) have 
been synthesised under microwave assisted Baker-Venkataraman transposition, Scheme 
52 (vide supra).
101
 
Additionally, it has been observed that the presence of hydroxyl groups at position -5 or 
7 is frequently required for higher biological activities.
143,144
 On the other hand, 
aminoflavones have been studied as tyrosine kinase inhibitors
145
 and as antimitotic 
agents.
146
 In light of these results, interest in the synthesis of flavones bearing both 
hydroxyl and amino groups on the A-ring grew, Figure 10. 
The synthesis of flavone 193 by a modified Baker-Venkataraman method has been 
reported recently.
147
 In this process, the 1,3-diketone intermediate 192 was prepared in 
one step by the reaction of 189 and benzoyl chloride (190), but this route required the 
use of relatively expensive lithium hexamethyldisilazide (LiHMDS) and low 
temperature (-78 
○С). Furthermore, compound 192 was neither isolated nor fully 
characterized. However, the method needs improving to avoid both the lengthy 
synthesis of the corresponding chalcone precursor and inconvenient low temperature 
preparation of the 1,3-diketone intermediate 192.
147
 Therefore, to avoid both the lengthy 
synthesis of the corresponding chalcone precursor and inconvenient low temperature 
preparation of the 1,3-diketone intermediate 192 the commonly used Baker-
Venkataraman rearrangement conditions was reinvestigated by Shufen et al.
148
 In their 
efforts, the synthesis of 191 was achieved from 2′,4′-dihydroxy-5′-nitroacetophenone 
(189) using 2.0 equivalents of benzoyl chloride in refluxing dry acetone in the presence 
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of anhydrous potassium carbonate, Scheme 60. Yields of the separated compounds 3-
benzoyl-7-hydroxy-6-nitroflavone (191) and 1-(2,4-dihydroxy-5-nitrophenyl)-3-phenyl-
1,3-propanedione (192) were 43%, and 13% respectively.
148
 
OH
HO
NO2
O
Cl
O
K2CO3
acetone
reflux
O2N
HO O
O
O
5% KOH/EtOH
OH
OO
HO
O2N
AcOH/H2SO4
O2N
HO O
O
H2N
HO O
O
+
189 190 (2.0 eq.) 191
192 193
194
Na2S2O4
EtOH/H2O
 
Scheme 60. The synthesis of flavone 194 by a modified Baker-Venkataraman method. 
These results showed that the hydroxyl group adjacent to the nitro group in 189 cannot 
be acylated under the selected reaction conditions. This was attributed to the strong 
intramolecular hydrogen bonding between the nitro and hydroxyl groups, i.e., resonance 
deactivation, which hinder the acylation of the latter. 
In a similar  manner, Ares et al. found a convenient large-scale preparation of 5-O-
pivaloylflavone 197 using KOt-Bu (2.2 equivalent) mediated diketone 196 synthesis as 
the key step, Scheme 61. The method has been successfully applied for the convenient 
synthesis of a number of flavone analogues. They combined a phenolic alkylation step 
with the rearrangement to provide a short  and efficient means of transforming 
dihydroxyacetophenones 195 into A-ring alkoxyflavones 197, Scheme 61.
86
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Scheme 61. Preparation of 5-O-pivaloylflavone 197. 
 
1.1.2.6.4 Synthesis of coumarins 
Coumarin (2H-1-benzopyran-2-one (169), Figure 11) is a plant-derived natural product 
which possesses a variety of pharmacological activities, such as anti-inflammatory,
149
 
antifungal,
150
 antimicrobial
151
 and anti-HIV activities.
152
 Furthermore, examples of 
isolated naturally occurring coumarins (dicoumarol, warfarin, and umbelliferone) are 
well known for their anticoagulant properties.
153
 Victor Snieckus documented a general 
method for the synthesis of substituted 4-hydroxycoumarins (154) (10 derivatives in 79-
95% overall yields) using his carbamoyl version of the Baker-Venkataraman 
rearrangement, (see Scheme 51 vide supra).
94
 In addition, the same authors declared 
that the strategy was also applicable for the synthesis of 4,6-dimethoxy-3,7-
dimethylcoumarins 155 and 156, (see Figure 6 vide supra).
94
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Figure 11. General structure of coumarin 169. 
 
1.1.2.6.5 Synthesis of anthrapyran antibiotics 
Indomycinones
154
 belong to the anthrapyran antibiotic family and occur mainly as their 
C-glycosides (eg. pluramycines, hedamycines, riboflavines, altromycines and 
indomycines), Figure 12.
155,156
 Due to their selective binding to DNA and their specific 
alkylation of guanine,
157,158
 they have found renewed interest in structural biology.
159
 
Additionally, a number of aglycones with the anthra[b]pyran nucleus have also been 
found in nature. For example, β-indomycinone (198)160 and δ-indomycinone (199)160 
have a C-6 side chain at C-2 while γ-indomycinone (200),154 kidamycinone (201),161 the 
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antihepatitic antibiotic AH-1763 IIa (202), and the neuroprotective espicufolin (203) 
have a C-4 side chain, Figure 11.
162
 Recently, several researchers have attempted the 
syntheses of premithramycinone (204),
163
 espicufolin (203),
164,165
 altromycinone  (205) 
and kidamycinone (201),
166
 and AH-1763 IIa
162
 (202) and this remarkable interest is 
attributed to their great biological properties, Figure 12. 
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Figure 12. Examples of anthrapyran antibiotics synthesised using the Baker-
Venakataraman rearrangement 
In an approach made by Krohn et al. for the synthesis of rac-γ-indomycinones, the 
Baker–Venkataraman  rearrangement was employed for the chain elongation to avoid 
the reduction and/ or oxidation steps connected with the organometallic reactions on the 
anthraquinone skeleton.
163,167
 The key Baker–Venkataraman rearrangement was induced 
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by refluxing the ester 206 in THF with lithium hydride to offer the β-diketo-
anthraquinone 207 in 97% yield, Scheme 62.
162
 The acid-catalysed cyclisation to 
anthrapyranone 208, then underwent a few further steps to offer rac-200. A similar 
protocol has been used to prepare the corresponding 11-methyl ether of γ-indomycinone 
200 as well, Scheme 62.
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Scheme 62. The synthesis of rac-γ-indomycinones. 
The Baker–Venkataraman reaction has become employed widely in the synthesis of a 
large group of anthrapyran antibiotics.
161,163,168
 Similarly, the synthesis of aromatic 
polyketide derived natural products and the biomimetic-type synthesis of 
anthracylines
169
 and angucyclines
170
 includes the construction of β-diketo side chains on 
an aromatic or quinoide nucleus.
171
 As such, to produce such β-diketo products Krohn et 
al. attempted an enantioselective acyl transfer reaction with α-oxygenated esters under 
Baker–Venkataraman conditions, Scheme 63.167 
In this effort, the base-catalysed acyl transfer (Baker–Venkataraman reaction) of chiral 
2-acetyl-1-hydroxyanthraquinone esters (209) or (215) proceeds with virtually no 
racemisation to β-diketo-anthraquinone (S)-210 and (S)-216, Scheme 63 and 64. The 
next cyclisation step offered the enantiomerically enriched (>97% ee) anthra[1,2-
b]pyran 211 which is a close derivative of neuroprotective espicufolin (203). 
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Scheme 63. Synthesis of enantioenriched anthra[1,2-b]pyran 211. 
Furthermore, the Baker–Venkataraman reaction was applied to transform 
enantiomerically pure O-allyl-lactic ester 215 to ketides 216, Scheme 64, as well as, its 
cyclisation to anthrapyrans 217. The model reaction opened the way to synthesise 
enantiomerically pure 10-hydroxy-anthrapyranones of the indomycinones, 
rubiflavinones 212, pluramycines 213, or hedamycines 214, Figure 13.
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Figure 13. Examples of indomycinones containing a 10-hydroxy-anthrapyranone 
nucleus. 
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Scheme 64. Preparation of 2-allyloxy-substituted anthrapyranone 217. 
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The Baker–Venkataraman rearrangement of ester 215 afforded 53% of β-diketoalkyl-
anthraquinone 216. In the end, cyclisation of the β-diketoalkyl phenol 216 to 2-allyloxy-
substituted anthrapyranon 217 (94% yield) was excellent, since no cleavage and no 
isomerisation of the allyl protecting group occurred.
167
  
 
1.1.2.6.6 Synthesis of benzopyran derivatives 
Benz[b]indeno[2,1-e]pyran-10,11-diones 218, Figure 14, are known to enhance the 
biosynthesis of erythropoietin, a hematopoietic growth factor which stimulates 
differentiation and supports the survival of cells of the erythroid lineage.
172
 The 
methanol extract of the dried leaves and stems of Wrightia tomentosa revealed weak 
activity against human immunodeficiency virus type 1 reverse transcriptase (HIV-1 
RT). Thasana and Somsak showed that this effect was due to wrightiadione 219 Figure 
14,
173
 which is a rare and unusual oxygen heterocycle isolated from the bark of this 
medicinal plant of Thailand.
174
 This finding, and the reported interesting biological 
activity of benz[b]indeno[2,1-e]pyran-10,11-diones 218, motivated the authors to 
undertake a study of the synthesis of these compounds.
175
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Figure 14. General structure of benz[b]indeno[2,1-e]pyran-10,11-diones 218 and 
wrightiadione 219. 
Therefore, to develop an operationally simple, highly efficient reaction for the synthesis 
of benz[b]indeno[2,1-e]pyran-10,11-diones 218, the same authors envisaged that 
benz[b]indeno[2,1-e]pyran-10,11- dione 218c (isowrightiadione) could be obtained via 
the synthetic route shown in the retrosynthetic analysis in Scheme 65. It was expected 
that flavone 220 could be obtained by application of the Baker–Venkataraman 
rearrangement.
86,131,176–179
 Further cyclisation directly could then lead to the required 
compound, Scheme 65.
175
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Scheme 65. Retrosynthesis of isowrightiadione (218c). 
To investigate this route, acylation of 223 with mono-methylphthalate 224 using a 
Steglich esterification gave o-benzoylacetophenone 222 in 68% yield (Scheme 66). The 
intramolecular acylation of 222 was carried out with potassium hydroxide in pyridine, 
under reflux for 30 minutes to give the desired 1,3 diketone 221, Scheme 66. The 
mixture was then poured into 2M hydrochloric acid solution which led to the 
precipitation of a yellow solid in 72% yield.
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Scheme 66. Synthesis of isowrightiadione (218c). 
The elucidated structure of the recrystallized product was not the expected flavanone 
220 (R= Me) but instead the final target compound 218c. The rationalized mechanism 
for the formation of 218c could involve formation of the 1,3-diketone intermediate 221 
through the Baker–Venkataraman rearrangement, Scheme 67. After which, the diketone 
221 will intramolecularly cyclise to afford the 1,3-indanedione 225. Subsequently, the 
formed hemiketal 225 can dehydrate to give the ultimate product 218c as shown in 
Scheme 67.
175
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Scheme 67. The rationalised mechanism for the formation of 218c. 
 
1.1.2.6.7 Synthesis of aklanonic acid 
Aklanonic acid (226, which exists in equilibrium with the enol form 227 (when R= 
OH), Scheme 68) and its derivatives such as 4-deoxyaklavinone 228 (R= H) are starting 
materials of great interest for the microbial conversion of synthetically inaccessible 
derivatives of the antitumor agent aclacinomycin A (229).
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Scheme 68. Starting materials for the synthesis of aclacinomycin A (229). 
In this scene, the Baker-Venkataraman rearrangement (lithium hydride in THF ) has 
been utilised as a flexible method for the introduction of ketide side chains on 
anthraquinones 230 to afford the aklanonic acid derivatives (e.g. 231) in a very pure 
state and in high yield, Scheme 69.
169
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Scheme 69. Preparation of aklanonic acid derivatives 231. 
Similarly, the attachment of different oligoketide side  chains to the naphthoquinone 
nucleus have been carried out by Krohn and Schafer.
181
 In this case, after a number of 
trials they proved that the Baker-Venkataraman rearrangement of ester 232 was the best 
protocol for the side chain elongation with a variety of ketides, Scheme 70. Sodium 
hydride in THF was found to give the best results in the transformation of 232 to the 
rearranged product 233 (66%). The corresponding naphthoquinone precursors 233 
underwent base-catalysed cascade reactions to yield the 4-deoxyaklanonic acids 234, 
Scheme 70. 
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Scheme 70. Attachment of oligoketide side-chains to the naphthoquinone nucleus. 
In conclusion, like its analogue, the Truce-Smiles rearrangement, the Baker-
Venkataraman rearrangement  is regarded as a valuable reaction to construct new C-C 
bonds under mild conditions, as has been demonstrated with the synthesis of 
chromones, flavones, isoflavones, and coumarins, amongst other motifs. However, as 
with the Truce-Smiles rearrangement, to date, no enantioenriched chiral centres have 
been synthesised by virtue of this practical rearrangement. 
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CHAPTER TWO - RESULTS AN DISCUSSION 
2.1 Hypothesis and aims of the work 
Taking together all the applications and limitations of the asymmetric α-arylation and α-
acylation of carbonyl compounds, it was envisaged that it would be possible to produce 
an asymmetric α-arylation and α-acylation of carbonyl compounds via the Truce-Smiles 
and Baker-Venkataraman rearrangements; which to date have not been reported. 
 
2.1.1 Working hypothesis 
It is possible to synthesise asymmetric, sterically hindered tertiary or quaternary centres, 
through the Truce-Smiles and Baker-Venkataraman rearrangements. 
 
2.1.2 Aims of the work 
The study was intended to lead to the development of a novel method for the synthesis 
of asymmetric α-arylated and α-acylated carbonyl compounds through the Truce-Smiles 
and Baker-Venkataraman rearrangements respectively, with the following aims: 
1. To design and develop a novel method for the asymmetric synthesis of sterically 
hindered tertiary or quaternary centres via the Truce-Smiles and Baker-
Venkataraman rearrangements, Scheme 71. 
2. To expand the potential of the developed methodology towards the synthesis of 
pharmaceutically relevant intermediates and drugs. 
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Scheme 71. Expected asymmetry induction (shown when R
3
= chiral auxiliary). 
 
2.2 Asymmetric α-arylation of carbonyl compounds via the Truce-Smiles 
rearrangement 
α-Arylated carbonyl compounds are commonly occurring motifs in biologically 
interesting molecules
28
 and important classes of medication such as cannabinoid CB1-
receptor ligands 238, phosphodiesterase inhibitor 239, disopyramide
29
  240 and opioids 
(for example: diphenoxylate 241),
30
 (see Figure 15), however, the synthesis of such 
compounds is synthetically challenging and new methods are therefore of high interest 
to the pharmaceutical industry.
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Figure 15. α-Arylated carbonyl compounds. 
Equally, the diarylmethanol and diarylmethane framework are considered to be 
privileged structures in important intermediates and precursors for the synthesis of 
pharmacologically and biologically active compounds, such as: antihistaminic 
pheniramines 243a-c, methyl phenidates (244), clemastine (245) and pipradrols 246, 
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1,4-dihydropyridine derivatives (with potent and long-lasting hypotensive effect), and 
cizolirtine (a novel non-opioid analgesic 247), Figure 16.
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Figure 16. Pharmacologically active compounds prepared from diarylmethanol and 
diarylmethane frameworks. 
Therefore, developing novel routes to such compounds will help with their continued 
exploitation in medicinal chemistry. These requirements inspired us to study the 
development of asymmetric metal-free α-arylations of carbonyl compounds as an 
alternative synthetic approach that operates under mild conditions, especially since 
wide-ranging achiral substrates have recently been successful in this rearrangement 
under relatively mild conditions,
42,43,183,184
 but also because such a mild, scalable 
method, amenable to asymmetric induction, has yet to be developed. The question 
therefore was, could the Truce–Smiles rearrangement be developed to meet these 
needs? 
 
2.2.1 The use of phase transfer catalysts  
Recently, our group expanded the Truce-Smiles rearrangement by applying it to 
functionalised substrates in order to make them more synthetically useful building 
blocks (for example, as demonstrated with the synthesis of indole 63, Scheme 72), and 
it was shown that homologous ketones 235
23
 could also react resulting in chiral, 
racemic, α-arylated products.31  
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Scheme 72. Expanding the Truce-Smiles rearrangement to synthesise indole 63. 
To further expand the utility of this method towards asymmetric α-arylated carbonyl 
compounds, the development of new asymmetric conditions were required to enable the 
synthesis of products not currently covered under the conditions known to date. For 
example, increasing substrate functional group tolerance; preventing any product 
racemisation, therefore allowing access to products with high enantioselectivities; as 
well as controlling regioselectivity in substrates with more than one enolisable position.  
F
NO2
NO2
O
CO2C2H5+
cinchona alkaloid 
(250a-f), PTC
248 249
O
CO2C2H5
O2N NO2
252 15-87% ee
O
CO2C2H5
O2N NO2
()-251
CsOH, TBAI
N
R1O N
+
R2
H
X-H
H
250a R1= allyl,R2= Bz, R3= H, X= Br
250b R1= allyl, R2= ethylanthracene, R3= H, X= Br
250c R1= Bz, R2= Bz, R3= H, X= Br
250d R1= Bz, R2= Bz, R3= H, X= Cl
250e R1, R2= H, R3= OMe, X= Cl
250f  R1, R2, R3= H, X= Cl
catalyst=
250
R3
non-asymmetric route
asymmetric route
 
Scheme 73. Non-asymmetric α-arylation method developed into asymmetric variant.182 
The best way to overcome such drawbacks is to exploit established non-asymmetric 
methods and develop them into asymmetric variants (Scheme 73) by the judicious 
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choice of chiral auxiliary reagents, by which, a quick and efficient method for 
generating chiral products could potentially be achieved. 
Jørgensen developed non-asymmetric methods for α-arylation of 1,3-dicarbonyl 
compounds into asymmetric variants, and he demonstrated that chiral induction could 
also be achieved using chiral phase-transfer catalysts based on the cinchona alkaloids 
(such as 250a-f), when he worked on an asymmetric nucleophilic aromatic substitution 
reactions (SNAr) (Scheme 73, Table 1).
182,185
 
  
Table 1. Screening catalysts and conditions for the organocatalytic (15 mol %) SNAr 
addition of 2-carboethoxy-cyclopetanone (249) to 2,4-dinitro-1-fluorobenznene (248). 
Entry Catalyst (temp, 
○
C) Yield (%) ee (%) 
1 TBAI (r.t.) 90 - 
2 250a (r.t.) 80 15 
3 250b (r.t.) 80 10 
4 250c (r.t.) 70 -7 
5 250d (r.t.) 90 rac 
6 250d (-20) 90 rac 
7 250e (r.t.) 82 46 
8 250e (0) 85 60 
9 250e (-20) 89 80 
10 250e (-40) 89 87 
Further relevant examples of interest by Jørgensen (Scheme 73 and 74) reveals various 
nucleophilic aromatic substitution reactions to produce enantioenriched products (e.g. 
252, 255, and 257).
182,185
 In their work, 1,3-dicarbonyl compounds react with 2,4-
dinitro-1-fluorobenznene (248) or 1,4-quinones (254, 256) to undergo enantioselective 
α-arylation using organocatalysts (cinchona alkaloids (250a-f)). The high 
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enantioselectivities observed in the PTC-mediated reactions normally arise from 
electrostatic interactions in the ion pair between the quaternary ammonium salt and the 
nucleophile, which then react in a stereocontrolled manner with the electrophile.  
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Scheme 74. Jørgensen's work (enantioselective α-arylation of 1,3-dicarbonyl 
compounds).
182,185
 
However, although the enantiomeric excesses obtained were excellent (252→ 15-87%, 
255→ 94% and 257→ 80% ee), there is still room for improvement if the method is to 
become generic, since this method was solely restricted to the α-arylation of 1,3-
dicarbonyl compounds (e.g. 249), Scheme 73.
182,185
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Since the Truce-Smiles rearrangement is an intramolecular variation of the SNAr 
reaction,
2
 it was expected that such phase-transfer catalysts (e.g. 250) could force 
asymmetry in this rearrangement in a similar fashion to Jørgensen's work (Scheme 75). 
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Scheme 75. Postulated asymmetric induction using a chiral phase-transfer catalyst based 
on the cinchona alkaloids.
186,187
 
This work originates from the need to develop new methods for the asymmetric α-
arylation of carbonyl compounds, and this is expected to be achieved by extending 
previous work on the Truce-Smiles rearrangement (Scheme 75).
2
 
Unfortunately, previous efforts by our group to develop an asymmetric Truce-Smiles 
rearrangement based on Jørgensen's work met with failure.
188
 Despite screening a 
number of phase transfer catalyst based on the cinchona alkaloids (varying the loading 
amount of the catalyst), different solvents, bases, varying temperature (from -20 
○
C- r.t.) 
and varying the reaction time from 16 hours to 5 days, the maximum enantiomeric 
excess obtained for the aryl transfer was 1.2% which is arguably within experimental 
error, Scheme 76. 
Results and Discussion 
62 
 
N
R1O N
+
R2
H
Cl-
H
H
250d R1, R2= Bz
250f R1, R2= H
250j R1= Bz, R2= H
OH O
+
F
NO2
solvents, temp.
base, cat.
OH O
NO2
solvent: THF, DCM, Et2O, PhMe, EtOAc, MeCN
base: CsOH, KOH, NaOH, K2CO3
cat.: (+)-cinchonidine, N-benzyl-cinchonidinium chloride,
         O-benzyl-N-benzyl-cinchonidinium chloride 
temp: -20 C-r.t.
time: 16h- 5 days
261 60 262
catalyst=
 
Scheme 76. Previous efforts to develop an asymmetric Truce-Smiles rearrangement 
based on Jørgensen's work. 
In addition, in order to see if better level of enantioselectivities could be achieved via an 
intramolecular variant, the rearrangement of diarylether 263, under the same conditions 
as above, was attempted. However, in this case, even with 50% loading of the catalyst 
250d in DCM (0.1 M) using KOH (5 eq.) at -20 
○
C for 2 days, only 15% ee was 
obtained, Scheme 77. 
solvents, temp.
base, cat. 250
OH O
NO2
O O
NO2
263 262 60%, 15% ee  
 Scheme 77. The enantioselective rearrangement of diarylether 263 using a phase 
transfer catalyst based on the cinchona alkaloids. For conditions see Scheme 76. 
Based on these low levels of enantioselectivity, this route was temporarily abandoned, 
since it was anticipated that better levels of selectivity may be achieved with chiral 
auxiliaries as an approach to develop an asymmetric variant of the Truce-Smiles 
rearrangement. By performing the reaction under already existing established 
conditions, but with addition of a chiral auxiliary, the hope of inducing asymmetry in 
Truce-Smiles rearrangement could be achieved; such methods will be described in more 
details below. 
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2.2.2 The use of chiral auxiliaries
189
 
In 1981 chiral oxazolidin-2-one auxiliaries were introduced, popularised by David 
Evans in 1982, and have been used widely in organic synthesis since to influence the 
outcome of numerous asymmetric reactions like the aldol reaction,
190
 alkylation 
reactions
191
 and Diels-Alder reactions
192,193
 and the conditions for their synthesis and 
use are widespread.
189
 The oxazolidinones are substituted at the 4 and 5 positions to 
render them chiral. Through steric hindrance and chelation the substituents influence the 
direction of incoming groups, Scheme 78, causing a preference for facial selectivity to 
occur.  
O
NH
O
O
R
Cl
n-BuLi, THF, -78 C
O
N
O
M
R
O
Si face
blocked
O
N
O
O
R
i) base, THF
ii) E+
O
N
O
O
R
E
O
N
O
O
R
E
E+= CH3I (NaHMDS, -78 C)             91                          9  
E+= PhCH2Br (LDA, 0 C)                 99                          1
264
269
267 268266265
Scheme 78. Chiral oxazolidin-2-one auxiliaries in asymmetric alkylation reactions. 
As shown in Scheme 78, the N-acyl oxazolidinones  (266) are able to form enolates 
(269), most commonly with LDA or NaHMDS. Using such strong bases, the enolates 
are formed entirely in the Z-form. The metal counterion is chelated to the oxazolidinone 
oxygen atom (269), making one face of the enolate (the Re face), point away from the 
isopropyl group of the oxazolidinone 264, and therefore much more available to the 
electrophile than the Si face. The selectivity obtained ranges from good (small 
electrophiles, such as CH3I and EtBr) to excellent (for more bulky electrophiles).
191
 The 
auxiliary can be subsequently removed e.g. through hydrolysis. 
Even though there is only a single rotatable bond linking oxazolidinones to the 
substrate, other factors such as chelation or dipole-moment minimization often enhance 
the production of the preferred conformations in which the oxazolidinone’s 
substituent(s) efficiently shields one of the molecule’s diastereotopic faces. As a 
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consequence of that, certain rotamers possess greater energetic preferences which lead 
to better stereoselectivities being achieved in different cases (Scheme 78).
189
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Scheme 79. Proposed use of chiral auxiliaries to introduce chirality into the Truce-
Smiles rearrangement (left) and a proposed transition-state (right). 
The ready availability of these auxiliaries (Figure 17), high diastereoselectivity obtained 
for their transformations and facile introduction and cleavage of the auxiliary make 
them popular.
189
 The Truce-Smiles precursor, with the incorporated chiral auxiliary 
(270), should therefore give rise to the required stereoselective rearrangement, and give 
up enantiopure products, presumably via a chelated 5-membered chiral transition-state 
(Scheme 79). Therefore, by judicious choice of substituted starting materials which 
incorporate the chiral auxiliary it was hoped it would be possible to prepare asymmetric 
quaternary centres as shown in Scheme 79. 
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Figure 17: Some of the commercially available oxazolidinone chiral auxiliaries. 
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2.2.2.1 The Truce-Smiles rearrangement on oxazolidinone-based substrates 
Based on the known success of oxazolidinone chiral auxiliaries (Figure 17) in imparting 
asymmetry in the reactions in which they take part, initial attempts were focused on 
preparing achiral oxazolidinone-based substrates and to test them (for example, those 
compounds containing an 2-oxazolidinone 284, Scheme 80) and see whether they 
would undergo a Truce-Smiles rearrangement or not, before moving on and explore the 
chiral enantiopure analogues. Unfortunately, despite attempting both reported
194
 and 
unreported conditions (Table 2) to make the 2-oxazolidinone-based substrates 284 from 
the reaction between 2-coumaranone (281) and 2-oxazolidinone (282), no success in 
preparing them was achieved. 
Table 2. Conditions attempted for the synthesis of 2-oxazolidinone based substrates 284 
from 2-coumaranone (281) in THF.  
Auxiliary Base Temp Duration 
2-oxazolidinone (1.55 eq.) NaH (1.5 eq.) r.t. 5 h 
2-oxazolidinone (1.55 eq.) NaH (1.5 eq.) 60 
○
C 3 h 
2-oxazolidinone (2.0 eq.) n-BuLi (2.1 eq.) r.t. 16 h 
OH
O
OH O
O
277 281
O
O
N
O
O
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toluene, 6h
Dean-Stark
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O
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Scheme 80. Failed attempts to make the 2-oxazolidinone based substrate 284. 
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A probable reason for the lack of success here could be due to the fact that either 2-
coumaranone (281) is not reactive enough as an electrophile, or the deprotonated 2-
oxazolidinone  is not nucleophilic enough; a proposal which is partly supported by the 
complete lack of literature detailing a reaction between 2-oxazolidinone (282) and 
lactones in general. Similarly, further support is gleaned from the fact that most 
reactions of 2-oxazolidinone (282) as a nucleophile react with acyl chloride counterparts  
(e.g. 280) not cyclic esters.
24,195,196
 As such, attempts to make the acid chloride from our 
precursor (2-hydroxyphenyl acetic acid (277)), which is more reactive than the lactone 
(2-coumaranone (281)), were performed, Scheme 80. For such a route it was necessary 
to protect the phenolic hydroxyl group to prevent it from cyclising onto the soon to be 
formed acid chloride and forming 2-coumaranone (281) on treatment with base, 
therefore the phenolic hydroxyl group was protected as its benzyl ether using benzyl 
bromide (278)
197
 in the hope that it could be deprotected (to the required substrate 284) 
at a later date ready to perform the Truce-Smiles rearrangement, Scheme 80.  
Despite, a number of reported protocols for such a transformation, the reaction failed to 
produce the protected 2-oxazolidione-based Truce-Smiles substrate 283 in our 
hands.
24,195,196
 
 
2.2.2.2 RAMP or SAMP as chiral auxiliaries 
The Enders SAMP/RAMP hydrazone alkylation reaction  is one of the most common 
methods for the asymmetric alkylation of aldehydes and ketones, in which 
an asymmetric carbon-carbon bond formation reaction is facilitated by pyrrolidine chiral 
auxiliaries. This method was pioneered by E. J. Corey
198
 and D. Enders in 1976, and 
was further developed by D. Enders and his group.
189
 
The method is usually a three-step sequence; the first step is to form 
a hydrazone between (R)-1-amino-2-methoxymethylpyrrolidine (RAMP 286) or (S)-1-
amino-2-methoxymethylpyrrolidine (SAMP 287) (both are commercially available) and 
a ketone or aldehyde, Scheme 81. Afterwards, the hydrazone (288 or 291) 
is deprotonated by lithium diisopropylamide (LDA) to form an aza-enolate, which 
reacts with alkyl halides or other suitable electrophiles to give alkylated hydrazone 
species with the simultaneous generation of a new chiral centre. Finally, the alkylated 
ketone or aldehyde can be regenerated by ozonolysis or hydrolysis, Scheme 81.
199
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Scheme 81. The asymmetric alkylation of aldehydes and ketones. 
The first Enders SAMP/RAMP hydrazone alkylation began with the synthesis of the 
hydrazone from a N,N-dialkylhydrazine and a ketone or aldehyde, Scheme 82.
200
 The 
hydrazone was deprotonated on the α-carbon by a strong base, such as LDA, leading to 
the formation of a resonance stabilized anion - an aza-enolate. 
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Scheme 82. The first Enders SAMP/RAMP hydrazone alkylation. 
After deprotonation, the aza-enolate chelates with the lithium cation chelating both the 
nitrogen and oxygen, Scheme 83. There are two possible options for lithium chelation. 
One is that lithium is antiperiplanar to the C=C bond, leading to the conformation of ZC-
N; the other one is that lithium and the C=C bond are on the same side of the C-N bond, 
leading to the EC-N conformer. There are also two available orientations for the chelating 
nitrogen and R
2
 group, being either EC=C or ZC=C. Accordingly, the possible four 
different aza-enolate geometries corresponding to rotation around the C=C and C–N 
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bonds are 298a, 298b, 298c and 298d for the Enders' SAMP/RAMP hydrazone 
alkylation reaction, Scheme 83. 
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Scheme 83. The possible conformations of the aza-enolate chelates. 
In both cyclic and acyclic systems, trapping experiments,
201
 x-ray analysis
202
 and 
spectroscopic investigations and calculations
203,204
 have showed that one 
specific stereoisomer of the aza-enolate is favoured over the other three possible 
candidates. Therefore, although four isomers are possible for the aza-enolate, only one 
( 298a or ECCZCN), with the stereochemistry of its C=C double bonds being E and that 
of its C-N bond being Z stereochemistry, is dominant (EC=C ZC-N) for both cyclic and 
acyclic ketones.
202
  
The favoured aza-enolate 298a is the dominant intermediate for the subsequent 
alkylation reaction. There are two possible faces for accessing any electrophile to react 
with, Scheme 84. The steric interaction between the pyrrolidine ring and the 
electrophilic reagent hinders the attack of the electrophile from the top face. On the 
contrary, when the electrophile attacks from the bottom face, such unfavourable 
interaction does not exist. Therefore, the electrophilic attack proceeds from the 
sterically more accessible face (298a).
205
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Scheme 84.  Diastereoselective alkylation of a SAMP hydrazone. 
Furthermore, chelation of the lithium cation with the methoxy group is one of the most 
important features of the transition state for Enders' hydrazone alkylation reaction. It is 
necessary to have this chelation effect to achieve high stereoselectivity. The 
development and modification of Enders' hydrazone alkylation reaction mainly focus on 
the addition of more steric hindrance on the pyrrolidine rings of both SAMP and 
RAMP, while preserving the methoxy group for lithium chelation. The most famous 
four variants of SAMP and RAMP are SADP (300), SAEP (301), SAPP (302)  and 
RAMBO (303), Figure 18.
206,207
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Figure 18. Some variants of RAMP and SAMP. 
Hydrazones are usually very stable towards hydrolysis or other solvolysis conditions, 
suggesting that they require rather vigorous reaction conditions to be removed from the 
products. So far, three methods for cleaving the hydrazones have been 
reported.
208
 Oxidative cleavage is the most frequently used method due to the high 
yields obtained, but most oxidants may also react with olefins and other 
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oxidisable functional groups present. The oxidants most used are ozone (e.g. Scheme 
85, 305→ 306), sodium periodate, mCPBA, and peracetic acid. 
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Scheme 85. Ozonolysis of hydrazone 305. 
Although hydrolytic cleavage is the mildest method, the low yields obtained for 
relatively complicated substrates is a major problem. The reagents that are frequently 
used are methyl iodide with aqueous hydrogen chloride (Scheme 86, 308→ 309),209 
cupric salts, and other Lewis acids.
210
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 Scheme 86. Hydrolysis of hydrazone 308. 
Interestingly, Nicolaou attempted successfully the total syntheses of swinholide A (313) 
(an antifungal and cytotoxic marine isolate)
211
 and CP-225,917 (314) (a potent inhibitor 
of squalene synthase and farnesyl transferase)
212
 by utilising this alkylation 
methodology on both ketone- and aldehyde-derived RAMP hydrazones, as illustrated in 
Scheme 87. 
 
Results and Discussion 
71 
 
N
N
OMe
LDA then
O I
93%, one diastereomer
N
N
OMe
O
MeO
OMe
N
N
H OMe
TBSO t-BuLi then
CO2t-BuBr
99%, one diastereomer
N
N
H
TBSO
CO2t-Bu
O
O
O
O O
CO2HOH
HO
O
314
OMe
OH OH OH
O
OH
O
O
HO
O
OMe
OH OH
MeO
OOH
O
O
Swinholide A 313
310
311
312
315
316
317
OMe
Scheme 87. RAMP-hydrazone alkylations in natural product synthesis. 
Furthermore, the mild conditions used in the construction and removal of the 
hydrazones have made them an attractive protocol in the synthesis of synthetic 
intermediates for medicinally interesting natural products and other related organic 
compounds, such as the natural products (-)-C10-desmethyl arteannuin B, a structural 
analogue of the antimalarial,  artemisinin,
213
 the polypropionate metabolite (-)-
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denticulatin A and B isolated from Siphonaria denticulata,
214
 the potent inhibitor 
of sterol synthesis, zaragozic acid A,
215
 and the effective anticancer drugs epothilones A 
and B.
216
  
Such precedent inspired the use of RAMP or SAMP to induce chirality into our Truce-
Smiles rearrangement substrates. In order to apply such Enders' auxiliaries to the 
rearrangement, it was decided to obtain ketone-based substrates, and react them (for 
example 2-hydroxypropiophenone (261)) with RAMP (286) or SAMP (287). 
Unfortunately, despite the wide range of literature precedent no reaction occurred 
between 261 and 286, presumably because of salt formation occurring between the NH2 
of RAMP (286) and the phenolic OH from 261, Scheme 88. 
N
NH2
OMeOH O
+
N
NH3
OMe
O O
+
261 286  
Scheme 88. Salt formation occurring between RAMP (286) and 2-
hydroxyacetophenone  (261). 
Based on this undesired reaction, it was proposed to mask the phenolic hydroxyl group 
using the migrating aryl group (for example (1-fluoro-2-nitrobenzene (60)) rather than 
to resort to a protection/deprotection strategy. It is shown that extremely mild conditions 
can be used to prepare the similar substrates directly from commercially available 
material, in which the reactions are performed using equimolar amounts of both the 
ketone 261 and 1-fluoro-2-nitrobenzene (60) along with potassium carbonate (2.5 
equiv) in dimethyl sulfoxide at room temperature, Scheme 89.
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Scheme 89. Masking  the phenolic hydroxyl group using the migrating aryl group.  
However, as demonstrated by Snape, while revisiting the Truce-Smiles rearrangement, 
it was observed that on such exact substrates the isolated yield of the arylated ketone 
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intermediate was negligible because of the faster Truce-Smiles rearrangement, Scheme 
90.
31
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Scheme 90. Facile rearrangement of 59 to the C-arylated product 62.  
Therefore, in order to try and isolate the O-arylated product 263, it was better to protect 
the ketone functional group first. This can be achieved by the reaction of ketone 261 
with ethylene glycol, under Dean-Stark conditions, to prepare an acetal 318, Scheme 91.  
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Scheme 91. Protection of the ketone functional group by formation of an acetal. 
Following this scheme, acetal 318 was successfully prepared, and reacted with 60 to 
offer the O-arylated acetal 319 in 85% yield, Scheme 91. Following a successful 
synthesis of 319, the next step was the hydrolysis of the acetal in a mixture of 
acetone:water, containing para-toluenesulfonic acid (PTSA) as catalyst,  to regenerate 
the required carbonyl 263 in quantitative yield, Scheme 92. 
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Scheme 92. Hydrolysis of acetal 319. 
Having now prepared the required substrate (263), the synthesis of hydrazone 320 could 
be attempted between 263 and both RAMP (286) and SAMP (287), after which the 
prepared hydrazone 320 could undergo the attempted Truce-Smiles rearrangement 
under the established reaction conditions, in the hope  of generating the 
diastereomerically enriched product 321, Scheme 93. 
O
NO2
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N
OH N
N
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NO2
RAMP 286
established Truce-Smiles
rearrangement conditions
OMe
263 320 321
MeO
N
NLi
O
L
L
R1
Re face 
blocked
O
NO2
323
Scheme 93. Proposed rationale for generating diastereomerically enriched products. 
The final step would then be the hydrolysis of the diastereomeric product 321 to give 
the enantiopure product 324 (Scheme 94). Hydrazones are a particular type of imine and 
therefore can be hydrolysed in strong acid at reflux. Unfortunately, in this case, such 
vigorous conditions may cause racemisation at the carefully crafted chiral centre due to 
acid catalysed keto-enol tautomerism (epimerisation, see compound 325) which would 
lead to a loss of chiral induction (Scheme 94). As such other means would be needed 
which are applicable to hydrolyse the hydrazone under mild conditions, e.g. 
quaternisation followed by hydrolysis (Scheme 95) or by applying an 
oxidation/ozonolysis protocol, Scheme 96. 
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Scheme 94. Racemisation under vigorous reaction conditions. 
In order to perform such quaternisation and hydrolysis,  the hydrazine  321 would be 
subjected to methyl iodide in order to alkylate one of the nitrogens of the auxilary. 
These ionic species (326, 327) are more readily hydrolysed under  less aggressive acidic 
conditions and this hopefully without the concomitant racemisation, to offer the final 
enantiopure product 324, Scheme 95. 
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Scheme 95. Quaternisation and hydrolysis of hydrazones. 
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Scheme 96. Ozonolysis of 321 for hydrazone removal. 
Additionally, oxidation/ozonolysis may also be applicable by cleaving the double bond 
of the hydrazone 321 with ozone to generate the asymmetric product 324, Scheme 96. 
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Unfortunately, when attempting the strategy outlined in Scheme 93, the prepared diaryl 
ketone-based substrates 263 did not react with RAMP (286) under all conditions 
attempted, Scheme 97. 
O
NO2
N
N
OO
NO2
OMe
H2N
N
+
OMe
conditions
286263 320  
Reaction conditions: diaryl ketone 263 (1 eq.), RAMP (286) (1 eq.), toluene (0.1 M), 
Dean-Stark; or diaryl ketone 263 (1 eq.), RAMP (286) (1.1 eq.), toluene-4Å molecular 
sieves (0.1 M), Dean-Stark. 
Scheme 97. Attempts to make hydrazone 320. 
Nevertheless, despite this disappointment, and the fact that more success was being 
observed in a parallel strategy (Figure 19, page 77), the RAMP/SAMP strategy was 
temporarily abandoned in the hope of developing the rearrangement with amide 
substrates. 
 
2.2.2.3 The Truce-Smiles rearrangement on amide based-substrates 
Initial attempts focused on preparing achiral derivatives because the chiral version is 
costly and it was necessary to establish the reaction conditions rapidly, yet affordably. 
Therefore, it was decided to prepare and test a range of amide based-substrates 328 
(Figure 19, Box 1) to acertain their suitability in the Truce-Smiles rearrangement, and 
which were prepared because, to our knowledge, these kind of substrates have not been 
studied as precursors in the Truce-Smiles rearrangement before. Moreover, such amide 
substrates can be rendered chiral by the judicious choice of additional substituents (for a 
detailed explanation on the C2-symmetric auxiliaries attempted see section 2.2.2.4), 
Figure 19 Box 2. 
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Figure 19. Attempted Truce-Smiles rearrangement substrates (achiral, Box 1); Box 2 
shows three commercially available chiral amines with which to potentially make the 
reaction asymmetric. 
Work by Erickson and McKennon had  demonstrated that the analogous ester substrates 
had been seen to undergo a Truce-Smiles rearrangement, during their work on the 
synthesis of some anti-fungal compounds,
217
 and that under typical rearrangement 
conditions (NaH, THF, T≥0 ○C) such esters undergo the rearrangement through an 
intramolecular nucleophilic attack of the ester enolate onto the electrophilic proximal 
diarylether to generate an α–aryl compound, Scheme 98. However, unfortunately, such 
Truce-Smiles products spontaneously cyclise and tautomerise to form substituted 
benzofuran derivatives, which in doing so, racemises any chiral induction that may have 
been incorporated through other means (see enol form of 331, Scheme 98). 
Unfortunately, since ester substrates (i.e. 329, Scheme 98) readily tautomerise they 
cannot induce chirality so easily. Moreover, due to facile C-O bond rotation, C2-
symmetric auxiliaries cannot be used to develop a simple asymmetric variant. 
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Scheme 98. Loss of any induced chirality in 331. 
However, C2-symmetrical chiral auxiliaries can render amide enolates (Figure 19, Box 
2) enantiopure, compounds which maintain their selectivity due to the associated 
restricted C-N bond rotation.
218–220
 Moreover, since amide substrates are less vulnerable 
to cyclisation, the loss of any induced stereochemistry through tautomerisation should 
be minimal. 
The amide substrates (acetamide 333a and propanamide 337a, Scheme 99) were 
prepared from the ring opening of 2-coumaranone (281) or dihydrocoumarin (332) by 
nucleophilic attack of the amine (dibenzylamine or pyrrolidine) to prepare the 
corresponding amides; the products which theoretically could also be rendered 
enantiomerically pure with chiral amines (Figure 19, Box 2), ready for an asymmetric 
Truce-Smiles rearrangement to be attempted, if suitable conditions for an achiral 
rearrangement could be identified. 
At room temperature in dimethyl sulfoxide for 18.5 hours the diarylethers (334a and 
338a) were obtained, compounds that did not rearrange further, despite similar 
conditions being well established for such a rearrangement.
2,31
  It was proposed that the 
bulkiness of the dibenzylamine moieties was preventing any rearrangement taking place 
through a steric clash with the newly incorporated phenyl ring (see compound 334a, 
Figure 20).  
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Reaction conditions: lactone 281 or 332 (1 eq.), amine (1 eq.), toluene (0.1M), reflux, 4-
6 h; See Table 3 and 4 for the second step. 
Scheme 99. Preparation of amide substrates and their subsequent rearrangement. 
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Figure 20. Proposed clash between the phenyl rings in the diarylether of an acetamide 
based substrate preventing Truce-Smiles rearrangement. 
As such, a less bulky amide moiety, such as pyrrolidine, was sought to test if this was 
the case. However, after preparation of the pyrrolidyl-amides based substrates (333b 
and 337b) by the same method (Scheme 99), again there was no rearrangement 
observed under the same reaction conditions for either substrates. 
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Despite this, partial success in the reaction was achieved when it was found that leaving 
the reaction for longer and at higher temperatures resulted in rearranged diarylethers 
(335) and rearranged product (336) along with the corresponding diarylethers (334), 
Scheme 99 (see Table 3 for the results and conditions attempted). 
Table 3. Yield and conditions for making diarylethers (334), rearranged diarylethers 
(335), and rearranged product (336) of acetamide-based substrates in DMSO with 
K2CO3. 
Entry 
FNB 
(60) eq.
[a]
 
Temp. (
○
C) Time (h) (334a) %
[b]
 (335a) % (336a) % 
1 0.5 r.t.
[c]
 19 57 0 0 
2 0.5 60 8 12 27 8 
3 1 r.t. 19 37 5 6 
4 1 60 2 complex mixture 
5 1 r.t.-60 5 58 14 17 
6 1 r.t.-60 7 27 72 0 
7 1 r.t. 68 58 40 0 
8 2 r.t. 21 98 0 0 
9 2 60 20 complex mixture 
 
   
(334b) % (335b) % (336b) % 
10 1 r.t. 5 90 0 0 
11 1 60 5 43 19 20 
[a]
 FNB= 1-fluoro-2-nitrobenzene (60), 
[b]
 isolated yields based on the stoichiometry of 
FNB, 
[c]
 r.t.= room temperature.  
As shown in Table 3, it was found that increasing the temperature from room 
temperature to 60 
○
C (compare entries 3 with 5 or 6) allowed the rearranged product to 
be formed, however when increasing the number of equivalents of 1-fluoro-2-
nitrobenzene (60) to two equivalents, rather than the reaction going to completion, as 
expected, it stopped at the diarylether stage (entry 8). Therefore, it was proposed, rather 
impractically, that reducing the equivalents of 60 to 0.5 eq. may increase the ratio of 
rearranged products, through some unknown effects. Unfortunately, in the event at 
room temperature (entries 1, 3 and 8), this hypothesis was found not to be true. 
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Moving on to study the homologous substrates 337, The extended chain between the 
aryl ring and amide moiety in the propanamide-based diarylethers are longer by one 
extra methylene unit, a feature which was incorporated to prevent the proposed steric 
clash with the newly incorporated phenyl ring (as shown previously in Figure 20). In 
these substrates a 6-membered transition state should be adopted which appears be more 
common for the rearrangement. 
In that regard, there is evidence for both a 6-membered transition state for this type of 
rearrangement
23,24,196
 as well as for 5-membered transition states,
22,25,27,196,221
 both of 
which proceed via a spirocyclic-intermediate, whereby the spirocyclic Meisenheimer 
complex 339 (Scheme 100) is stabilised by the presence of the electron withdrawing 
nitro group at the ortho position.
222,223
 However, despite such precedent, only the 
acetamide-based substrates 333 gave any rearranged products, albeit in modest to good 
yields, whereas, despite testing a range of known conditions for similar rearrangements, 
the propanamide-based substrates 337 don’t rearrange and stop at the diarylether stage 
in quantitative yields (see Table 4 for results).
23,24,196
 
Table 4. Yield and conditions for making diarylethers of propanamide-based substrates 
(337)  using K2CO3 in DMSO. 
FNB (60) eq.
[a]
 Temp. (°C) Time (h)
[b]
 338a %
[c]
 
1 r.t.
[d]
 6 90 
1 60 2 98 
1 60 3 100 
   338b % 
1 r.t. 5 92 
[a]
 FNB= 1-fluoro-2-nitrobenzene (60); 
[b]
 when these reactions were left for 3 days only 
338 was observed; 
[c]
 isolated yields; 
[d]
 r.t.= room temperature. 
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Scheme 100. Five-membered transition state for the Truce-Smiles rearrangement of 
acetamide-based substrates 333. 
In order to find the best conditions for the Truce-Smiles rearrangement to occur, and 
before the chiral derivatives could be tested, a range of alternative conditions were 
studied using different solvents, bases, and temperatures, as shown in Table 5. Here it 
was deemed prudent to study the intramolecular rearrangement process alone (334a to 
336a, Scheme 101) rather than the two step process, since that would simplify the 
analysis of the crude reaction products as well as allowing efforts to concentrate on the 
complicated rearrangement step as opposed to the simple and established intramolecular 
SNAr step.  
In this regard, diarylether 334a was prepared and isolated from its corresponding amide 
and fluoro-2-nitrobenzene (60) and its rearrangement studied under a variety of 
conditions, Table 5. With regards to the diarylether of the analogous propanamide 
substrates (i.e. 338), trying to force the reaction conditions to rearrange the pure, 
isolated diarylethers (338b and 338a), met with failure, despite varying the solvent 
(DMSO, DMF, THF and DCM), base (K2CO3, CsOH, NaH, NaOMe) and temperature 
(r.t.→100 °C) for a reaction time of 6 hours; in all cases and conditions tested, this 
diarylether did not rearrange and only ever gave the unreacted starting materials. 
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Scheme 10. The attempted rearrangement of diarylether of acetamide-based substrate 
334a. 
Table 5. The conditions tested for the attempted rearrangement of diarylether of 
acetamide-based substrate 334a. 
Solvent Base (1.5 eq.) Room temp 60 
○
C 100 
○
C 
DMSO 
K2CO3 N.R
[a]
 C.M
[c]
 C.M 
NaH trace
[b]
 C.M C.M 
NaOMe N.R trace C.M 
CsOH N.R trace C.M 
DCM 
K2CO3 N.R N.R N.R 
K2CO3 (+TBAI) N.R N.A
[d]
 N.A 
NaOMe N.R N.R N.R 
CsOH trace N.R N.R 
 
CsOH (+TBAI) ~19 % N.A N.A 
THF 
K2CO3 N.R N.R N.R 
NaH N.R N.R N.R 
NaOMe N.R N.R N.R 
CsOH N.R N.R N.R 
DMF 
K2CO3 N.R N.R N.R 
NaH N.R N.R N.R 
NaOMe trace N.R N.R 
[a]
 N.R= no reaction; 
[b]
 by NMR;
 [c] 
C.M=
 
complex mixture; 
[d] 
N.A= not attempted. 
As can be seen from Table 5, all reactions in DCM, THF and DMF failed to give any 
rearranged products, except when CsOH/DCM or DMF/NaOMe were used, and in those 
cases, only trace amounts of product were observed by crude NMR. However, when 
explored further, the reaction in DCM with cesium hydroxide monohydrate as base, was 
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partially optimised and shown capable of supporting the rearrangement of diarylether 
334a, but only in the presence of a phase transfer catalyst (TBAI), which presumably 
transfers the inorganic base into the organic reaction media. Conversely, complex 
mixtures are often observed in DMSO with this intramolecular rearrangement, 
especially at elevated temperatures; nevertheless, product was observed with NaH, 
NaOMe and CsOH as base. This is contradictory to the intermolecular case (Scheme 
72)  where clean rearrangement occurs in DMSO. 
Having attempted to optimise the rearrangement and observing only a poor relationship 
between the conditions used, and the success of the rearrangement, it was decided to 
push forward with the previously established conditions (DMSO, K2CO3) and pursue 
the reaction further. Moreover, during this optimisation stage, it was found (Table 3) 
that the ratio of products obtained was dependent on the amide used. Therefore, 
attention was turned to acetamide-based substrates (333, Scheme 103), and a small 
study was embarked upon to see what effects on the rearrangement ratios were seen 
with amides prepared from a range of different amines, Scheme 102 and Table 6. For 
the synthesis of amides 333a-e, see the chemistry outlined in Scheme 99.   
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Scheme 102. Truce-Smiles rearrangement with acetamide substrates (333a-e
218
). See 
Table 6 for the reaction conditions. 
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Table 6. Reaction of acetamide substrates (333) with 60.
[a]
 
Entry Rearrangement 
precursor 
Product Yield (%)
[b]
 
 
 
1 
 334a 40 
333a 335a 23 
 336a 37 
2 
 334b 61 
333b 335b 0 
 336b 33 
3 
 334c 54 
333c 335c 24 
 336c 21 
4 
 334d 45 
333d 335d 6 
 336d 45 
5 
 334e 68 
333e 335e 21 
 336e 10 
[a]
 Reaction conditions: 60 (1.05 eq.), 333 (1.0 eq.), K2CO3 (2.5 eq.), DMSO (0.1M), 60 
°C, 24 h. 
[b]
 Isolated yields based on the stoichiometry of FNB (60). 
As can be seen from Table 6, the diarylether (334) is the major isolated product in all 
cases. Since the α-protons of the amide are also benzylic they should be acidic enough 
to be readily abstracted to form the desired amide enolate with K2CO3, prior to its 
intramolecular attack onto the proximal diarylether, formed in situ. In the event, the 
rearrangement appears to occur via a five-membered cyclic intermediate 339, Scheme 
103, and the desired rearranged diarylether (335) and rearranged only (336) products are 
also produced in modest yields. 
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Scheme 103. Proposed mechanism for the successful rearrangement via a five-
membered transition state and intermediate. 
Despite consuming all starting material (333) in these reactions, a mixture of the three 
possible products was usually formed (Table 6) with only 1.05 eq. of 60. As must be the 
case here, diarylether 334 rearranges intramolecularly to 336 faster than 60 reacts 
intermolecularly with 333. As such, 336 and 333 exist together during the reaction; 
reaction of 333 ultimately giving 334 and/or 336, and reaction of 336 giving 335. It was 
also demonstrated that isolated diarylethers (i.e. 334), can rearrange cleanly to 336 
under the standard rearrangement conditions (K2CO3, DMSO) in good yield (50% 
isolated yield, 100% based on recovered starting material). Additionally, attempts at 
reaction optimisation show that when the reaction is performed for 24 hours, the 
rearrangement (334 to 336) proceeds in other solvents (DCM, DMF, PhMe and THF), 
and with alternative bases (CsOH, NaH, NaOMe) as well, although such reactions were 
only studied by crude NMR, unlike the reaction/rearrangement of 333 to 334/335/336 
which only works in polar aprotic solvents such as DMSO and DMF; the x-ray crystal 
structure of 336a can be seen in Figure 21. 
N
O
O2N
OH
336a  
Figure 21. 
 
X-ray crystal structure of 336a (see appendix).
224
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In order to facilitate the future development of this reaction as an asymmetric variant, 
attempts were made to force the reaction by increasing the molar equivalents of 1-
fluoro-2-nitrobenzene (60), increasing the reaction temperature and changing base, 
Table 7, in the expectation that the complete formation of the rearranged products (335 
or 336) would occur. 
Table 7. Optimisation of the reaction between 333b and 60.
[a]
 
Entry 60 (eq.) Base (eq.) Temp. (°C) Product 
ratio
[b]
 
    334b 335b 336b 
1 2.0 K2CO3 (2.5) 25 80 20 0 
2 2.0 K2CO3 (2.5) 60 58 42 0 
3 2.0 K2CO3 (2.5) 100 49 51 0 
4 2.0 NaH (2.5) 60 40 55 5 
5 5.0 K2CO3 (2.5) 25 97 3 0 
6 5.0 K2CO3 (2.5) 60 70 30 0 
7 5.0 K2CO3 (2.5) 100 62 38 0 
8 5.0 NaH (2.5) 60 71 29 0 
9 10.0 K2CO3 (2.5) 25 100 0 0 
10 10.0 K2CO3 (2.5) 60 100 0 0 
11 10.0 K2CO3 (2.5) 100 100 0 0 
12 10.0 NaH (2.5) 60 54 46 0 
[a]
 Reaction conditions: All reactions were carried out with 333b (1.0 eq.), in DMSO 
(0.1 M) for 24 h. 
[b]
 Ratios based on 
1
H NMR integration of diagnostic signals relating 
to the newly generated CH of the rearranged products (335b and 336b) and the CH2 of 
the diarylether (334b). 
Surprisingly, upon increasing the number of molar equivalents of 60 from 
2.0→5.0→10.0 eq. the amount of diarylether (334b) also increased (Table 7), at all 
temperatures studied (25, 60, 100 °C), rather than an increase in the ratio of the 
rearranged products (335b and 336b), as was expected. The proposed rationale for the 
reaction halting at the diarylether (334b) stage may be due to the increase in the 
equivalents of the electrophile stabilising the electron-rich enolate of the diarylether 
(334b) formed during the first stage of the reaction rendering it unable to react further.  
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The assumption that the presence of excess 60 may be affecting the stability of the 
enolate resulted in a stronger base and alternative counter ion being examined; Table 7 
outlines the results of replacing K2CO3 with NaH. As can be seen, increasing the 
number of equivalents of 60 with NaH as base, at 60 °C, results in an irreversible 
deprotonation, which leads to an increase in the amount of rearranged diarylether 
(335b) formed compared to 334b, which peaks in the case with 10 eq., where an 
increase in the total rearranged products increased from zero (with K2CO3) to 46% (with 
NaH). Possibly, the smaller counterion (Na
+
) and irreversible deprotonation enables the 
formation of a tighter ion-pair thus favouring the rearrangement, whereas the more 
dissociated ion-pair with K
+
 is stabilised by the excess electrophile. 
NO2
F
OH O
NO2
338
O
R
60 337
O
R
NEt2
N N
O
R = NBn2,
N
, , ,
+
a b c d e
see Table 8
 
Scheme 104. Attempted Truce-Smiles rearrangement with propanamide-based 
substrates (337a-e
218
); see Table 8 for the reaction conditions. 
Despite observing a variety of products from these amides in the acetamide case, when 
the equivalent propanamide substrates were prepared and tested, Scheme 104 and Table 
8, again, only the diarylether products were observed under all conditions attempted 
(see below). Such results confirm that, at least on these substrates and under these 
conditions, the Truce-Smiles rearrangement doesn't occur via a six-membered transition 
state. 
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Table 8. Reaction products of propanamide-based substrates 337 with 60.
[a]
 
Entry Rearrangement precursor Product Yield (%)
 [b]
 
1 337a 338a 92 
2 337b 338b 92 
3 337c 338c 87 
4 337d 338d 90 
5 337e 338e 90 
[a]
 Reaction conditions: 337 (1.0 eq.), 60 (1.05 eq.), K2CO3 (2.5 eq.), DMSO (0.1M), 60 
°C, 24 h. 
[b]
 Isolated yields. 
As can be seen from Table 8, with precursors based on propanamide (337) structures no 
Truce-Smiles rearrangement occurred; instead only the diarylether products (338a-e) 
were isolated in near quantitative yields. In efforts to force the propanamide based 
substrates to undergo the rearrangement, the reaction temperature was increased to 100 
°C, but no rearrangement was observed at all, neither with the pyrrolidyl (337b) nor the 
dibenzyl (337a) derivatives; only the diarylethers (338b and 338a) were isolated, again 
in quantitative yields. Similarly, even when the reaction was left for 3 days at room 
temperature resulted in the same products being formed.  
Based on these collective findings, it is proposed that the rearrangement fails on the 
propanamide substrates due to the relatively high pKa of the α-protons of the amide 
(337), either when formed in situ or from isolated material. This is partially confirmed 
in the acetamide cases above where the same protons are also benzylic as well as alpha 
to the amide carbonyl, and the rearrangement works in those cases. 
 
2.2.2.4 Synthetic efforts to prepare chiral derivatives of the Truce-Smiles 
rearrangement precursors  
2.2.2.4.1 Amide-based chiral derivatives 
Chiral auxiliaries with C2-symmetry are well established at providing high levels of 
asymmetric control in numerous organic reactions, such as: reductions,
225–227
 Diels–
Alder reactions,
226,228
 halolactonisations,
229,230
epoxidation reactions
231
 and alkylation 
reactions of enolates.
229,232
Additionally, chiral amides have been extensively used as 
their lithium amides
233–239
 within organic synthesis as effective reagents for a wide 
range of chemical transformations including enantioselective addition reactions,
240,241
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reductions,
242,243
 alkylations,
244
 deprotonations,
245–247
 desymmetrisations
248,249
 and 
kinetic resolutions.
250,251
 
One particular example of interest is the work carried out by Kim et al. who attempted 
the synthesis of enantiopure β-mercaptocarboxylic acid (340) via the asymmetric 
conjugate addition of thioacetic acid to methacrylamide with chiral amine auxiliaries, 
Scheme 105.
252
 The enantiopure β-mercaptocarboxylic acid derivatives are key 
intermediates in the synthesis of some pharmaceutically important compounds, such as 
the antihypertensive drug captopril
253
  (341) and diltiazem (342),
254
 Figure 22. 
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Figure 22. Structure of enantiopure β-mercaptocarboxylic acid (340), captopril (341) 
and diltiazem (342). 
Kim et al. showed that the use of chiral auxiliaries with C2-symmetry resulted in 
excellent stereoselectivities (˃99% de) and good yields (80-90%) in the conjugate 
addition of thioacetic acid to the chiral methacrylamides, Scheme 105 (see Table 9 for 
conditions, yields, diastereomeric excess and the configuration of the major product).
252
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Reaction conditions: i) chiral  amines, DCM, TEA, 0 
○
C-r.t.; ii) AcSH, toluene, r.t.; iii) 
BBr3, DCM, 0.5 h and then aq. 1 M HCl, 70 
○
C, 4 h. 
Scheme 105. The conjugate addition of thioacetic acid to the chiral methacrylamides 
Table 9. Conditions, yield, percent de and major enantiomers of 345. 
Entry R 
Temp. (
○
C)/    
time 
Yield (%) de (%) R/S (major) 345 
1 
N
MeO
MeO
 
r.t./ 7 days 88 ˃99 S 
2 
N
PhPh
 
r.t./ 14 h 40 60 R 
3 
N
 
r.t./ 20 h 82 ˃99 S 
Based on this work and having established promising conditions for the achiral version 
of the amide-based substrates for the Truce-Smiles rearrangement (Scheme 103), 
preparation of the chiral substrate (for example 333f, Scheme 106) began starting with 
the reaction between 2-coumaranone (281) and (−)-bis[(S)-1-phenylethyl]amine (347) 
(see Table 10 for conditions studied). Unfortunately, under all conditions attempted 
(Table 10), none of the desired product (333f) was observed. Despite the exact same 
reaction being reported in the literature.
218
 This failure was attributed to the mild 
basicity and nucleophilicity of the chiral amine as well as the presence of α-substituents 
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(two methyl groups), which presumably increases the steric repulsion in the formation 
of an amide when it attacks the carbonyl carbon of 2-coumaranone (281), Scheme 
106.
255
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Scheme 106. The achiral and chiral versions of the amide-based substrates for the 
proposed Truce-Smiles rearrangement. 
Once prepared, the chiral acetamide-based substrate 333f would be subjected to the 
already established Truce-Smiles rearrangement conditions to ascertain the level of any 
diastereoselectivity induced, Scheme 107. 
OH
N
O
Ph
Ph
333f
F
NO2
+
established Truce-Smiles 
rearrangement conditions
OH
N
O
Ph
Ph
NO2
level of diastereoselectivity
induced?
60 336f
 
Scheme 107. The proposed enantioselective Truce-Smiles rearrangement. 
Despite numerous attempts it was not possible to prepare the chiral acetamide based 
substrate 333f by applying the procedure shown in Scheme 106. A strong base (n-butyl 
lithium) and established literature methods (see Table 10 for conditions attempted)
256
 
were tested in order to make the chiral acetamide based substrate 333f from the ring 
opening of 2-coumaranone (281) with (-)-bis[(S)-1-phenylethyl]amine (347) (Scheme 
108), but unfortunately, the product could not be prepared.  
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Reaction conditions: 2-Coumaranone (281) (1.0 eq.), (-)-bis[(S)-1-phenylethyl]amine 
(347) (1.5 eq.). For different conditions attempted see Table 10. 
Scheme 108. Failed attempts to prepare the chiral acetamide based substrate 333f. 
Table 10 Conditions attempted for making a chiral version of the Truce-Smiles 
rearrangement precursor 333f. 
Solvent Base Temp. Duration 
toluene - Reflux 19 h 
THF n-BuLi (1.5 eq.)  r.t. 6 h  
toluene - Reflux 24 h 
THF n-BuLi (1.5 eq.) r.t. 46 h 
toluene - Microwave: 150 
○
C, 300 W 
then 180 
○
C, 300 W 
30 minutes then 
15 minutes 
ethanol - Microwave: 150 
○
C, 150 W 
then 170 
○
C, 150 W 
30 minutes then 
30 minutes 
Furthermore, this unsuccessful result also can be partially supported by the corrigendum 
of Juaristi et al. when they attempted the synthesis of β-amino acids by the 
enantioselective alkylation and protonation of prochiral enolates.
257
 They declared that 
the preparation of 2-(2-hydroxyphenyl)-N,N-bis-(1S-a-phenylethyl)acetamide (333f), by 
refluxing 2-coumaranone (281) and (S,S)-bis-α-phenylethylamine  (347) in toluene 
(Scheme 108) would not occur,  and also that the reaction did not proceed even in the 
presence of strong Lewis acids such as diethylaluminium chloride, in a sealed ampoule, 
or under microwave irradiation. Moreover, Juaristi et al. demonstrated that the less 
bulky chiral amine 348 does react readily with 2-coumaranone (281) even under mild 
conditions to afford the chiral amide 349, Scheme 109.
256
 However, the chiral 
compound 349 was not prepared and used here since it is not C2-symmetric. 
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O
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CH3H2N
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95% yield
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N
281 348 349  
Scheme 109. The less bulky chiral amine 348 does react readily with 281. 
After the failure to secure a synthesis of 333f by the reaction of 347 with lactone 281 
(Scheme 108), attention turned to the precedent set by Muniz et al. who developed a 
successful route to the chiral acetamide-based substrate 333f, using (2-hydroxyphenyl)-
acetic acid (277) as starting material (Scheme 110). In their work, they protected the 
phenolic hydroxyl group of (2-hydroxyphenyl)-acetic acid (277) with a benzyl group, 
then converted the protected acid 279 to its acid chloride by reaction with thionyl 
chloride. The freshly prepared acid chloride intermediate was then reacted with (S,S)-
bis-phenylethylamine (347) to offer the protected enantiopure chiral amide 350 in 45% 
yield. Finally the protected amide (350) underwent hydrogenolysis to afford the desired 
enantiopure chiral substrate 333f, Scheme 110.  
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Scheme 110. Alternate approaches to the chiral acetamide-based substrate 333f. 
When applying the above same protocol to our case, the protected acid 279 was 
successfully prepared in 85% yield. Unfortunately, the reaction between the prepared 
acid chloride in situ with the chiral amine (347) did not offer the required protected 
chiral substrate 350, Scheme 111. 
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Scheme 111. The attempted preparation of 350 using an alternative approach. 
In order to check whether the failure of the reaction was due to the substrate (the acid 
chloride formation step) or the chiral amine, the methyl ester of 2-hydroxyphenyl acetic 
acid  (277) was used after masking the phenolic OH (with benzoyl 351a or benzyl 351b, 
Scheme 112). In the hope of offering the chiral amide which can be hydrolysed (in case 
of 350b) or hydrogenated (in case of 350a) to give the desired chiral amide substrate. 
Again, because the chiral amine 347 was poorly nucleophilic it could not attack the 
carbonyl of the ester substrate, therefore, no reaction occurred, Scheme 112. 
347
Ph N
H
Ph
+
O
N
O
Ph
Ph
O
O
O
351a R= benzyl
351b R= benzoyl
350a R= benzyl
350b R= benzoyl
R R
conditions
 
Reaction conditions: microwave: 351a-b (1 eq.) and 347 (1 eq.), 150 
○
C, 300 W for 30 
minutes in toluene or 200 
○
C, 300 W for 2 h in ethanol; or 200 
○
C, 300 W for 30 
minutes in chlorobenzene;  or 351a-b (1 eq.) and 347 (1 eq.) refluxed in toluene for 24 
h; or refluxed in ethanol for 24 h. 
Scheme 112. The attempted synthesis of the masked chiral amide 350. 
Surprisingly, under the same reaction conditions, substrate 351b reacted with an achiral 
amine (dibenzylamine, 346) and gave  the achiral amide analogue 352b in 98% yield, 
Scheme 113. This result supports the fact that the chiral amine (347) is too bulky (due 
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the presence of the two methyl groups) than the achiral amine (dibenzylamine, 346) and 
thus cannot attack the carbonyl carbon of 351b and make the corresponding chiral 
amide substrate 350b. 
346
Ph N
H
Ph
+
O
N
O
Ph
Ph
O
O
O
351b 352b 98%
Ph
O
Ph
O
condition
 
Reaction condition: 351b (1 eq.) and 346 (1 eq.) refluxed in toluene for 24 hours. 
Scheme 113. Preparation of the achiral amide 352b. 
Furthermore, the acid chloride of the derivative 2-methoxyphenyl acetic acid (353) was 
also subjected to the reaction with chiral amine 347 in a hope of preparing the O-
methylated chiral substrate 355, Scheme 114. If prepared successfully it could be 
potentially demethylated with borontribromide.  
346
O
N
O
Ph
Ph
O
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OH
353
356 98%
O
O
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354
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N
O
Ph
355
Ph
347
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Reaction conditions: i) (COCl)2, DCM, DMF, 1-3 h; ii) TEA, DMAP, DCM, r.t.→ 40 
○
C, 24 h; or 354 (1 eq.), 347 (1 eq.), toluene, reflux, 24 h. 
Scheme 114. The attempted preparation of the O-methylated chiral substrate 355. 
Unfortunately, this procedure only gave a negligible yield of the corresponding chiral 
amide 355, Scheme 114. In order to determine why the reaction failed, i.e., whether the 
acid chloride intermediate 354 had been formed or not, during a subsequent reaction a 
small sample was taken from the reaction mixture and reacted with the less bulky 
achiral amine 346. This reaction did give the corresponding achiral amide 356 in 98% 
yield, confirming the formation of the acid chloride 354 in situ, Scheme 114, and that 
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failure of the reaction was more likely due the undesired steric bulk of 347, as seen 
before.  
 
2.2.2.4.2 Ketone-based chiral derivatives 
Having experienced problems in preparing enantiomerically pure amide-based Truce-
Smiles rearrangement analogues, it was proposed that a possible reason might be the 
position of the carbonyl group on the alkyl section of the amide-based Truce-Smiles 
rearrangement precursors, i.e., the problems might be due to the amide-based substrates. 
As such, a shift back towards the attempted synthesis of 2-hydroxyacetophenone- or 2-
hydroxypropiophenone-based substrates (357) for the rearrangement was made (Figure 
24, Box 1), but this time with C2-symmetrical chiral amine auxiliaries, Figure 24, Box 
2. 
OH O
R1
357
N
Ph
Ph
N
R2
R1=
'
Box 1
N
R1=
Box 2
R2= H, CH3
Ph
Ph
 
Figure 24. 2-Hydroxyacetophenone- and 2-hydroxypropiophenone-based Truce-Smiles 
rearrangement substrates 357 with their chiral version (Box 2). 
This plan began by applying the literature precedent shown in Scheme 115,
258
 with the 
attempted bromination of 2-hydroxyacetophenone (59) and 2-hydroxypropiophenone 
(261),
259
 which would give the mono-brominated ketones 360. These brominated 
compounds 360 could then be reacted with amines (see Scheme 116 Box 1 and Box 2 
for achiral and chiral amines, respectively) to offer the required ketone-based Truce-
Smiles rearrangement precursors 357.
258
 Any subsequent successful Truce-Smiles 
rearrangement products would then give compound 361, Scheme 116. 
O
R
R= N N N
O
ON
, , ,
O
Br i) TEA, THF
ii) amines
358 359  
Scheme 115. Literature precedent for the preparation of α-amino ketone based 
substrates 359. 
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Scheme 116. The proposed ketone based substrates to undergo the rearrangement. 
Unfortunately, the bromination reaction
259
 (Scheme 117) only gave 66% yield (by 
NMR) of the mono-brominated product 360a, but due to its similar Rf value to the 
corresponding precursor (2-hydroxyacetophenone (59)) its isolation was not possible. 
We were unable to separate it by derivatisation with either 1-fluoro-2-nitrobenzene (60) 
or acetyl chloride. Furthermore, in an attempt to achieve its isolation, the mixture was 
reacted with (-)-bis[(S)-1-phenylethyl]amine (347) and pyrrolidine in separate 
experiments but they did not give rise to any products either. Similarly, bromination of 
2-hydroxypropiophenone (261) to prepare 360b was also unsuccessful. 
59   R=H
261 R=Me
362
OH O
CuBr2
OH O
Br
+
reflux, 16h
EtOAc, chloroform
OH O
+
R
R R
59   R=H
261 R=Me
360a R=H
360b R=Me  
Scheme 117. Bromination of 2-hydroxyacetophenone (59) and 2-
hydroxypropiophenone (261) 
Precedent for such a reaction was also taken from Yu et al. who attempted the synthesis 
of the hydantoin based tumour necrosis factor-α (TNF-α) converting enzyme inhibitors 
(TACE). As shown in Scheme 118, the chlorinated propanone 363 reacted with 
dibenzylamine to give 364, which was further converted to a hydantoin via the 
Bucherer–Bergs reaction.260 Reductive debenzylation yielded the desired amine 365. 
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Hydantoin 365 was coupled with 5-methoxy-2-nitrobenzoic acid to afford amide 366 
which was converted to 367 in the presence of zinc and NaOH in low to moderate 
yield.
261
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Reaction conditions: i) Bn2NH, Et3N, THF, r.t., 3 days, 89%; ii) KCN, (NH4)2CO3, 
EtOH/H2O (1:1), 70 
○
C 8 h, 86%; iii) H2, 50 psi, Pd(OH)2/C, EtOH/MeOH (5:1), r.t., 48 
h, 95%; iv) 5-methoxy-2-nitrobenzoic acid, EDCI, HOBT, NMM, DMF, r.t., 16 h, 85%; 
v) Zn, NaOH, MeOH/H2O (1:1), 75 
○
C, 20 h. 
Scheme 118. The synthesis of hydantoin based tumour necrosis factor-α (TNF-α) 
converting enzyme inhibitors (TACE). 
Supported by such precedent, and in light of the failure met in Scheme 117, pure 
bromo-2-hydroxyacetophenone (360a) was purchased from Sigma Aldrich and reacted 
with dibenzylamine (346) in dichloromethane in the presence of triethylamine to give 2-
(dibenzylamino)-1-(2-hydroxyphenyl)ethanone (368a)) in 52% yield which was 
characterised by 
1
H NMR and 
13
C.
260
 However, in a similar manner to that already 
observed with other substrates, reaction with chiral (-)-bis[(S)-1-phenylethyl]amine 
(347)  using the same reaction conditions failed to give the corresponding chiral product 
368b, Scheme 119. 
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Scheme 119. The attempted preparation of the chiral ketone-based susbtrates. 
Based on these failed results, and on the assumption that the anomaly was due the bulky 
chiral amine not the substrate, attempts at the reaction were made with other related C2-
symmetrical chiral amines (369 and 370) which are also comercially available, Figure 
23.   
369
HN
OMe
OMe
HN
370
OH
O
R
333g R= 369
333h R= 370  
Figure 23. Other commercially available C2-symmetrical chiral amines 
In the event, the trial began with (2R,5R)-(-)-2,5-bis(methyl)pyrrolidine (369). Like its 
achiral derivative (pyrrolidine), it was hoped that (2R,5R)-(-)-2,5-bis(methyl)pyrrolidine 
(369) would reacted with 2-coumaranone (281) at reflux in toluene,
218
 to offer the 
desired product 333g (Scheme 120). Fortunately, this time, the chiral substrate 333g 
was prepared and isolated in good yield (73%), presumably because the small methyl 
groups cause less steric hindrance than the two phenyl groups of 347 and therefore, they 
do not prevent the nucleophilic substitution with 281 occurring. After which, 333g was 
subjected to the typical rearrangement reaction conditions (60 (1.05 eq.), K2CO3 (2.5 
eq.), DMSO (0.1M), r.t., 24 h), a reaction which resulted in a diastereomeric mixture of 
rearranged products 335 (1.7:1 dr, 5%), 336 (1:1.9 dr, 36%), along with the diarylether 
334 (54%), Scheme 115. 
Results and Discussion 
101 
 
N
O
O
NO2methyl group 
prevents
Re face attack
Si face attack
OH
N
O
333g
O
O
N
O2N
NO2 OH
O
N
NO2
336g 1:1.9 dr
60
K2CO3, DMSO
+
371
O
N
O
334g
O2N
O
O +
281 369
HN
OH
N
O
333g 73%
toluene
reflux
+
 335g 1.7: 1 dr
K
 
Scheme 120. Reaction between enantiomerically pure amide 333g, and 60, showing the 
diastereomeric rearranged products produced. Compound 371 outlines a suggested 
mechanism through which the partial diastereoselectivity was achieved. 
Despite the successful rearrangement, the overall yields of rearranged products when 
using (2R,5R)-(-)-2,5-bis(methyl)pyrrolidine (369) was only 41% (335 (5%) and 336 
(36%)), therefore, the reaction was repeated with (2S,5S)-(+)-2,5-
bis(methoxymethyl)pyrrolidine (370) in the hope of giving improved yields the of 
rearranged products, Scheme 121. 
Accordingly, the same reaction as that depicted in Scheme 121 was repeated and an 
enantiomerically pure substrate (333h) was prepared from the reaction of (2S,5S)-(+)-
2,5-bis(methoxymethyl)pyrrolidine (370) with 2-coumaranone (281) at reflux in 
toluene;
257
 the product 333h was isolated in excellent yield (99%). Again, presumably 
the success of the reaction means that the amine (370) must not be too bulky as to 
prevent reaction with lactone 281. In the event, subjecting 333h to the typical 
rearrangement reaction conditions (60 (1.05 eq.), K2CO3 (2.5 eq.), DMSO (0.1M), r.t., 
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24 h) resulted in a slightly improved yield of diastereomeric mixtures of rearranged 
products (335h (1.6:1 dr, 10%) and 336h (1:1.6 dr, 45%)), Scheme 121.  
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Scheme 121. Reaction between enantiomerically pure amide 333h, and 60, showing the 
diastereomeric rearranged products produced. 
Through observation of all related 
1
H NMR of the rearanged products, it appears as 
though there is a diagnostic 
1
H NMR signal for the CH proton for amides 336a-e and 
335a-e, where, in all cases with compound 335, the newly formed CH resonates furthest 
downfield at values greater than 6.0ppm (presumably the result of an additional 
electron-deficient ring in these structures), whilst four out of the five amides 
incorporating the structure of compound 336, resonate at upfield values of less than 
6.0ppm, such that their average values can be summarised as 6.29±0.15 (for 335a-e, 
where the error is ± standard deviation) and 5.77±0.42 (for 336a-e – see Experimental 
Section). As such, this diagnostic feature enabled us to both determine the identity of 
rearranged products (335h and/or 336h) formed in the asymmetric reaction from the 
crude 
1
H NMRs, and determine the diastereomeric ratios obtained for each (i.e. (S,S,S)-
335h:(R,S,S)-335h and (S,S,S)-336h:(R,S,S)-336h.
262
 Figure 24 outlines the diagnostic 
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section of the 
1
H NMR of the crude reaction mixture from the scheme shown in Scheme 
121. 
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Figure 24. Diagnostic section of the 
1
H NMR of the diastereomers of 335h (6.29 and 
6.18ppm) and 336h (5.99 and 5.92ppm) as determined from the CH signal of the α-
proton to the amide. 
Using these diagnostic signals it can be calculated that the presence of the enantiopure 
auxiliary resulted in rearranged products with a dr= 1.6:1 (335h) and dr= 1:1.6 (336h). 
Furthermore, when the rearrangement was carried out on the chiral analogue of 333f 
possessing the chiral auxiliary—trans-dimethylpyrrolidine (333g)—the ratios were dr= 
1.7:1 and dr= 1:1.9 respectively for the analogous products. Moreover, it is also possible 
that the dr induced during the reaction is actually higher than that observed in the crude 
1
H NMR since the rearranged products are prone to racemisation due to the increased 
acidity of the CH proton on migration of the aromatic ring (pKa of phenol ~18.0 
(DMSO) and pKa of 1,1-diphenylcarbonyls ≥18.75 (DMSO).263 Therefore, in an effort 
to ascertain whether the dr observed was kinetic or thermodynamic, a rearrangement of 
pure isolated 334h was performed in which aliquots were taken and quenched every 
hour, and their NMR analysis performed. The results indicated an initial dr of 1:1 (after 
1 h) which changed to 1.35:1 (after 4 hours), and then surprisingly swapped over to 
1:1.54 after 5 hours, a ratio that did not change further over the course of the reaction (7 
hours). Although these diastereomeric ratios are relatively low, they are un-optimised, 
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and thus suggest potential may exist in this mild method for generating enantio-enriched 
chiral centres with chiral auxiliaries via an aryl-migration rearrangement reaction.   
Moreover, attempts to optimise the dr were attempted by subjecting 334h to a range of 
rearrangement conditions [solvent (DMSO, DMF, THF, PhMe, CHCl3 and DCM), base 
(K2CO3, CsOH, NaH, NaOMe)], but under all conditions tested, the same 
(thermodynamic) ratio of ~1:1.6 was obtained. These results prompted us to propose 
that the rearrangement is not as simple as first presumed, but that the known role of the 
starting (and presumably product) phenols (i.e. 333h and 336h) to act as enantiopure 
Brønsted acids (as has been shown in the asymmetric protonation of amide enolates),
256
 
may be playing a part; an effect that needs further investigation.  
This proposed limitation of in situ epimerisation could potentially be mitigated through 
the preparation of quaternary centres, therefore, to this end, diarylether 334h was 
subjected to α-methylation with methyl iodide (372) prior to its attempted 
rearrangement, upon which, if successful, a non-epimerisable quaternary carbon centre 
would be formed, Scheme 122. 
O
O
NO2N
373
OMe
OMe
O
N
O
334h
OMe
OMe
O2N
MeI 372
 
Scheme 122. The attempted preparation of a C-methylated product. 
Unfortunately, α-methylation did not result in a C-methylated product, but instead gave 
the methyl enol ether 374 (50% yield), Scheme 123. 
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Reaction conditions: diarylether 334h (1 eq.), NaH (1 eq.), MeI (1 eq.), THF (0.1 M), 
r.t., 24 h. 
Scheme 123. Attempted α-methylation of diarylether 334h. 
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To prevent waste of the costly chiral diarylether 334h, it was proposed to alkylate the 
starting material (2-coumaranone (281)) with an alkylating agent at the start, to make 3-
methyl-2-coumaranone (377 R= CH3) in order to prevent the rearranged products (379) 
from racemisation (Scheme 124). As shown in Scheme 124, if the substrate is not 
alkylated at the α-position it would undergo Truce-Smiles rearrangement to give a 
compound which in turn may enolise (375). After work up, the enolate intermediate 
would be protonate non-selectively giving racemised products (see compound 376). 
However, when the Truce-Smiles rearrangement precursor is alkylated at the α-position 
to the carbonyl carbon (such as compound 377) it should undergo such a rearrangement, 
with no enolisation (see compound 378) as there is no α-proton to the carbonyl carbon 
to be abstracted by the base, and therefore there will be no loss in any asymmetry which 
is generated during the aryl transformation step, Scheme 124. 
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Scheme 124. Proposed mechanism for racemisation in the Truce-Smiles product (top) 
and α-alkylated precursors which may give enantioenriched products (bottom). 
To test the hypothesis shown in Scheme 124, α-alkylation of 2-coumaranone (281) with 
methyl iodide was attempted as a method to make 3-methyl-2-coumaranone (377, 
Scheme 125). Unfortunately, none of the reported conditions attempted provided the 
desired methylated product 377, Table 11. The pKa for the α-hydrogen in cyclic esters 
(i.e., lactones such as 281) is about ~23-25 however using stronger bases such as LDA 
(pKa ~35) should easily be able to abstract the α-proton to give the enolate intermediate 
to attack methyl iodide. Despite this, there are no known reported methods for the  α-
methylation of 281, and in all cases attempted here the reaction provided 2-
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hydroxyphenyl acetic acid (277), which suggested base catalysed hydrolysis was taking 
place despite efforts being made to remove water in these reactions.
264
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Scheme 125.  The attempted α-methylation of 2-coumaranone (281). For conditions 
attempted see Table 11. 
Table 11. Conditions attempted to make 3-methyl-2-coumaranone (377) using methyl 
iodide (1 eq.) and 2-coumaranone (1 eq.). 
Condition Solvent Base Time Temp 
1 THF NaH (1 eq.) 16 h r.t. 
2 THF TEA (1 eq.) 16 h r.t. 
3 DMF K2CO3 (1 eq.) 16 h r.t. 
4 THF LDA (1.2 eq.) 16 h -5 
○
C 
Due to the negative results of α-alkylation, both prior to and after arylation, attention 
was turned to a more reactive species in the hope of α-acylating diarylether 334h with 
methylchloroformate (380) prior to its attempted rearrangement. In this case, with such 
a Truce-Smiles substrate as 381 (Scheme 126), a non-epimerisable quaternary carbon 
centre would be formed. 
With methylchloroformate (380) as electrophile, the diarylether 334h was successfuly 
α-acylated and a pleasing diastereomeric ratio of 11:1 (83% de) was achieved in the 1,3-
dicarbonyl product 381 in 57% yield, indicating that the chiral auxiliary is capable of 
inducing diastereoselectivity in these substrates, although no efforts was made to 
ascertain the absolute structure of the newly incorporated chiral centre. 
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Reaction conditions: diarylether 334h (1 eq.), NaH (1.5 eq.), methylchloroformate 380 
(1.05 eq.), THF (0.1 M), r.t., 24 h. 
Scheme 126. The α-acylation of diarylether 334h with methylchloroformate (380). 
Despite Jørgensen's work, who has revealed a successful nucleophilic aromatic 
substitution reaction to produce eneantiopure products from 1,3-dicarbonyl compounds 
(see section 2.2.1),
182,185
 attempts to produce a quaternatry carbon centre via aryl 
migration of this 1,3-dicarbonyl compound 381, using the standard rearrangement 
conditions, resulted in failure; possibly due to competing ester hydrolysis consuming 
base, or the newly introduced group imparting increased steric hindrance that cannot be 
overcome under the standard conditions of rearrangement. Nevertheless, that a major 
diastereomer of the 1,3-dicarbonyl had indeed been produced was confirmed when, 
subject to the rearrangement conditions, it was shown to epimerise to 54% de by crude 
NMR. 
In summary, the preliminary efforts to produce an asymmetric Truce-Smiles 
rearrangement—a new and potentially mild method to produce enantiomerically 
enriched α-aryl carbonyl compounds—met with modest success as demonstrated in the 
application of the rearrangement to novel amide substrates. It has also been 
demonstrated that amide precursors that proceed through a five-membered spirocyclic 
transition state rearrange, whereas those proceeding through a six-membered transition 
state don’t, but stop at the diarylether stage. In the initial efforts, only modest 
diastereoselectivies (dr= max. 1.7:1) are observed. 
 
2.3 Towards an asymmetric α-acylation of carbonyl compounds via the Baker-
Venkataraman rearrangement 
1,3-Dicarbonyl compounds (the products from the Baker-Venkataraman rearrangement) 
are  very useful synthetic platforms owing to the presence of contiguous reaction sites 
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with  an  alternative  electrophilic  and  nucleophilic  character, which can be modulated 
by the nature of the substituents, Figure 25. Recent studies revealed that 1,3-dicarbonyl 
compounds can undergo different mono, domino  and  multi-component  reactions to 
offer a variety of achiral and chiral products,
265
 such as the naturally occurring anti-
Alzheimer product huperzine A,
266
 the  polyprenylated phloroglucinol natural product 
clusianone,
267
 the potassium  channel  opener  ZD0947,
268
 1,4-dihydropyridines  (an 
important  class of bioactive molecules and also interesting biomimetic reducing 
agents),
269
 the Ipecacuanha alkaloid emetine and Alagium alkaloid tubolisine,
270
 SNAP-
7941,  a  potent  melanin concentrating hormone receptor antagonist,
271
 and the alkaloid 
(–)-lupinine,272 Figure 25. 
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Figure 25. 1,3-Dicarbonyl compounds: a powerful synthetic platform. 
As mentioned previously (Section 1.2), the Baker-Venkataraman rearrangement can be 
regarded as an O→C acyl migration with a mechanism similar to its Truce-Smiles aryl 
rearrangement analogue. Based on this, it was considered that in a similar manner chiral 
auxiliaries could be used to induce chirality during acyl group migration, Scheme 127. 
+
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Scheme 127. Expected asymmetry induction (R
3
= chiral auxiliary). 
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2.3.1 The Baker-Venkataraman rearrangement on amide based-substrates 
In order to assess the strategy depicted in Scheme 127 and attempts to make a chiral 
version of the Baker-Venkataraman rearrangement,  it was decided to utilise the already 
prepared Truce-Smiles rearrangement precursors,  because it had been proven that such 
acetamide-based substrates (333a-e) are susceptible to the related Truce-Smiles 
rearrangement. Accordingly the plan was to acylate these precursors with variety of 
acetylating groups, Scheme 128. 
auxiliary included 
for generating
a chiral enolate
N
O
alternative auxiliary
R= CH3, OCH3, Ph
N
O
K
O
O
methoxymethyl 
group prevents
Re face attack
Si face attack
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N
O
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O
N
OMeO
R
established
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OR
OMe
OMe
MeO
OMe
R
386 387
388
333h
O
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Scheme 128. Attempted rearrangement of an enantiomerically pure amide, such as 386. 
Compound 388 outlines a plausible mechanism through which the asymmetry could be 
induced. 
Once the reaction conditions had been established for an achiral version of the Baker-
Venkataraman rearrangement, the chiral version would be attempted. To do that the 
already chiral Truce-Smiles rearrangement precursors would be utilised to induce the 
asymmetry during the acyl transformation (Scheme 128) since it was observed that they 
can induce (albeit weak) asymmetry in the case of the Truce-Smiles rearrangement and 
that excellent diastereoselectivities are seen when an acyl group is involved, Scheme 
126. 
The process began with acetamide-based rearrangement precursors (333) because 
successful rearrangements had been observed with both the chiral and achiral versions 
previously (with both a bulky R
1
 group (333a) and a small R
1
 group (333b)). The plan 
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was to acylate these acetamides with different acyl groups and then to perform the 
Baker-Venkataraman rearrangement using established conditions found in the literature 
for such a rearrangement, Scheme 129, and determine types of product produced. 
R2= methyl, methoxy, phenyl
O
O
R2OH
acylation
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Baker-Venkataraman 
rearrangement conditionsR
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O
N N
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NN Ph
Ph
, , ,R
1=
333 389 390
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a b g h
 
Scheme 129. The proposed acylation and subsequent rearrangement on amide-based 
substrates. 
The acetamide-based rearrangement precursors 333a,b acylated cleanly with a variety 
of acetylating groups to offer the acetylated Baker-Venkataraman rearrangement 
precursors  389a-f in excellent yield (93-100%), Scheme 130 and Table 12. 
Consequently, the acetylated acetamides were subjected to a variety of reaction 
conditions to give the corresponding Baker-Venkataraman rearranged 1,3-dicarbonyl 
products (390a-f).  
However, during the reactions, despite the strenuous use of anhydrous solvents, 
molecular sieves and following procedures found in the literature,
3,82,86,123,273
 none of 
the acetylated Baker-Venkataraman rearrangement precursors 389a-f (see Table 12) 
gave the rearranged product 290a-f presumably because, these acetamide derived 
precursors suffered from facile hydrolysis (see Table 12 for percent of hydrolysis), 
Scheme 130. 
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, TEA, DMAP
DCM, r.t., 16h
R1
O
conditions
389a-f 390a-f
333a R1= N,N-dibenzyl amino
333b R1= pyrrolidyl
O
R2
OR2
HO
see Table 12
R2
O
Cl
	  R1	                                R2
a	N,N-dibenzyl amino	     methyl
b	N,N-dibenzyl amino	     phenyl
c	N,N-dibenzyl amino	     methoxy
d	pyrrolidyl	                      methyl
b	pyrrolidyl	                      phenyl
f	 pyrrolidyl	                      methoxy
 
Reaction conditions:  NaH (2.5 eq.), anhydrous THF (0.1M), reflux, 1-2 h; or NaH (3 
eq.), DMSO (0.1M), r.t., 2-3 h; NaH (2.5 eq.), toluene-4Å molecular sieves (0.1M), 100 
○
C, 1-2 h; KOtBu (2.2 eq.), anhydrous THF-4Å molecular sieves (0.1M), reflux, 1 h; 
KOtBu (2 eq.), DMF (0.1M), r.t., 1-2 h; NaH (2.5 eq.), anhydrous THF-4Å molecular 
sieves (0.2M), reflux, 1-2 h. 
Scheme 130. Attempted acylation and concomitant rearrangement of acetamide-based 
precursors. 
Table 12 Acetamide-based precursors 389a-f used in the Baker-Venkataraman 
rearrangement 
Entry R
1
 R
2
 
Acylated 
products
 
(%)
[a]
 
Hydrolysed 
products (%) 
a N,N-dibenzyl amino methyl 96 100 
b N,N-dibenzyl amino phenyl 100 100 
c N,N-dibenzyl amino methoxy 99 100 
d pyrrolidyl methyl 100 100 
e pyrrolidyl phenyl 93 100 
f pyrrolidyl methoxy 100 100 
 
[a]
 Isolated yields. 
As can be seen from Table 12, the acylated acetamide-based substrates  389a-f  fully 
hydrolysed under the rearrangement conditions used. These results can partially be 
supported by the fact that the acylated acetamide-based substrates  389a-f presumably 
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rearrange via a five-membered cyclic intermediate 391 (Scheme 131), which can 
undergo a presumably slower Baker-Venkataraman rearrangement, or a faster 
hydrolysis to give the rearranged product 390a-f or the hydrolysed product 333a,b, 
respectively, Scheme 131. 
	  R1	                      R2
a	N,N-dibenzyl amino	  methyl
b	N,N-dibenzyl amnio	  phenyl
c	N,N-dibenzyl amino     methoxy
d	pyrrolidyl	                   methyl
b	pyrrolidyl	                   phenyl
f	 pyrrolidyl	                   methoxy
333a R1= N,N-dibenzyl amino
333b R1= pyrrolidyl
O
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O
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Scheme 131. A plausible mechanism behind the hydrolysis of the acylated acetamide-
based substrates  389a-f. 
It was proposed that the Baker-Venkataraman rearrangement failed here because the 
acylated acetamide based substrates 389a-f were not able to form a six-membered cyclic 
intermediate 394 as is the case in almost all Baker-Venkataraman rearrangements 
reported.
64,67
 On this basis, the acylated propanamide-based rearrangement precursors 
392a-f were employed in hope that they would undergo the rearrangement via a six-
membered cyclic intermediate 394, Scheme 132. 
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a	N,N-dibenzyl amino	  methyl
b	N,N-dibenzyl amnio	  phenyl
c	N,N-dibenzyl amino     methoxy
d	pyrrolidyl	                   methyl
b	pyrrolidyl	                   phenyl
f	 pyrrolidyl	                   methoxy
337a R1= N,N-dibenzyl amino
337b R1= pyrrolidyl
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Scheme 132. The proposed acylation and subsequent rearrangement of propanamide-
based substrates. 
Although, the propanamide-based substrates 337a,b acetylated successfully (89-100% 
yield, as shown in Table 13), despite attempting different documented conditions the 
acylated propanamide-based substrates  392a-f failed to undergo the Baker-
Venkataraman rearrangement. Instead, like their acylated acetamide-based analogues 
389a-f, they underwent facile hydrolysis, Scheme 132 and Table 13.
3,14,86,273
 
 
 
 
 
 
Results and Discussion 
114 
 
	  R1	                      R2
a	N,N-dibenzyl amino	  methyl
b	N,N-dibenzyl amnio	  phenyl
c	N,N-dibenzyl amino     methoxy
d	pyrrolidyl	                   methyl
b	pyrrolidyl	                   phenyl
f	 pyrrolidyl	                   methoxy
337a R1= N,N-dibenzyl amino 
337b R1= pyrrolidyl
, TEA, DMAP
DCM, r.t., 16h
Rearrangement
OH R1
O
O R1
O
OH R1
O
392a-f 393a-f
R2 O
R2
O
Cl
R2
O
Reaction conditions:  NaH (2.5 eq.), anhydrous THF (0.1M), reflux, 1-2 h; or NaH (3 
eq.), DMSO (0.1M), r.t., 2-3 h; NaH (2.5 eq.), toluene-4Å molecular sieves (0.1M), 100 
○
C, 1-2 h; KOtBu (2.2 eq.), anhydrous THF-4Å molecular sieves (0.1M), reflux, 1 h; 
KOtBu (2 eq.), DMF (0.1M), r.t., 1-2 h; NaH (2.5 eq.), anhydrous THF-4Å molecular 
sieves (0.2M), reflux, 1-2 h. 
Scheme 132. The attempted acylation and concomitant rearrangement of propanamide-
based precursors. 
Table 13. Propanamide-based rearrangement precursors 337a,b prepared for the 
attempted Baker-Venkataraman rearrangement 
Entry R
1
 R
2
 
Acylated  
products
 
(%)
[a]
 
Hydrolysed 
products (%) 
a N,N-dibenzyl amino methyl 91 100 
b N,N-dibenzyl amino phenyl 100 100 
c N,N-dibenzyl amino methoxy 93 100 
d pyrrolidyl methyl 100 100 
e pyrrolidyl phenyl 94 100 
f pyrrolidyl methoxy 89 100 
[a]
 Isolated yields. 
In order to determine whether the Baker-Venkataraman rearrangement reaction failure 
was due to the amide-based substrates or the acyl group, a literature example using a 
carbamoyl group was prepared and tested. 
When Snieckus et al. attempted the synthesis of substituted 4-hydroxycoumarins 
(Scheme 134), they found that N,N-diethyl-carbamoyl  Baker-Venkataraman  
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rearrangement  precursors 152 underwent such a rearrangement to afford the 1,3-
dicarbonyl products 153 in modest to excellent yields (78-97%), Scheme 134.
94
 
O O
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N
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reflux, 1-3h
OH O
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O
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R1= H, CH3
R2= 3-OCH3, 5-OCH3, 6-OCH3, 6-Cl, C4H4, 4,5-OCH2O
152
 
Scheme 134. N,N-Diethyl-carbamoyl precursors 152 rearranged to 1,3-dicarbonyl 
products 153. 
Accordingly, the pyrrolidine-based substrate (333b) (Scheme 135) was acylated 
successfully using N,N-diethyl carbamoyl chloride (395) to give the carbamoyl-based 
Baker-Venkataraman rearrangement precursors  396 in good yield (57%), Scheme 135. 
N
OH
conditions
O
N
O
Cl+
N
O
O
N
O
333b 395 396  
Reaction condition: pyrrolidine-based substrate (333b) (1 eq.), N,N-diethyl carbamoyl 
chloride (395) (1.1 eq.), TEA (1.5 eq.), DMAP (0.1 eq.), DCM (0.1 M), r.t., 16 h.  
Scheme 135. Carbamoylation of pyrrolidine-based substrate (333b). 
Despite the precedent set by Snieckus et al. showing that carbamoyl groups readily 
undergo the Baker-Venkataraman rearrangement using sodium hydride (2.5 equivalent) 
(Scheme 134), the reaction again failed in our case. The diagnostic signal in the crude 
1
H NMR would be a singlet for one proton around 4.00 ppm as an indication for the 
rearranged product, however instead we found a singlet for two protons at 3.70 ppm 
with a singlet for a phenolic OH at 10.37 ppm, which both indicate the hydrolysed 
product (333b). Additionally, more documented Baker-Venkataraman rearrangement 
conditions were also tried but in all cases they resulted in 100% hydrolysed product. 
68,69
 These results would support that the problem with the Baker-Venkataraman 
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rearrangement reaction can be attributed to the amide-based substrate, as presumably 
they suffer from faster hydrolysis compared to the rate of rearrangement, Scheme 136.  
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OH
N
ON
 
Scheme 136. Attempted rearrangement of the carbamoylated pyrrolidine-based 
substrate (333b). 
 
2.3.2 The Baker-Venaktaraman rearrangement on ketone-based substrates 
The rearrangement of o-aroyloxyacetophenones 113 to o-hydroxydibenzoylmethanes 
114 by basic reagents (such as sodium amide, sodium ethoxide, potassium carbonate, 
sodium hydroxide) have been reported numerous times in the literature, Scheme 137. 
68-
76
  
O
O
O OH O O
114113
basic reagents
R R
R= CH3, OH, OCH3
 
Scheme 137. The rearrangement of o-aroyloxyacetophenones 113 to o-
hydroxydibenzoylmethanes 114. 
With such a huge precedent, therefore, instead of using the amide-based (acetamide and 
propanamide-based) precursors, ketone-based substrates were  prepared, and subjected 
to different literature based Baker-Venkataraman rearrangement conditions in the hope 
of forcing the Baker-Venkataraman rearrangement, Scheme 138.
68,69
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Scheme 138. The proposed ketone-based substrates studied in the rearrangement. 
Although the ketone-based Baker-Venkataraman rearrangement substrates could be 
acylated successfully with benzoyl chloride, when subjected to the rearrangement (see 
Scheme 139) no rearranged products were detected in any of the conditions attempted 
except NaH/DMSO (when R
1
=H). Interestingly, under these NaH/DMSO conditions, 
the acylated ketone-based substrate 398a (R
1
=H, Scheme 139) did undergo the Baker-
Venkataraman rearrangement when refluxed for one hour to give the rearranged product 
400a (R
1
= H) in excellent yield (96%), Scheme 139. However, repeating the same 
procedure with compound 398b failed to give the Baker-Venkataraman rearranged 
product (see Table 14 for results).  
OH
R1
O
R1, TEA, DMAP
DCM, r.t., 16h
OH
conditions
O O O
R1
59   R1= H
261 R1= Me
400a R1=H
O
Ph
Ph
O
Ph Cl
O
398a  R1= H
398b  R1= Me  
Reaction conditions: NaH (2.5 eq.), toluene-4Å molecular sieves (0.1M), 100 
○
C, 2 h; or 
KOtBu (2.2 eq.), anhydrous THF-4Å molecular sieves (0.1M), reflux, 1 h; or KOtBu 
(2.2 eq.), DMF (0.1M); or NaH (3 eq.), DMSO (0.1M), reflux, 1 h. 
Scheme 139. The attempted rearrangement of ketone-based substrates. 
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Table 14. Ketone-based substrates (59 and 261) for the attempted Baker-Venkataraman 
rearrangement using NaH (3 eq.), DMSO (0.1M), reflux, 1 h. 
Entry R
1
 Acylated products 
398 %
[a]
  
Rearranged 
products 400 % 
Hydrolysed 
products %  
a H 100 96 4 
b Me 61 0
[b]
 100 
[a]
 Isolated yields; 
[b]
 In all cases the remaining yield is made up of the corresponding 
hydrolysed products (59 and 261). 
Having experienced little success in preparing and rearranging chiral racemic Baker-
Venkataraman substrates (400, R
1
=Me), attention was turned to the conditions of 
Snieckus, wherein his group demonstrated some success in the development of a 
carbamoyl variant of the rearrangement. As such, a couple of Sniekus's compounds 
were prepared in order to repeat his results and gain confidence in being able to 
successfully perform the Baker-Venkataraman rearrangement. Once this success had 
been achieved efforts would turn back to the rearrangement in the presence of chiral 
auxiliaries. 
In the event, while optimising the conditions for this carbamoyl version of the Baker-
Venkataraman rearrangement, it was noticed that the substrates underwent a dual 
process which includes a Baker-Venkataraman rearrangement-retro-Claisen cascade 
under the reaction conditions in which water was not strenuously removed. A 
phenomenon that was not observed under strictly anhydrous conditions (wherein the 
desired rearrangement occurred). 
 
2.3.3 The Baker-Venkataraman-retro-Claisen cascade 
Having observed this interesting cascade process taking place, along with the fact that 
up to now, difficulty had been experienced in preparing compounds such as 401 with 
chiral R
1
 groups, it was decided to focus a little effort onto this process to see if it was 
A] general to this class of compounds, and B] synthetically useful. Scheme 140 shows 
the summary of the newly discovered cascade reaction whereby the starting material 
(401) appears to act as an "R
1
" donor and the carbamoyl chloride (402) acts as an "R
1
" 
acceptor to generate the new amide products 404. 
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R3= C2H5, C6H5
R2-R3= morpholino
R4= H, Br, CH3
OH O O
N
R3
R2
OH
+
OH O
R1 R1
404
NaH
R4 R4
O
N
R2
R3
Cl
+
401 402 403
 
Scheme 140. The Baker-Venkataraman-retro-Claisen cascade. 
The Baker-Venkataraman rearrangement, by which 1,3-diketones (406) are formed, has 
been regarded as an intramolecular Claisen acylation, Scheme 141. However, in the 
classical Claisen acylation reaction the ketone  (410) and ester functions (409) are not 
present in the same molecule, however, both of these functions are present ortho to one 
another in compounds 405 undergoing the Baker-Venkataraman transformation, 
Scheme 141.
77
 This rearrangement is not to be confused with the Dieckmann 
rearrangement which is considered to be an intramolecular Claisen in which cyclised 
(not rearranged) products are obtained. 
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Scheme 141. The difference between the Baker-Venkataraman-retro-Claisen cascade 
and retro-Claisen reaction. 
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2.3.3.1 The Claisen and retro-Claisen reactions 
The Claisen condensation is a powerful reaction for carbon-carbon bond formation and 
was discovered by Rainer Ludwig Claisen in 1881.
274
 From his publications from 1881 
to 1896, it was shown that this reaction can occur with two different substrates sets; 
either two different carboxylic esters (409) with 410 (R
3
= OR) or esters 409 with 
ketones 410 (R
3
= alkyl), reacting in basic media to offer β-keto esters or β-diketone 
(1,3-dicarbonyl compounds) 411, Scheme 142.
275,276
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Scheme 142. The Claisen and retro-Claisen reactions. 
For the Claisen rearrangement to be successful, at least one of the starting materials 
must be enolisable (have an α-proton next to the carbonyl group and be able to 
undergo deprotonation to form the enolate anion). Initially, the reaction begins through 
enolate formation, followed by a nucleophilic attack of it on the  ester, this is followed 
by elimination of the leaving group (alkoxide), and an aqueous acidic work up will offer 
the final product. If the conditions are not carefully selected, the Claisen condensation is 
accompanied by side-reactions such as O-acylation, self-condensation, decarboxylation, 
and the retrograde process known as the retro-Claisen reaction.
277
 
From a biochemical point of view, both the Claisen condensation and retro-Claisen 
reaction are widely observed in the biochemistry of 1,3-dicarbonyl compounds (411).  
The required thioesters (412) are biosynthesised through a biocatalysed condensation, 
and both the Claisen condensation and retro-Claisen reaction have powerful parts in the 
biosynthesis of fatty acids and polyketides and in the degradation of fatty acids and in β-
oxidation, respectively, Scheme 142. These reactions are catalysed by an enzyme and 
the enzymatic Claisen condensation and retro-Claisen reaction have been extensively 
studied and reviewed.
278–281
 
The retro-Claisen reaction is regarded as a preferable choice in the breakdown of 
carbon-carbon bonds, attributed to early demonstrations of the retro-process under 
concentrated or basic reaction conditions.
282
 Furthermore, the retro-Claisen reaction has 
been extended beyond simple hydrolysis to a variety of substrates, and a wide range of 
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reactants, catalysts and reaction conditions have been used. In addition, different 
nucleophiles (O, N, S functionalities) have been documented to participate in the retro-
Claisen cleavage of the parent 1,3-dicarbonyl compounds 411, through intermediate 413 
that undergoes carbon-carbon bond scission to regenerate 409 and 410 from, Scheme 
143.
283
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Scheme 143. The retro-Claisen cleavage of the 1,3-dicarbonyl compounds 411. 
Connor and Adkins discovered that 1,3-dicarbonyl compounds  (411, R
1
= R
3
= alkyl) are 
more prone to basic hydrolysis and alcoholysis resulting in carbon-carbon bond 
cleavage, than keto esters (411, R
1
=alkyl; R
3
= OR), Scheme 143.
284
 Changing the 
concentration of the base in the alcoholic media has only superficial influence on the 
rate of the retro-reaction. Profoundly, α-substitutions between the carbonyls has a 
crucial effect on the cleavage scenario. For example, α,α-disubstituted 1,3-dicarbonyl 
compounds are cleaved more easily than the α-mono-substituted compounds, since in 
the presence of base, α-mono-substituted compounds enolise and any subsequent 
reaction stops, whereas α,α-disubstituted cannot enolise at all and can therefore undergo 
the retro-reaction.
285,286
  It was also found that water, sodium alkoxides and aluminium 
alkoxides can effectively induce retro-Claisen pathways.
284
 
 
2.3.3.1.1 The Baker-Venkataraman-retro-Claisen cascade on ketone-based 
substrates 
While attempting to expand the achiral version of the Baker-Venkataraman 
rearrangement a new series of carbamoyl-based substrates 415 were attempted. 
Unexpectedly, it was demonstrated that the carbamoyl-based substrate (R
2
= R
3
= C2H5) 
when heated at reflux with sodium hydride (2.5 eq.) in THF for 1-3 hours, afforded a 
mixture of the desired rearranged products 416, unwanted hydrolysed products (59 or 
261) as well as unexpected by-products, salicylic acid (403) and amide 404, Scheme 
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144. However, as mentioned previously, Snieckus et al. demonstrated that using 2.5 
equivalents of sodium hydride in THF, toluene or xylene forced the carbamoylated 
Baker-Venkataraman  rearrangement  precursors 152 (Scheme 134, vide supra) to 
undergo such a rearrangement when heated at reflux for 1-3 hours to offer the 1,3-
dicarbonyl products 153 in good to excellent yields (78-97%). Therefore, based on these 
conflicting results, attempts were made to study and exploit them to see if the 
unexpected reaction was more general. 
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Scheme 144. The Baker-Venkataraman-retro-Claisen cascade on ketone-based 
substrates. 
Upon examining this reaction in more detail, it was observed (Table 15) that refluxing 
the carbamoyl-based Baker-Venkataraman rearrangement substrate 415c (R
1
= R
2
= Me; 
R
3
= Ph) with sodium hydride (2.5 equivalents) in THF (0.2 M) for an extended period 
of 24 hours, again offered a mixture of hydrolysed product (261, 17%), salicylic acid 
(403, 42%) and the amide (404, 41%), but on this occasion, no rearranged product 416c 
was observed. As can be seen in Table 15, when a longer reaction time is employed (i.e. 
24 h rather than 1-3 h) the Baker-Venkataraman rearranged product (416c) must form in 
situ and subsequently undergo the second reaction, i.e. the intramolecular retro-Claisen 
rearrangement, to give increased yields of salicylic acid (403) and amide 404c. 
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Table 15. A Table to show the product yields in three separate reactions: i) 
carbamoylation; ii) Baker-Venkataraman rearrangement (anhydrous); and iii) Baker-
Venkataraman-retro-Claisen cascade. 
Substrates 
Carbamoylation 
reaction 
Baker-Venkataraman 
reaction 
Baker-Venkataraman-retro-
Claisen cascade reaction 
414 415 %
[a]
 416% 404% 403% 
a 27 74 0
[c]
 45 
b 32 N.A
[b]
 0
[c]
 50 
c 76 92 41 42 
d 94 N.A 0
[c]
 27 
[a]
 Isolated yields; 
[b]
 N.A= not attempted; 
[c]
 In these cases the 0% yield may be the 
result of having lost the amide product through evaporation of the reaction mixture, not 
necessarily that was not formed during the reaction. 
As can be seen from Table 15 carbamates 415a,b,d did not yield any isolated amide 
(404) products, whilst carbamate 415c gave amide 404c in 41% yield. However, this 
does not mean that amides 404a,b,d did not form during the reaction, simply that they 
might be volatile, due to their low molecular weight, and thus would be evaporated in 
vacuo after workup. Nevertheless, that the amide must have formed during the reaction 
is evidenced by the formation of salicylic acid (403, 27-50%) - see the proposed 
mechanism in Scheme 146. 
However, as expected, when the same carbamoyl-based Baker-Venkataraman 
rearrangement substrates 415 were heated at reflux for the shorter time of 1-3 hours, in 
anhydrous THF containing sodium hydride and 4Å molecular sieves, only the 
rearranged products 416 were obtained, as well as the cyclised product 417, Scheme 
145. For example, when compound 415c (R
1
= R
2
= CH3; R
3
= C6H5) was exposed to the 
these conditions it gave 48% of rearranged product 416c and 44% cyclised product 417, 
Scheme 145. 
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415c
416c
+
417  
Scheme 145. The Baker-Venkataraman rearrangement of carbamoyl-based substrates 
415c in anhydrous THF. 
Based on these results, it was postulated that a Baker-Venkataraman-retro-Claisen 
cascade had occurred to give this mixture of products (see Scheme 146 for a plausible 
mechanism). Here, a proton would be abstracted by sodium hydride to form enolate 418 
and in turn this enolate would attack the carbonyl of the acyl group to form a six-
membered cyclic intermediate which would collapse to generate the Baker-
Venkataraman rearranged product 416. Nucleophilic addition of trace water could 
attack the rearranged product and consequently a retro-Claisen carbon-carbon bond 
cleavage would occur to give salicylic acid 403 and amide derivatives 404. 
R1= H, methyl
R2= methyl, ethyl
R3= ethyl, phenyl
R2-R3= morpholino
415
OH O O
N
R3
R2
R1
-OH
OH O O
N
R3
R2
OH
+
O O
R1
O
N
R2
R3
R1
Baker-Venkataraman rearrangement
416
retro-Claisen rearrangement
403 404
O
O
NO
R1
R3
R2
NaH
418
 
Scheme 146. The postulated mechanism for the Baker-Venkataraman-retro-Claisen 
cascade. 
Evidence for this proposed mechanism was obtained when the reaction was performed 
with an N-Me, N-Ph-carbamate (i.e. 415), in a THF:MeOH solution and the 
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corresponding methyl salicylate was obtained, and its presence confirmed, by NMR and 
mass spec., rather than the usual salicylic acid which is obtained when water is present. 
The reaction kinetic profiles of 1,3-dicarbonyl substrates in aqueous alkali media have 
been reported by Pearson and Mayerle.
287
 In their kinetic studies, they proposed that the 
reaction begins through an intermediate 420. A general base-catalysed limiting step 
produces a double ionic intermediate 421, followed by fast carbon-carbon bond 
cleavage offering the cleavage products 422 and 423, Scheme 147.
287
 
R1
OH O
R2
R1
O
O +
R1= alkyl, aryl
R2= R3= H, alkyl, aryl
R4= alkyl, aryl, O-alkyl, O-aryl
420
R1
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R4
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O
R4
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R2 R3
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R3 R
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R1
O O
R2
O
R3 R
4
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fast step
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R2
R3
 
Scheme 147. The reaction kinetic profiles of 1,3-dicarbonyl substrates  419 in aqueous 
alkali media. 
However, in order to demonstrate the generality of this proposed Baker-Venkataraman-
retro-Claisen cascade, five more 2'-hydroxypropiophenone derivatives 424 were 
acylated successfully with N-methyl-N-phenyl carbamoyl chloride to give the 
corresponding carbamoyl-based Baker-Venkataraman rearrangement substrates 425. 
Repeatedly, it was found that four of the carbamoyl-based substrates attempted 425a-e 
(except 425c) underwent the Baker-Venkataraman-retro-Claisen cascade to give the 
corresponding salicylic acid derivatives 403 and the amides 427, when refluxed with 
sodium hydride in THF for 24 hours, Scheme 148. For different R groups see Table 16. 
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OH
O O
O
R1
R2
O
N
Ph
N
O
Ph
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OH O
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R1
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a
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403 427
	  R1	             R2
a	CH3	          CH3
b	CH3	          Br
c	acetyl	        H
d	benzoyl	     H
e	ethylbenzyl  H
anhydrous conditions
non-anhydrous conditions
 
Reaction conditions: a) sodium hydride (2.5 eq.),  reflux, 1-3 h, anhydrous THF-4Å 
molecular sieves (0.2 M); b) sodium hydride (2.5 eq.),  reflux, 24 h, THF. 
Scheme 148. Attempts to demonstrate the generality of this proposed Baker-
Venkataraman-retro-Claisen cascade. 
 
Table 16. A Table to show the product yields in three separate reactions: i) 
carbamoylation; ii) Baker-Venkataraman rearrangement (anhydrous); and iii) Baker-
Venkataraman-retro-Claisen cascade. 
Substrates 
Carbamoylation 
reaction 
Baker-Venkataraman 
reaction 
Baker-Venkataraman-retro-Claisen 
cascade reaction 
424 425 %
[a]
 426% 427% 403% 
a 63 22 85 25 
b 96 N.A
[b]
 60 43 
c 50 N.A 100% hydrolysis
[c]
 
d 91 0 8
[d]
 0 
e 99 58 42 42 
 [a]
 Isolated yields; 
[b]
 N.A= not attempted; 
[c]
 In all cases the remaining yields is made of 
the corresponding hydrolysed products (424). 
[d]
 In the case of substrate 425d, a 
different rearranged product 430 was formed instead of the expected amide 427d (for a 
detailed explanation see Scheme 150). 
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As can be seen from Table 16, only substrate 425c (R
1
= acetyl, R
2
= H) failed to 
undergo the Baker-Venkataraman-retro-Claisen cascade. Instead the hydrolysed product 
424c was detected as the sole product. This result can be rationalised by the fact that the 
1,3-dicarbonyl system in 425c could enolise, tautomerise and stabilise the enolate 
intermediate 428, therefore, although it might undergo a slow rearrangement it would 
no doubt suffer from a faster hydrolysis step, Scheme 149. 
OOON
O
Ph
OOON
O
Ph
OHOON
O
Ph
NaH
425c 428 429
   fast
hydrolysis
    slow 
rearrangement
OOOH
O N
Ph
OHOOH
424c426c  
Scheme 149. The rationalised mechanism behind the hydroylsis of 425c. 
In the case of substrate 425d, a different rearranged product (430) was formed instead 
of the expected amide 427d. The rationale behind the formation of compound 430 from 
substrate 425d (R
1
= benzoyl, R
2
= H) was that there was a choice of electrophile for the 
hydrolysis step to choose from. For example, this substrate underwent the Baker-
Venkataraman rearrangement step to give the rearranged intermediate 426d 
(Scheme150), then in the retro-Claisen rearrangement step, the nucleophilic water has 
two options where to attack (see pathways A and B, Scheme 150) based on the near-
symmetrical compound 426d. Based upon product structure the water must have 
attacked the benzoyl carbon (pathway A) during the retro-Claisen step to give product 
430 and benzoic acid (431), which was simply washed away during the aqueous 
workup. This result was observed only in anhydrous conditions giving 33% yield of 
430, and in normal THF only 8% of 430 was detected due to faster competing 
hydrolysis of 425d to give 424d in 92% yield, Scheme 150. 
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Scheme 150. The proposed mechanism for the formation of compound 430. 
The above rationalisation is also supported by the work of Hauser et al. when they 
documented alcoholysis experiments on the asymmetric aryl substituted diketones (p-
methoxy (432a), p-chloro (432b), p-nitro dibenzoylmethanes (432c)), Scheme 151.
288
 
They demonstrated that there are two possible ester cleavage products,  independent of 
the α-substitution, but the ester of the stronger acid was identified and isolated in higher 
yields (42%, 60% and 80% for p-methoxy, p-chloro, p-nitro dibenzoylmethanes, 
respectively). They noticed that the cleavage on the aroyl side of 1,3-diketone towards 
benzoate 433a-c was chemoselective, and was attributed to the charge delocalisation 
capability and stability of the anion intermediates.  
X
O O
alkaline hydrolysis
85% in ethanol, 25 C
X
O
OH
O
+
433a X= OMe   42%
433b X= Cl       60%
433c X= NO2    80%
432a-c 434
 
Scheme 151. Alcoholysis of the asymmetric aryl substituted diketones 432a-c. 
Furthermore, unexpectedly Rouchaud et al. observed similar chemoselectivity, when 
they studied sulcotrione (herbicide agent 435) soil metabolism in summer corn crops, 
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Scheme 152.
289
 They found that in the soil of summer corn crops, sulcotrione (435) was 
transformed into the herbicide metabolite 436,  and thereafter successively into ketone 
437 and acid 438. 
O
soil metabolism
O
HO
+
538 14%
435
O
O
Cl
SO2CH3
Cl
SO2CH3
O Cl
SO2CH3
O Cl
SO2CH3
OO
HO
436  60%
+
437 16%  
Scheme 152. Sulcotrione's (435) soil metabolism in summer corn crops. 
Having followed up and investigated this novel Baker-Venkataraman rearrangement-
retro-Claisen cascade, further work is required if it is to become an established 
synthetic protocol in the chemists' repertoire of reactions. Moreover, such development 
may also suggest that opportunities occur to apply the reaction to molecules of 
biological interest and natural products. Similarly, as a result of following up this 
interesting reaction, it was necessary to abandon the asymmetric Baker-Venkataraman 
rearrangement (Scheme 129 (vide supra)) - a reaction which also appears worthy of 
further investigation for similar reasons. 
In summary, the acylated amide-based substrates (389a-f and 392a-f) did not rearrange, 
instead they suffered from facile hydrolysis, while the carbamoylated ketone-based 
substrates (415a-d and 425a-e) did, however, the latter substrates  underwent Baker-
Venkataraman rearrangement-retro-Claisen cascade under established conditions. In 
this cascade, the starting material  401 acted as the alkyl donor and the carbamoyl (402) 
as alkyl acceptor, Scheme 153. 
 
Results and Discussion 
130 
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R2= CH3, C2H5
R3= C2H5, C6H5
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R4= H, Br, CH3
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Scheme 153. General scheme for the Baker-Venkataraman rearrangement-retro-Claisen 
cascade.
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CHAPTER THREE - CYCLOOXYGENASE ACTIVITY 
3.1 Cyclooxygenase (COX) activity of diarylethers 334b, 440, diclofenac sodium 
(445) and its methyl ester, 452 
The synthesis of diarylether derivatives has been studied in recent times and numerous 
reviews observed that they possess anticancer, antimicrobial, and anti-inflammatory 
activities.
290–293
 Moreover, the diarylethers of the amide-based Truce-Smiles 
rearrangement precursors (e.g. 334b) prepared herein have close structural similarity to 
non-steroidal anti-inflammatory drugs (NSAIDs), especially diclofenac (439) which is 
the most commonly prescribed of the NSAIDs, Figure 28, and these were also studied 
for their COX-inhibition activity. 
O
NO2
334b
O
N
NH
OH
O
Cl
Cl
439
O
NO2
440
O
OH
 
Figure 28. Structure of diarylethers 334b, 440 and diclofenac sodium (445). 
 
3.1.1 COX and prostaglandin production  
Cyclooxygenase  (COX, also known as prostaglandin H synthase or PGHS)  is a 
bifunctional enzyme exhibiting both COX and peroxidase activities.  The COX 
component is the  rate-limiting  enzyme  responsible  for  the conversion of arachidonic 
acid (AA 441) to a hydroperoxy endoperoxide (PGG2 442), Scheme 154. While the 
peroxidase component reduces the endoperoxide to the corresponding alcohol (PGH2 
443), the precursor of prostaglandins, thromboxanes and prostacyclines.
294,295
 It is now 
well established that there are two distinct isoforms of COX, COX I  and  COX II,  
which contain distinct peroxidase and active COX sites.
296
 The most expressed COX 
isoform  is COX I which is detected constitutively in almost all tissues such as kidney,  
spleen  and  the  gastrointestinal  mucosa and is involved in normal cellular 
homeostatsis,
297
 while the  COX II isoform expression is  low,  or  not  detected during  
normal and  non-pathological  conditions  in  most  mammalian  tissues. Although COX 
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I is constitutively expressed in almost all tissues,  both COX I and COX II are of 
pharmacological importance in pathological states.
296
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Scheme 154. The biosynthesis of prostaglandins. 
A variety of stimuli, such as phorbol esters, lipopolysacharides and cytokines, growth 
factors, tumour  promoters  and  environmental  stresses leads to the induced expression 
of the COX II isoform, leading to the production of prostaglandins, mediating 
inflammation and pain.
298
  COX II is  largely  expressed  by  resident  activated  
macrophages  with  predominantly  proinflammatory effects, therefore, COX II is 
regarded as a  possible target for treating metabolic disorders  associated  with  
overweight  and  obesity.
299
 Inducible COX II is responsible for the biosynthesis of 
prostaglandins under acute inflammatory conditions.
300,301
 Therefore, COX II is 
believed to be the target enzyme for the anti-inflammatory activity of non-steroidal anti-
inflammatory drugs (NSAIDs).
300
 Arachidonic acid (AA 441)  enzymatically converts 
to the hydroperoxy endoperoxide prostaglandin G2 (PGG2 442) by the action of the 
COX isoforms. Afterwards, PGG2 is converted  to  prostaglandin  H2  (PGH2 443),  a  
precursor  of  the  series-2  prostanoids,  through peroxidase  activity  after  diffusion  to  
COX activity 
133 
 
the  peroxidase  site  (Figure  29).
296
  Eicosapentaenoic  acid (EPA) and 
docosahexaenoic acid (DHA) are also  metabolised  by COX isoforms, and compete for 
the same set  of  enzymes.   Arachidonic acid  is  converted  mainly into    pro-
inflammatory  mediators,  which  act  as  potent mediators producing cytokines.
302
 On 
the other hand  the produced mediators such as PGE3 and LTB5  are known to  have 
anti-inflammatory properties.
303
  PGH2  is  converted to  PGE2  (the  most  studied  of 
the prostaglandins) by prostaglandin E synthase (PGES). PGE2 has been shown to have  
one of  the highest  concentrations  in adipose tissue compared  to  other  
prostaglandins,  however,  because  of  the  large number of prostaglandins and their 
complex regulation, through multiple receptors, it  is hard to  point out a  specific  
function  of  each  prostaglandin.
304
  Prostaglandins  have  several  physiological  
functions  in  the  body  and  are found  in  most  tissues  and  organs.
305
  In addition, 
during  acute  inflammation,  prostaglandins  are synthesised  by  local  cells;  while  in  
chronic  inflammation, prostaglandins will be formed by monocytes and macrophages.  
Arachidonate
Prostaglandin G2
Prostaglandin H2
PGD2, PGE2, PGF2, PGI2, TXA2
COX II
inducible
COX I
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Figure 29. Prostaglandin production depends on COX I and COX II  activity.  Overview  
of  the pathways  of prostanoids  derived  from  PGH2.
306
  NSAIDs  affect  both  the  
constitutive  and  inducible  form  of  COX activity. COX I and COX II activity play 
different roles in physiological processes. (+) means induction and (-) means inhibition 
of activities.  
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3.1.2 Non-steroidal anti-inflammatory drugs (NSAIDs) 
Non-steroidal anti-inflammatory drugs (generally abbreviated: NSAIDs)  are  a  class of  
medications  possessing  anti-inflammatory,  analgesic  and  anti-pyretic activities, by 
virtue of their abilities to inhibit the COX isoforms.
307
 NSAIDs impact upon COX I and 
COX II, (Figure 29),  and  inhibit  production  of  both  prostacyclin  and  thromboxane  
(TXA2),  and  differ  from selective COX II inhibitors which affect only prostacyclin 
production but not TXA2. NSAIDs are among the most prescribed drugs worldwide for 
the  treatment of acute  and  chronic  pain, with 70 million prescriptions annually, and 
over 30 billion over-the-counter tablets sold.
308
 NSAIDs reduce prostaglandin syntheses 
by  inhibiting the rate-limiting  COX enzyme, and the accessibility  of the enzyme is 
shown to be directly related to the quantity of prostaglandin production (Figure 29).
309
  
Furthermore, it has recently been revealed that there is an inflammatory component in 
the pathogenesis of Alzheimer disease.
310,311
 In fact, immunochemistry completed on 
post mortem Alzheimer disease brains revealed that numerous inflammatory 
components are associated with neuritic plaques
312
 and epidemiological studies have 
shown that therapy with anti-inflammatory drugs reduces the risk of developing 
Alzheimer disease.
313–317
 Few researchers have attempted to understand the mechanisms 
by which NSAIDs can protect the nervous system from the ravages caused by 
Alzheimer disease, but importantly, many observations have shown data which indicate 
that an anti-inflammatory therapy reduces the risk of developing Alzheimer disease in 
subjects without a genetic predisposition.
318,319
 
    
3.1.3 Diclofenac analogues 
Diclofenac belongs to the non-steroidal anti-inflammatory class of drugs (NSAIDs) 
which play an important role in the treatment of osteoarthritis, rheumatoid arthritis,
320
 
spondylitis
321
 and ocular inflammation.
322,323
 Diclofenac is a widely used drug which 
acts through inhibition of the cyclooxygenase enzyme isoforms (COX I and COX II), 
leading to the peripheral inhibition of prostaglandin synthesis. Due to the fact that 
prostaglandins cause sensitisation of the pain receptors, the inhibition of their synthesis 
is responsible for its analgesic effects.
324
 Nevertheless there are numerous side effects 
associated with the long-term use of diclofenac. 
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The common side effects associated with NSAID therapy may vary from 
gastrointestinal irritation to internal bleeding, and a few cases even turn out to be 
fatal.
325–327
 The gastrointestinal irritation in the NSAID therapy is due to the interaction 
of the drug with COX I, while the clinical efficacy is attributed to the COX II inhibition. 
Additionally, the therapeutic utility in the treatment of inflammation by a few selective 
COX II inhibitors like celecoxib, rofecoxib, valdecoxib and etoricoxib have already 
been established.
328,329
 These studies suggest that a single amino acid replacement, an 
isoleucine residue at position 523 in COX I by valine in COX II, is responsible for the 
selectivity of many COX II inhibitors.
330
 
Unfortunately, the analysis of clinical trial data revealed that vascular events associated 
with the use of COX II inhibitors, such as non-fatal myocardial infarction (MI), non-
fatal stroke, and death might be from a vascular event such as MI or 
stroke.
331,332
 Therefore, Merck started to voluntarily withdraw its COX II inhibitors 
rofecoxib from the market in September 2004.
331
 Moreover, traditional NSAIDs were 
also found to have cardiovascular risks, leading to similar boxed warnings.
331
 The cause 
of the cardiovascular problems became, and remains, a subject of intense 
research.
333 
Results in 2012 confirmed that the adverse cardiovascular effects are most 
likely due to inhibition of COX II in blood vessels leading to a decrease in the 
production of prostacyclin in blood vessels. Prostacyclin usually prevents platelet 
aggregation and vasoconstriction, so its inhibition can lead to excess clot formation and 
higher blood pressure.
333
 
Therefore, a prodrug formation approach has been considered through the masking of 
the carboxylate moiety of these drugs in order to minimise gastrointestinal related side 
effects and also to improve their delivery characteristics.
334,335
 Taking advantage of the 
presence of enzymes in living systems capable of hydrolysing esters, bioreversible 
esters have received considerable attention among the many possible prodrug 
approaches. In drug discovery, as well as drug development, prodrugs have become an 
established tool for improving physicochemical, biopharmaceutical, or pharmacokinetic 
properties of pharmacologically potent compounds, thereby increasing developability 
and usefulness of a potential drug.
336,337
 By utilising the prodrug approach, one strategy 
that could be useful is to temporarily mask the carboxylic acid function of the NSAIDs 
so that the prodrug hydrolyses in vivo to release the active parent NSAID.
338–340
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In order to counter the side effects of sodium diclofenac many papers report on the 
controlled release of diclofenac,
341,342
 and the use of the polymeric prodrugs (such as 
444). In the latter case, diclofenac was attached to poly(p-chloromethylstyrene), 
polyvinyl chloroacetate or polyoxyethylene by esterification methods, Figure 30.
343
 The 
results obtained from their synthesis and in vitro hydrolysis gives an insight into in vivo 
behaviour. However, the development of such systems into a drug product will require a 
truly multidisciplinary approach. 
R= poly(p-chloromethylstyrene),
     poly(vinyl chloroacetate),
     poly(oxyethylene)
NH
Cl
Cl
444
R
O
 
Figure 30. Enzyme-cleavable prodrug of diclofenac. 
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Reaction conditions: i) ICH2OCOC(CH3)3, Na2CO3, DMA, -15 
○
C, 1h; ii) 
ICH2OCOOCH(CH3)2, Na2CO3, DMA, -10 
○
C, 0.75 h; iii) BrCH2CH2OCOCH3, 
Na2CO3, DMA, 55 
○
C, 5.5 h. 
Scheme 155. Synthesis of some diclofenac ester prodrugs. 
Bandgar et al. attempted the synthesis of new diclofenac ester prodrugs with the aim of 
obtaining enzymatically labile drugs with less ulceration than the parent drug diclofenac 
sodium 445. In their approach, treatment of diclofenac sodium  445 with iodomethyl 
pivolate, iodomethylisopropyl carbonate, and 2-acetoxyethyl bromide in the presence of 
sodium carbonate in dimethylacetamide (DMA), offered diclofenac ester prodrugs 446, 
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447, and 448 in a straightforward manner in good yields (84%, 87%, 85%, 
respectively), as illustrated in Scheme 155. 
Interestingly, ulcer index (UI) studies showed that the diclofenac ester prodrugs 446, 
447, and 448 possess substantially less ulcerogenicity  (UI= 6, 8 and 40, respectively) 
than the parent diclofenac sodium (UI= 63). These diclofenac ester prodrugs underwent 
facile enzymatic transformation to regenerate the parent drug diclofenac in both rat liver 
microsome and rat plasma. Additionally in vitro and in vivo studies, revealed that 
prodrug 446 could potentially emerge as a potent and an alternative drug to diclofenac 
sodium (445) for the prevention of gastrointestinal disorders. 
  
3.1.4 In vitro COX assays 
Non-steroidal anti-inflammatory agents can inhibit COX I and/ or COX II action in one 
of several ways: 1) by inhibition of enzymatic activity, or 2) by inhibition of COX II 
mRNA and protein levels in cells. COX inhibitors of natural origin are reported to 
interfere on several levels, as reviewed by Perera  et al.
344
 A variety of assays have been 
described to evaluate  the in vitro  inhibition of COX. Experimental conditions, which 
differ between assays, include among others the following: the enzyme source (human 
or animal), the cell system used (intact normal cells, cell lines, or transfected cells), the 
method of enzyme purification (purified enzymes, microsomal, or whole cells assays), 
and the COX II inducing agent (e.g., lipopolysaccharide (LPS), tumour necrosis factor 
(TNFα), or interleukin-1 (IL-1)).345 
In addition to the above mentioned parameters, the source and concentration of 
arachidonic acid, incubation time with drug, protein concentration, and the method for 
detection of activity (i.e., prostaglandins or thromboxanes produced) vary in enzymatic 
activity assays. Consequently, all of these experimental conditions have contributed to 
significant variation in IC50 values and COX II selectivity ratios reported in the 
literature.
346
 Commonly used detection methods to analyse the amount of produced 
prostaglandins and thromboxanes are: enzyme immunoassay (EIA), radio immunoassay 
(RIA), or a radiotracer method.
347,348
 The latter method, which mostly uses radio-
labelled substrates to measure the amount of radio-labelled prostaglandins produced 
after the COX catalysis, is quantified with scintillation counting or HPLC.
349,350
 The 
scintillation proximity assay (SPA), a development of traditional scintillation counting, 
is widely used in high throughput screenings (HTS), since the method can be adapted to 
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robotics.
351
 To detect enzymatic activity, another approach is to use a polarographic 
oxygen electrode to measure the amount of oxygen consumed during conversion of 
arachidonic acid to PGG2.
352
 
Furthermore, COX enzyme assays can be selected by various criteria, although they 
must be feasible and reproducible, and be appropriate for the investigation. The assay 
that most resembles in vivo situations is the human whole-blood assay that uses intact 
human cells.
345
 Assays with purified enzymes are appropriate for studying drug-
interactions with the active sites of an enzyme. Human cell lines or human recombinant 
enzymes in microsomal assays are more convenient for high-throughput investigations 
of structure-activity relationships.
345
 The latter assays are also more suited for 
investigations of clinical relevance. For initial investigations of COX I and COX II 
inhibition of plant extracts and fractions containing a complex biomass, an assay using 
purified enzyme is preferable. Furthermore, a bioassay used for plant extracts needs to 
be suitable to a complex biomass with compounds that are coloured, sticky, and 
hydrophobic.
353
 In addition, the assay must be reproducible, feasible, and reasonably 
inexpensive. 
 
3.1.5 The principle of in vitro COX activity assay 
The COX activity assay carried out here was Cayman's COX fluorescent inhibitor 
screening assay
354
 which uses a convenient fluorescence-based method for screening 
both bovine COX I and human recombinant COX II for isozyme-specific inhibitors. 
The COX component converts arachidonic acid (441) to a hydroperoxy endoperoxide 
(442 PGG2), and the peroxidase component reduces the endoperoxide to the 
corresponding alcohol (443 PGH2), the precursor of prostaglandins, thromboxanes and 
prostacyclines, Scheme 156.
294,295
 The assay utilises the peroxidase component of 
COXs. The reaction between PGC2 (442) and 10-acetyl-3,7-dihydroxyphenoxazine (449 
ADPH) produces the highly fluorescent compound resorufin (450). Resorufin 
fluorescence can be easily analysed with an excitation wavelength of 530-540 nm and 
an emission wavelength of 585-595 nm, Scheme 156. 
COX activity 
139 
 
COOH
Cyclooxygenase
COOH
O
O
COOH
O
O
HO
443 PGH2
Peroxidase
441 AA
442 PGG2
N
OHO OH
O
N
OO OH
449 ADPH (10-acetyl-3,7-dihyroxyphenoxazepine)
450 resorufin
(Ex. 530-540/ Em. 585-595)
HOO
 
Scheme 156. The principle of Cayman's COX fluorescent inhibitor screening assay. 
 
3.2 Synthesis of diclofenac analogues 
3.2.1 Previous work 
A search for non-steroidal anti-inflammatory drugs that had reduced toxicities and a 
longer duration of action was commenced by number of researchers.
355,356
 
Unexpectedly, it was noticed  that some NSAIDs (e.g. indomethacin, ibufenac) and a 
series of experimental compounds investigated by Smith, Kline and French resembled 
plant growth regulators, such as indole-3-acetic acid,
357
 phenylacetic acid
358
 and 
naphthalene-1-acetic acid.
359
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Modifying well known NSAIDs into selective  COX II  inhibitors  represents  an  
interesting  strategy,  and diclofenac  and  many  other  NSAIDs  have  been  
successfully  elaborated  into  selective  COX II  inhibitors.  For example, Novartis  
have  described  the conversion of diclofenac (439) into lumiracoxib (451),  a 
compound which  exhibits  500-fold  selectivity  for  COX II  over  COX I  (Figure  
31).
360
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Lumiracoxib (451)  
Figure 31. Modification of diclofenac (439) to lumriacoxib (451). 
Additionally, recent studies and reviews have shown that diarylether derivatives possess 
anticancer, antimicrobial, and anti-inflammatory activities.
290–293
 In addition, the amide-
based Truce-Smiles rearrangement precursors 334a-e and 338a-e are structurally 
analogous to diclofenac 439 the most widely used NSAID, Figure 32 (the dashed circles 
indicate the differences between diclofenac sodium (445) and its analogous compounds 
prepared herein 452, 440, 334a-e and 338a-e). 
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Figure 32. The differences between diclofenac sodium (445) and its analogous 
compounds prepared herein. 
Furthermore, Sivaraj et al., in their attempt to discover  new, safer and potent agents for 
the treatment of inflammatory diseases, designed some heterocyclic analogues of 
diclofenac (such as 453, 454) by replacing the carboxylic acid of diclofenac with less 
acidic heterocycles, Figure 33.
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Figure 33. Some heterocyclic analogues of diclofenac. 
Sivaraj et al.  screened their prepared heterocyclic analogues for analgesic, anti-
inflammatory and ulcerogenic potential. Most compounds exhibited significant 
analgesic and anti-inflammatory activity and are devoid of the deadlier gastrointestinal 
toxicities, however the heterocyclic analogues denoted by 453 exhibited the most 
prominent and consistent anti-inflammatory activity.
293
 
 
3.2.2 This work 
Based on Sivaraj and others work, it was proposed that the diarylethers of amide-based 
Truce-Smiles rearrangement precursors 334a-e and 338a-e (section 2.2.2.3) might have 
useful anti-inflammatory, analgesic, and antipyretic properties like diclofenac, due to 
their close structural similarity. 
In order to test this hypothesis, the compounds 334a-e and 338a-e, previously prepared 
and discussed in Chapter 2, by refluxing the lactones (281 or 332, Scheme 157) with the 
amines in toluene to afford the corresponding amides (333a-e and 337a-e) in excellent 
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yields, were studied. The amides were subsequently reacted with 1-fluoro-2-
nitrobenzene (60) in DMSO at room temperature (to minimise Truce-Smiles 
rearrangement for substrates based on 333) to offer the desired diarylethers 334a-e and 
338a-e in moderate to good yields (see Table 17 and Scheme 157). 
O
NO2
O
R
NEt2
N N
O
R= NBn2,
N
, , ,
a b c d e
n
O
O
OH
O
R
n
n
281 n= 1 
332 n= 2
333 n= 1 
337 n= 2
334 n= 1 
338 n= 2
(i) (ii)
 
Reaction conditions: i) amine (1.5 eq.), lactone 281 or 332 (1 eq.), toluene (0.1 M), 
reflux, 6 h; ii) amide 333a-e and 336a-e (1 eq.), 1-fluoro-2-nitrobenzene (60) (1.05 eq.), 
K2CO3 (2.5 eq.), DMSO (0.1 M), r.t., 24 h. 
Scheme 157. Synthesis of diarylethers 334a-e and 338a-e. 
Table 17. Isolated yields of the amides 333a-e and 337a-e and their corresponding 
diarylethers 334a-e and 338a-e. 
Entry n Amides 333 (%) Diarylethers 334 (%) 
a 1 95 64 
b 1 89 93 
c 1 98 83 
d 1 81 40 
e 1 96 74 
  Amides 337 (%) Diarylethers  338 (%) 
a 2 98 100 
b 2 100 100 
c 2 78 87 
d 2 82 90 
e 2 100 90 
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Along with the amide-based Truce-Smiles precursors above, diclofenac methyl ester 
452, has also prepared from refluxing diclofenac sodium (445) in methanol containing a 
few drops of conc. H2SO4. The desired methyl ester of diclofenac (452) was prepared in 
88% yield, along with a lactam product 453 in 12% yield, presumably formed from 
attack of the nitrogen onto the methyl ester carbonyl, Scheme 158. 
NH
ONa
O
Cl
Cl
NH
O
O
Cl
Cl
445 452 88%
N
Cl
Cl
MeOH, reflux
conc. H2SO4
+
453 12%
O
 
Reaction conditions: diclofenac sodium (445) (1 eq.), conc. H2SO4 (few drops), 
methanol (0.1 M), reflux, 3 h.  
Scheme 158. Synthesis of diclofenac methyl ester. 
Furthermore, a closely related analogue to diclofenac, 2-(2-(2-
nitrophenoxy)phenyl)acetic acid (440) was also prepared through three successive steps, 
Scheme 159. The first step was the preparation of 2-hydroxyphenyl acetate methyl ester  
(454) (100%) from refluxing 2-hydroxyphenyl acetic acid (277) in acidic methanol. 
This esterification procedure was required to protect the acid  277, since exploratory 
work in the early stages of this thesis had shown that the Truce-Smiles rearrangement 
does not work on acid substrates. Secondly, the methyl ester 454 was reacted with 1-
fluoro-2-nitrobenzene (60) in the presence of K2CO3 in DMSO at room temperature to 
give the desired methyl ester of 2-(2-(2-nitrophenoxy)phenyl)acetic acid (455) in 30% 
yield. Finally, 2-(2-(2-nitrophenoxy)phenyl)acetate methyl ester (455) was hydrolysed 
in aqueous basic THF to afford the final product (440) in 100% yield. 
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Reaction conditions: i) 2-hydroxyphenylacetic acid (277) (1 eq.), conc. H2SO4 (few 
drops), methanol (0.1 M), reflux, 16 h; ii) 2-hydroxyphenylacetate methyl ester (454) (1 
eq.), 1-fluoro-2-nitrobenzene (60) (1.05 eq.), K2CO3 (1 eq.), DMSO (0.1 M), r.t., 16 h; 
iii) methyl 2-(2-(2-nitrophenoxy)phenyl)acetate (455) (1 eq.), basic THF solution (THF: 
1M NaOH; 50:50; 0.1 M), r.t., 16 h. 
Scheme 159. Synthesis of 2-(2-(2-nitrophenoxy)phenyl)acetic acid (440). 
 
3.2.3.  In vitro COX assay 
Upon closer inspection of the literature, it appears as though the distance between the 
acidic centre and the flat aryl surface is critical for the analgesic and anti-inflammatory 
activities observed by the diarylethers which have to-date been studied, and that 
increasing this distance to two or three carbons generally diminishes activity.
361–363
. As 
such, the propanamide-based Truce-Smiles rearrangement precursors (338a-e) were not 
tested because of their increased distance between the amide carbonyl and the flat aryl 
surface. Therefore, instead, only the acetamide-based Truce-Smiles rearrangement 
substrates were screened, since the distance between the amide carbonyl and  the flat 
surface is the same as the distance in diclofenac itself.  
The diarylether of pyrrolidyl-acetamide (334b) was selected as a prototype within its 
group in the hope that its chiral analogue may be more active as a pure enantiomer. 
Moreover, to enable a comparison with diclofenac sodium (445) to be made its methyl 
ester  452 as well as 2-(2-(2-nitrophenoxy)phenyl)acetic acid (440) were screened for 
their activity against COX. The reason behind testing the methyl ester of diclofenac 
(452) was to compare it directly with the diarylether of pyrrolidyl acetamide (334b) and 
also to see how the decrease in acidity affects the interaction with its target receptor. 
The COX inhibitory activity assay was carried out by applying the in vitro Cayman's 
COX fluorescent inhibitor screening protocol in which the inhibitors were tested against 
both bovine COX I and human recombinant COX II, Table 18. 
354
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Table 18. In vitro COX assay results.  
COX I % inhibition 
Conc. 
nM 
diclofenac 
sodium 445 
diclofenac methyl 
ester 452 
diarylether  
acid  440 
diarylether pyrrolidyl 
acetamide 334b 
20 62 10 26 25 
200 76 35 33 37 
2000 92 58 45 37 
COX II % inhibition 
Conc. 
nM 
diclofenac 
sodium 445 
diclofenac methyl 
ester 452 
diarylether  
acid 440 
diarylether pyrrolidyl 
acetamide 334b 
20 68 22 28 44 
200 88 33 28 53 
2000 98 54 29 70 
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Indomethacin 456 ester analogue 457 amide analogue 458  
Figure 34. Indomethacin and its ester and amide analogues. 
As can be seen from Table 18, only the diarylether of pyrrolidyl amide 334b showed 
any appreciable activity (70% inhibition at 2000 nM) against COX II. This greater COX 
II selectivity is attributed to introducing larger substituents (COOH replace by 
pyrrolidyl amide) to fit into the active site volume of COX II.
364
 Marnett et al. 
demonstrated similar results when they attempted to shift the enzyme selectivity of 
indomethacin (456) from COX I to COX II while maintaining potency at the same level 
and reducing the unwanted side-effects at the same time.
365
 In their studies they 
converted the non-selective NSAID 456 to  esters 457 and amides 458 in order to obtain 
selective COX II inhibitors, Figure 34.  
The acidic centre of diclofenac is crucial for activity as it interacts with the cationic site 
of the receptor, therefore, the more acidic the better the inhibition. Based on this, the 
reason behind the reduced activity of diarylether pyrrolidyl acetamide 334b against 
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COX I (25-37% inhibition) might be attributed to the fact that the amides are not acidic 
whereas their carboxylic acid analogues are.
361–363
 
Research by Atkinson et al. tested 117 derivatives of substituted (2-
phenoxyphenyl)acetic acids 459 (known as fenclofenac when R=2,4-Cl2) for their anti-
inflammatory activity, and demonstrated that those derivatives in which the ring B is 
substituted by mono- or di-nitro groups show the least activity, Figure 35.
366,367
 
Consistent with Atkinson et al. the diarylether acetic acid 440 prepared herein showed 
around 33% and 28% inhibitory activity against COX I and COX II, respectively (Table 
18). In their work, Atkinson attributed the reduced activity to a reduced interaction 
(through hydrophobic or charge transfer interactions) with the receptor in comparison to 
those derivatives 459 substituted by mono- or di-chloro group, Figure 35.
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O
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A
		                       COX II % inhibition at 50 nM
R=	2,3-Cl2	              51
	     2,4-Cl2	              36
	     2,4-(NO2)2	        0
	     2,4-(NH2)2	        0
	     4-Cl, 2-NO2	       4
	     4-Cl, 2-NH2	       4
	     2-Cl, 4-NO2	      19
 
Figure 35. Atkinson's derivatives of substituted (2-phenoxyphenyl)acetic acids 459 with 
their COX II percent of inhibiton. 
In summary,  it was observed that the diarylether of pyrrolidyl acetamide 334b 
possesses an appreciable activity against COX II which can be attributed to 
incorporating larger substituents to enable a better fit into the active site volume of 
COX II. However, the diarylether acetic acid 440 showed around 35% and 28% 
inhibitory activity against COX I and COX II respectively, due to a reduced interaction 
with the receptor, the result of being mono-nitro-substituted, a similar result of which 
was seen by Atkinson.
366,367
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CHAPTER FOUR - EXPERIMENTAL 
4.1 General information 
Commercially available reagents were used as received without purification. Analytical 
thin layer chromatography (TLC) was performed with plastic-backed TLC plates coated 
with silica G/UV254, in a variety of solvents. The plates were visualised by UV light 
(254 nm), p-anisaldehyde solution or KMnO4 solution. Flash column chromatography 
was conducted with Davisil silica 60Å (40-63 μm) under bellows pressure. Low 
resolution mass spectra were recorded on a Thermo FinniganLCQ Advantage MAX 
using electron spray ionisation (ESI) and high resolution mass spectra were recorded by 
the EPSRC National Mass Spectrometry Service, UK. 
1
H and 
13
C NMR spectra were 
recorded on a BrukerAvanceDPX 300 (300MHz) or a Bruker 400 (400MHz) 
spectrometer. All chemical shifts (δ) are quoted in parts per million (ppm) relative to a 
calibration reference of the residual protic solvent; CHCl3 (δH 7.26, s) or DMSO-d6 (δH 
2.50, pent.) was used as the internal standard in 
1
H NMR spectra, and 
13
C NMR shifts 
were referenced using CDCl3 (δC 77.16, t) or DMSO-d6 (δC 39.5, m) with broad band 
decoupling and the J values are measured in Hertz. Petroleum ether refers to the fraction 
which boils between 40-60 
○
C.  Melting points were measured on a Stuart® SMP10 
melting point apparatus and are uncorrected. [α]D was measured on JASCO P-2000 
polarimeter and IR spectra were recorded on a NICOLET iS10. 
 
4.2 Procedure for the synthesis of 2-coumaranone 
O
O
281  
To a solution of 2-hydroxyphenyl acetic acid (5g, 32.9 mmol) in toluene (70mL) was 
added p-toluenesulfonic acid (0.62g, 3.28 mmol). The resulting solution was stirred at 
110 
o
C under Dean-Stark conditions for 6 hours, after which it was allowed to cool, 
washed with sat. aq. NaHCO3 (3×30mL), brine (30mL) and extracted with ethyl acetate 
(2×30mL). The combined organic layers were washed with distilled water (30mL), 
dried (MgSO4), filtered and the solvent evaporated in vacuo to afford 2-coumaranone 
(4.23 g, 96%) as yellow crystals; Rf (30% EtOAc in petroleum ether): 0.76; m.p.= 51-
53 °C (EtOAc/petroleum) [(lit. m.p. 49-51 °C)
368
 (toluene)]; IR (neat, cmˉ¹): νmax 1794 
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(C=O stretching), 1051 (C-O stretching; ¹H NMR (CDCl3, 300MHz): δH 3.77 (s, 2H, 
CH2), 7.12-7.21 (m, 2H, Ar), 7.29-7.36 (m, 2H, Ar). ¹³C NMR (CDCl3, 75MHz): δC 
33.13 (CH2), 110.91, 123.16, 124.22, 124.76 (CH), 129.01, 154.81, 174.24 (C). MS 
(APCI m/z): 135 [M+H)
+
, (100%)]. 
 
4.3 General procedure for the synthesis of amides 333 and 337 
O
O
NEt2
N N
O
R= NBn2,
N
, , ,
a b c d e
+  amine
OH
R
O
n
n
281 n=1
332 n=2
333 n=1
337 n=2
N
N
O
O
g h
, ,
 
To a solution of 2-coumaranone (281) or dihydrocoumarin (332) (1 eq.) in toluene (0.1 
M) was added the amine (1.5 eq.). The resulting solution was stirred at 110 
o
C for 4-6 
hours, after which it was allowed to cool, acidified (1 M HCl to pH ca. 1-2), and 
extracted with ethyl acetate (2×30mL). The combined organic layers were washed with 
distilled water (2×30mL) and brine (30mL), dried (MgSO4), filtered and the solvent 
evaporated in vacuo to afford the pure amide directly or after flash column 
chromatography. 
 
N,N-Dibenzyl-2-(2-hydroxyphenyl)acetamide, 333a 
OH
N
O
Ph
Ph
333a  
After aqueous work-up the solvent was evaporated in vacuo to afford the title 
compound as yellow crystals (91%). Rf (20% EtOAc in petroleum ether): 0.66; m.p.= 
139-141 
oC (toluene); IR (neat, cmˉ¹): νmax 1613 (C=O stretching), 3064 (O-H 
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stretching), 1477 (C-O stretching), ¹H NMR (CDCl3, 300MHz): δH 3.81 (s, 2H, CH2), 
4.63 (s, 2H, NCH2), 4.64 (s, 2H, NCH2), 6.68-6.76 (m, 2H, Ar), 7.02 (dd, 1H, J= 1.5Hz, 
J= 8.0Hz, Ar), 7.14-7.21 (m, 5H, Ar), 7.26-7.41 (m, 6H, Ar), 10.07 (s, 1H, OH); ¹³C 
NMR (CDCl3, 75MHz): δC 37.18, 49.33, 51.26, (CH2), 118.33, 120.14 (CH), 120.99 (C), 
126.52, 127.91, 128.15, 128.42, 128.90, 129.23, 129.28, 130.70 (CH), 135.70, 136.28, 
157.06, 174.45 (C); MS (APCI m/z): 332 [M+H)
+
, (100%)]; HRMS FAB 
[M+H]
+
 332.1645, C22H21 NO2+H
+
 requires 332.1651. 
 
2-(2-Hydroxyphenyl)-1-(pyrrolidin-1-yl)ethanone, 333b 
OH
N
O
333b  
After aqueous work-up the solvent was evaporated in vacuo to afford the title 
compound as colourless crystals (89%). Rf (20% EtOAc in toluene): 0.42; m.p.= 120-
122 °C (EtOAc/petroleum ether); IR (neat, cmˉ¹): νmax 1610 (C=O stretching), 2959 
(OH stretching), 1094 (C-O stretching); ¹H NMR (CDCl3, 300MHz): δH 1.89 (pent, 2H, 
J= 6.0Hz, CH2CH2), 2.01 (pent, 2H, J= 6.0Hz, CH2CH2), 3.48 (t, 2H, J= 6.0Hz, CH2), 
3.68 (t, 2H, J= 6.0Hz, NCH2), 3.70 (s, 2H, NCH2), 6.81 (td, 1H, J= 1.0Hz, J= 8.0Hz, 
Ar), 6.99 (dd, 1H, J= 1.5Hz, J= 8.0Hz, Ar), 7.03 (dd, 1H, J= 1.0Hz, J= 8.0Hz, Ar), 7.19 
(td, 1H, J= 1.0Hz, J= 8.0Hz, Ar), 10.37 (s, 1H, OH); ¹³C NMR (CDCl3, 75MHz): δC 
24.53, 26.12, 39.03, 46.34, 47.77 (CH2), 118.44, 119.99, 121.06, 129.17 (CH), 130.56, 
157.35, 171.60 (C); MS (APCI m/z): 206 [M+H)
+
, (100%)]; HRMS FAB 
[M+H]
+
 206.1176, C12H15NO2+H
+
 requires 206.1176. 
 
2-(2-Hydroxyphenyl)-1-(piperidin-1-yl)ethanone, 333c 
333c
OH
N
O
 
Flash column chromatography (SiO2; 50% EtOAc in petroleum ether) afforded the title 
compound as a yellow crystals (98%). Rf (30% EtOAc in petroleum ether): 0.48; m.p.= 
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107-109 °C (EtOAc/petroleum ether); IR (neat, cmˉ¹): νmax 1616 (C=O stretching), 3166 
(OH stretching), 1039 (C-O stretching); ¹H NMR (CDCl3, 300MHz): δH 1.52-1.63 (m, 
6H, CH2CH2), 3.55 (t, 2H, J= 6.0Hz, NCH2), 3.61 (t, 2H, J= 6.0Hz, NCH2), 3.73 (s, 2H, 
CH2), 6.81 (t, 1H, J= 7.5Hz, Ar), 6.95 (d, 1H, J= 9.0Hz, Ar), 7.03 (d, 1H, J= 9.0Hz, Ar), 
7.16 (t, 1H, J= 7.5Hz, Ar), 9.87 (s, 1H, OH); ¹³C NMR (CDCl3, 75MHz): δC 24.25, 
25.36, 26.52, 36.41, 43.45, 48.16, (CH2), 117.99, 120.03 (CH), 121.11 (C), 128.91, 
130.18 (CH), 157.03, 171.17 (C); MS (APCI m/z): 220 [M+H)
+
, (100%)]; HRMS FAB 
[M+H]
+
 220.1331, C13H17NO2+H
+
 requires 220.1332. 
 
2-(2-Hydroxyphenyl)-1-morpholinoethanone, 333d 
333d
OH
N
O
O
 
Flash column chromatography (SiO2; 50% EtOAc in petroleum ether) afforded the title 
compound as a lemon-yellow crystalline solid (81%). Rf (30% EtOAc in petroleum 
ether): 0.34; m.p.= 123-125 °C (EtOAc/petroleum ether). IR (neat, cmˉ¹): νmax 1615 
(C=O stretching), 2931 (OH stretching), 1092 (C-O stretching); ¹H NMR (CDCl3, 
300MHz): δH 3.65-3.68 (m, 8H, CH2CH2), 3.74 (s, 2H, CH2), 6.83 (td, 1H, J= 1.5Hz, J= 
8.0Hz, Ar), 6.99 (t, 2H, J= 6.0Hz, Ar), 7.19 (td, 1H, J= 1.5Hz, J= 8.0Hz, Ar), 9.56 (s, 
1H, OH); ¹³C NMR (CDCl3, 75MHz): δC 36.31, 42.59, 47.29, 66.51, 66.65 (CH2), 
118.32, 120.36 (CH), 120.62 (C), 129.9, 130.17 (CH), 165.95, 171.71 (C); MS (APCI 
m/z): 222 [M+H)
+
, (100%)]; HRMS FAB [M+H]
+
 222.1125, C12H15NO3+H
+
 requires 
222.1125. 
 
N,N-Diethyl-2-(2-hydroxyphenyl)acetamide, 333e 
333e
OH
N
O
 
Flash column chromatography (SiO2; 15% EtOAc in petroleum ether) afforded the title 
compound as an off-white solid (96%). Rf (30% EtOAc in petroleum ether): 0.54; m.p.= 
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88-90 °C (EtOAc/petroleum ether); IR (neat, cmˉ¹): νmax 1618 (C=O stretching), 3173 
(OH stretching), 1090 (C-O stretching); ¹H NMR (CDCl3, 300MHz): δH 1.13 (t, 3H, J= 
7.5Hz, CH3), 1.29 (t, 3H, J= 6.0Hz, CH3), 3.39 (q, 2H, J= 6.0Hz, CH2CH3), 3.50 (q, 2H, 
J= 7.5Hz, CH2CH3), 3.71 (s, 2H, CH2), 6.82 (td, 1H, J= 1.5Hz, J= 8.0Hz, Ar), 6.97-7.04 
(m, 2H, Ar), 7.19 (td, 1H, J= 3.0Hz, J= 9.0Hz, Ar), 10.47 (s, 1H, OH); ¹³C NMR 
(CDCl3, 75MHz): δC 13.05, 14.94 (CH3), 37.06, 41.47, 43.67 (CH2), 118.41, 119.97 
(CH), 121.31 (C), 129.15, 130.54 (CH), 157.43, 172.83 (C); MS (APCI m/z): 208 
[M+H)
+
, (100%)]; HRMS FAB [M+H]
+
 208.1332, C12H17NO2+H
+
 requires 208.1332. 
 
1-[(2S,5S)-2,5-dimethylpyrrolidin-1-yl]-2-(2-hydroxyphenyl)ethanone 333g 
333g
OH
N
O
 
Flash column chromatography (SiO2; 5% EtOAc in toluene) afforded the title 
compound as a colourless solid (73%). Rf (20% EtOAc in toluene): 0.56; m.p. =142-
144 °C (EtOAc in toluene). [α]D= −69.8 (ethanol, c = 0.2 g/100ml). IR (neat, cmˉ¹): νmax 
1560 (C=O stretching), 2965 (OH stretching), 1035 (C-O stretching); ¹H NMR (CDCl3, 
300MHz): δH 1.15 (d, 3H, J= 6.0Hz, CH3), 1.31 (d, 3H, J= 6.0Hz, CH3), 1.57-1.61 (m, 
1H, CH), 1.66-1.71 (m, 1H, CH), 2.07-2.29 (m, 2H, CH2), 3.67 (d, 1H, HA/B, J= 15.0Hz, 
CHAHBAr), 3.73 (d, 1H, HB/A, J= 15.0Hz, CHBHAAr), 4.21-4.28 (m, 2H, CH2), 6.80 (t, 
1H, J= 7.5Hz, Ar), 6.97-7.03 (m, 2H, Ar), 7.17 (t, 1H, J= 7.5Hz, Ar), 11.01 (s, 1H, 
OH); ¹³C NMR (CDCl3, 75MHz): δC 19.02, 22.56 (CH3), 29.20, 30.84, 39.32 (CH2), 
53.99, 55.04 (CH), 118.54, 119.77 (CH), 121.62 (C), 129.14, 130.73 (CH), 157.55, 
172.18 (C); MS (APCI m/z): 234 [M+H)
+
, (100%)]. 
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1-((2S,5S)-2,5-Bis(methoxymethyl)pyrrolidin-1-yl)-2-(2-hydroxyphenyl)ethanone, 
333h 
333h
OH
N
O
O
O
 
Flash column chromatography (SiO2; 60% EtOAc in petroleum ether) to afford the title 
compound as yellow sticky oil (99%). Rf (30% EtOAc in petroleum ether): 0.42. [α]D= 
−53.43 (ethanol, c = 0.46 g/100ml). IR (neat, cmˉ¹): νmax 1618 (C=O stretching), 2929 
(OH stretching), 1040 (C-O stretching); ¹H NMR (CDCl3, 300MHz): δH 1.88-2.01 (m, 
3H, CH2CH2), 2.12-2.21 (m, 1H, CH2CH2), 2.25-3.54 (m, 10H includes 2(s, 3H) @ 
3.24 and 3.37, CH2OCH3), 3.73 (d, 1H, HA/B, J= 14.0Hz, CHAHBAr), 3.82 (d, 1H, HB/A, 
J= 14.0Hz, CHBHAAr), 4.20-4.27 (m, 2H), 6.81 (t, 1H, J= 6.0Hz, Ar), 6.97 (d, 1H, J= 
8.0Hz, Ar), 7.03 (d, 1H, J= 7.0Hz, Ar), 7.18 (t, 1H, J= 7.5Hz, Ar), 10.59 (s, 1H, OH); 
¹³C NMR (CDCl3, 75MHz): δC 25.81, 27.54, 39.53 (CH2), 57.69, (CH), 59.15 (CH3), 
59.41 (CH), 71.29, 74.79 (CH2), 118.49, 119.95 (CH), 121.62 (C), 129.18, 130.08 (CH), 
157.23, 173.46 (C); MS (APCI m/z): 294 [M+H)
+
, (100%)]; HRMS FAB 
[M+H]
+
 294.1702, C16H23NO4+H
+
 requires 294.1700. 
 
N,N-Dibenzyl-3-(2-hydroxyphenyl)propanamide, 337a 
OH O
N Ph
Ph
337a  
After aqueous work-up the solvent was evaporated in vacuo to afford the title 
compound as a colourless solid (92%). Rf (10% EtOAc in toluene): 0.63; m.p.= 148-150 
o
C (EtOAc/toluene); IR (neat, cmˉ¹): νmax 1613 (C=O stretching), 3181 (O-H stretching), 
1142 (C-O stretching); ¹H NMR (CDCl3, 300MHz): δH 2.82 (t, 2H, J= 6.0Hz, CH2CH2), 
3.01 (t, 2H, J= 6.0Hz, CH2C=O), 4.41 (s, 2H, NCH2), 4.58 (s, 2H, NCH2), 6.82 (td, 1H, 
J= 1.0Hz, J= 8.0Hz, Ar), 6.96-7.01 (m, 4H, Ar), 7.13-7.20 (m, 3H, Ar), 7.27-7.30 (m, 
6H, Ar), 9.31 (s, 1H, OH); ¹³C NMR (CDCl3, 75MHz): δC 25.00, 35.11, 48.98, 49.97 
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(CH2), 118.19, 120.40, 126.37, 127.78, 127.90 (CH), 128.10 (C), 128.15, 128.50, 
128.82, 129.17, 130.75 (CH), 135.48, 136.63, 155.37, 174.99 (C); MS (APCI m/z): 346 
[M+H)
+
, (100%)]; HRMS FAB [M+H]
+
 346.1807, C23H23NO2+H
+
 requires 346.1802. 
 
Pyrrolidyl-2-(2-hydroxyphenyl)propanamide, 337b 
OH O
N
337b  
After aqueous work-up the solvent was evaporated in vacuo to afford the title 
compound as colourless crystals (100%). Rf (50% EtOAc in petroleum ether): 0.51; 
m.p.= 151-153 
oC (EtOAc/toluene); IR (neat, cmˉ¹): νmax 1622 (C=O stretching), 1039 
(C-N stretching), 3283 (OH stretching); ¹H NMR (CDCl3, 300MHz): δH 1.78-1.98 (m, 
4H, CH2CH2), 2.66 (t, 2H, J= 6.0Hz, CH2CH2Ar), 2.94 (t, 2H, J= 6.0Hz, CH2C=O), 
3.33 (t, 2H, J= 7.5Hz, NCH2), 3.45 (t, 2H, J= 6.0Hz, NCH2), 6.82 (t, 1H, J= 6.0Hz, Ar), 
6.92 (dd, 1H, J= 1.0Hz, J= 8.0Hz, Ar), 7.04-7.12 (m, 2H, Ar), 9.90 (s, 1H, OH); ¹³C 
NMR (CDCl3, 75MHz): δC 24.40, 24.44, 26.05, 36.74, 46.31, 46.66 (CH2), 118.32, 
120.12, 128.09, 128.62 (CH), 130.73, 155.70, 172.42 (C); MS (APCI m/z): 220 [M+H)
+
, 
(100%)]; HRMS FAB [M+H]
+
 220.1332, C13H17NO2+H
+
 requires 220.1332. 
 
3-(2-Hydroxyphenyl)-1-(1-piperidyl)propan-1-one, 337c 
OH O
N
337c  
Flash column chromatography (SiO2; 50% EtOAc in petroleum ether) afforded the title 
compound as colourless crystals (78%). Rf (30% EtOAc in petroleum ether): 0.46; 
m.p.= 130-132 °C (EtOAc/petroleum ether). IR (neat, cmˉ¹): νmax 1619 (C=O stretching), 
3278 (OH stretching), 1013 (C-O stretching); ¹H NMR (CDCl3, 300MHz): δH 1.55-1.62 
(m, 6H, CH2CH2), 2.71 (t, 2H, J= 4.5Hz, CH2CH2Ar), 2.94 (t, 2H, J= 4.5Hz, CH2C=O), 
3.34 (t, 2H, J= 4.5Hz, NCH2), 3.55 (t, 2H, J= 4.5Hz, NCH2), 6.82 (t, 1H, J= 6.0Hz, Ar), 
6.91 (d, 1H, J= 9.0Hz, Ar), 7.5 (d, 1H, J= 9.0Hz, Ar), 7.11 (t, 1H, J= 7.5Hz, Ar), 9.87 (s, 
1H, OH); ¹³C NMR (CDCl3, 75MHz): δC 24.39, 24.82, 25.51, 26.21, 35.25, 43.39, 46.45, 
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(CH2), 118.14, 120.12, 128.06 (CH), 128.55 (C), 130.77 (CH), 155.69, 172.00 (C); MS 
(APCI m/z): 234 [M+H)
+
, (100%)]; HRMS FAB [M+H]
+
 234.1489, 
C14H19NO2+H
+
 requires 234.1489. 
 
3-(2-Hydroxyphenyl)-1-morpholino-propan-1-one, 337d 
OH O
N
O
337d  
Flash column chromatography (SiO2; 20% EtOAc in petroleum ether) afforded the title 
compound as a colourless solid (82%). Rf (30% EtOAc in petroleum ether): 0.29; m.p.= 
129-131 °C (EtOAc/petroleum ether). IR (neat, cmˉ¹): νmax 1618 (C=O stretching), 2974 
(OH stretching), 1035 (C-O stretching); ¹H NMR (CDCl3, 300MHz): δH 2.71 (t, 2H, J= 
6.0Hz, CH2CH2Ar), 2.96 (t, 2H, J= 6.0Hz, CH2C=O), 3.42 (t, 2H, J= 6.0Hz, NCH2), 
3.62 (m, 6H, NCH2OCH2), 6.84 (t, 1H, J= 5.5Hz, Ar), 6.92 (d, 1H, J= 9.0Hz, Ar), 7.05 
(d, 1H, J= 9.0Hz, Ar), 7.13 (td, 1H, J= 1.0Hz, J= 8.0Hz, Ar), 9.43 (s, 1H, OH); ¹³C 
NMR (CDCl3, 75MHz): δC 24.59, 35.11, 42.48, 45.73, 66.34, 66.76 (CH2), 118.11, 
120.34, 128.14 (CH), 128.21 (C), 130.76 (CH), 155.45, 172.64 (C); MS (APCI m/z): 
236 [M+H)
+
, (100%)]; HRMS FAB [M+H]
+
 236.1283, C13H17NO3+H
+
 requires 
236.1283.  
 
N,N-Diethyl-3-(2-hydroxyphenyl) propionamide, 337e
26 
OH O
N
337e  
The solvent was evaporated in vacuo to afford the title compound as a pale yellow solid 
(100%). Rf (30% EtOAc in petroleum ether): 0.41; m.p.= 128-130 °C (EtOAc/petroleum 
ether), IR (neat, cmˉ¹): νmax 1613 (C=O stretching), 3175 (OH stretching), 1071 (C-O 
stretching); ¹H NMR (CDCl3, 300MHz): δH 1.08 (t, 3H, J= 4.5Hz, CH3), 1.11 (t, 3H, J= 
4.5Hz, CH3), 2.71 (t, 2H, J= 6.0Hz, CH2C=O), 2.94 (t, 2H, J= 6.0Hz, CH2Ar), 3.26 (q, 
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2H, J= 9.0Hz, NCH2), 3.36 (q, 2H, J= 9.0Hz, NCH2), 6.81 (td, 1H, J= 3.0Hz, J= 9.0Hz, 
Ar), 6.91 (dd, 1H, J= 3.0Hz, J= 9.0Hz, Ar), 7.04 (dd, 1H, J= 1.0Hz, J= 8.0Hz, Ar), 7.11 
(td, 1H, J= 1.0Hz, J= 8.0Hz, Ar), 9.76 (s, 1H, OH); ¹³C NMR (CDCl3, 75MHz): δC 
13.02, 13.88 (CH3), 24.90, 35.04, 40.95, 42.09 (CH2), 118.13, 120.08, 128.05, 128.48 
(CH), 130.70, 155.69, 173.13 (C); MS (APCI m/z): 222 [M+H)
+
, (100%)]. HRMS FAB 
[M+H]
+
 222.1485, C13H19NO2+H
+
 requires 222.1489.
369
 
 
4.4 General procedure for the Truce-Smiles rearrangement reactions 
To a solution of the amide (333a-h, 337a-e) (1 eq.) in dimethylsulfoxide (0.1 M) was 
added potassium carbonate (2.5 eq.) and the resulting solution was stirred at room 
temperature for 30 minutes. 1-Fluoro-2-nitrobenzene (1.05 eq) was added and the 
reaction stirred for 24 hours at 60 °C. After which, the mixture was acidified with 
hydrochloric acid solution (1 M, 30mL). The product was extracted with ethyl acetate 
(2×30mL) and the combined organic layers were washed with distilled water (2×20mL), 
brine (10mL), dried (MgSO4), filtered and the solvent evaporated in vacuo to afford the 
crude residue which was purified by flash column chromatography. 
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2-(2-(2-Nitrophenoxy)phenyl)-N,N-dibenzylacetamide, 334a 
334a
O
N
O
NO2
Ph
Ph
 
Flash column chromatography (SiO2; 10% EtOAc in petroleum ether) afforded the title 
compound as a yellow oil (40%). Rf (30% EtOAc in petroleum ether): 0.49; IR (neat, 
cmˉ¹): νmax 1644 (C=O stretching), 1079 (C-O stretching), 1523, 1349 (N-O stretching); 
¹H NMR (CDCl3, 300MHz): δH 3.90 (s, 2H, CH2C=O), 4.55 (s, 2H, NCH2), 4.59 (s, 2H, 
NCH2), 6.88 (dd, 1H, J= 1.5Hz, J= 8.0Hz, Ar), 7.07 (dd, 1H, J= 1.5Hz, J= 8.0Hz, Ar), 
7.12-7.15 (m, 3H, Ar), 7.18-7.36 (m, 10H, Ar), 7.45 (dd, 1H, J= 1.5Hz, J= 8.0Hz, Ar), 
7.50 (dd, 1H, J= 1.5Hz, J= 8.0Hz, Ar), 7.97 (dd, 1H, J= 1.5Hz, J= 8.0Hz, Ar). ¹³C NMR 
(CDCl3, 75MHz): δC 34.80, 48.65, 50.38 (CH2), 118.83, 120.41, 123.04, 125.08, 125.67, 
126.53, 127.41, 127.64, 128.34, 128.61, 128.76, 128.98, 131.99, 134.46 (CH), 136.43, 
137.29, 141.00, 150.76, 153.65, 171.19 (C); MS (APCI m/z): 453 [M+H)
+
, (100%)]; 
HRMS FAB [M+H]
+
 453.1810, C28H24N2O4+H
+
 requires 453.1809. 
 
2-(2-(2-Nitrophenoxy)phenyl)-1-(pyrrolidin-1-yl)ethanone, 334b 
O
N
O
NO2
334b  
Flash column chromatography (SiO2; 100% petroleum ether) afforded the title 
compound as yellow oil (90%). Rf (30% EtOAc in petroleum ether): 0.39; IR (neat, 
cmˉ¹): νmax 1636 (C=O stretching), 1247 (C-N stretching), 1098 (C-O stretching), 1522, 
1345 (N-O stretching); ¹H NMR (CDCl3, 300MHz): δH 1.69-1.92 (m, 4H, CH2CH2), 
3.31 (t, 2H, J= 6.0Hz, NCH2), 3.43 (t, 2H, J= 7.5Hz, NCH2), 3.67 (s, 2H, CH2Ar), 6.90 
(dd, 1H, J= 1.5Hz, J= 8.0Hz, Ar), 6.95 (dd, 1H, J= 1.5Hz, J= 8.0Hz, Ar), 7.13-7.26 (m, 
3H, Ar), 7.41 (dd, 1H, J= 1.5Hz, J= 8.0Hz, Ar), 7.45 (dd, 1H, J= 1.5Hz, J= 8.0Hz, Ar), 
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7.92 (dd, 1H, J= 1.5Hz, J= 8.0Hz, Ar); ¹³C NMR (CDCl3, 75MHz): δC 24.43, 26.15, 
35.89, 45.93, 46.89 (CH2), 119.49, 119.56, 122.68, 125.41, 125.51 (CH), 127.84 (C), 
128.60, 132.01, 134.35 (CH), 140.64, 150.92, 153.09, 168.74 (C); MS (APCI m/z): 327 
[M+H)
+
, (100%)]; HRMS FAB [M+H]
+
 327.1343, C18H18N2O4+H
+
 requires 327.1339. 
 
2-[2-(2-Nitrophenoxy)phenyl]-1-(1-piperidyl)ethanone, 334c 
334c
O
N
O
NO2
 
Flash column chromatography (SiO2; 10% EtOAc in toluene) afforded the title 
compoundas a lemon-yellow solid (54%). Rf (50% EtOAc in toluene): 0.55; m.p.= 74-
76 °C (EtOAc in toluene). IR (neat, cmˉ¹): νmax 1642 (C=O stretching), 1068 (C-O 
stretching), 1584, 1350 (N-O stretching); ¹H NMR (CDCl3, 300MHz): δH 1.48-1.57 (m, 
4H, CH2CH2), 1.65-1.7 (m, 2H, CH2CH2), 3.52 (t, 2H, J= 6.0Hz, NCH2), 3.61 (t, 2H, J= 
6.0Hz, NCH2), 3.86 (s, 2H, CH2Ar), 7.03 (t, 2H, J= 9.0Hz, Ar), 7.29 (d, 1H, J= 6.0Hz, 
Ar), 7.34-7.41 (m, 2H, Ar), 7.53-7.62 (m, 2H, Ar), 8.04 (dd, 1H, J= 1.5Hz, J= 8.0Hz, 
Ar). ¹³C NMR (CDCl3, 75MHz): δC 24.37, 25.45, 26.16, 34.24, 42.88, 46.99 (CH2), 
119.28, 119.35, 122.72, 125.23, 125.52, 128.40, 131.31, 134.25 (CH), 127.70, 140.55, 
150.65, 152.55, 168.54 (C); MS (APCI m/z): 341 [M+H)
+
, (100%)]; HRMS FAB 
[M+H]
+
 341.1498, C19H20N2O4+H
+
 requires 341.1496.  
 
2-(2-(2-Nitrophenoxy)phenyl)-1-morpholinoethanone, 334d 
334d
O
N
O
NO2
O
 
Flash column chromatography (SiO2; 40% EtOAc in toluene) afforded the title 
compound as a lemon-yellow oil (45%). Rf (50% EtOAc in toluene): 0.37; IR (neat, 
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cmˉ¹): νmax 1642 (C=O stretching), 1068 (C-O stretching), 1584, 1350 (N-O stretching); 
¹H NMR (CDCl3, 300MHz): δH 3.47-352 (m, 8H, NCH2OCH2), 3.71 (s, 2H, CH2Ar), 
6.89 (m, 2H, Ar), 7.12-7.18 (m, 2H, Ar), 7.23 (t, 1H, J= 7.5Hz, Ar), 7.38-7.47 (m, 2H, 
Ar), 7.89 (d, 1H, J= 9.0Hz, Ar); ¹³C NMR (CDCl3, 75MHz): δC 34.09, 42.25, 46.37, 
66.64, 66.79 (CH2), 119.27, 119.53, 123.05, 125.44, 125.74 (CH), 127.09 (C), 128.79, 
131.46, 134.41 (CH), 140.75, 150.55, 152.62, 169.20, (C); MS (APCI m/z): 343 
[M+H)
+
, (100%)]; HRMS FAB [M+H]
+
 343.1288, C18H18N2O5+H
+
 requires 343.1288. 
 
N,N-Diethyl-2-[2-(2-nitrophenoxy)phenyl]acetamide, 334e 
O
N
O
NO2
334e  
Flash column chromatography (SiO2; 100% EtOAc in toluene) afforded the title 
compound as a yellow oil (74%). Rf (50% EtOAc in toluene): 0.73; IR (neat,cmˉ¹): νmax 
1638 (C=O stretching), 1098 (C-O stretching), 1526, 1368 (N-O stretching); ¹H NMR 
(CDCl3, 300MHz): δH 0.97 (t, 3H, J= 7.5Hz, CH3), 1.09 (t, 3H, J= 7.5Hz, CH3), 3.52 (m, 
4H, CH2CH3), 3.71 (s, 2H, CH2Ar), 6.90-6.98 (m, 2H, Ar), 7.15-7.29 (m, 3H, Ar), 7.39-
7.48 (m, 2H, Ar), 7.90 (dd, 1H, J= 1.5Hz, J= 8.0Hz, Ar). ¹³C NMR (CDCl3, 75MHz): δC 
12.74, 14.02 (CH3), 34.25, 40.31, 42.33 (CH2), 119.12, 119.34, 123.60, 125.11, 125.39 
(CH), 127.90 (C), 128.33, 131.49, 134.21 (CH), 140.44, 150.60, 152.73, 169.37 (C); 
MS (APCI m/z): 329 [M+H)
+
, (100%)]; HRMS FAB [M+H]
+
 329.1495, 
C18H20N2O4+H
+
 requires 329.1496. 
 
2-(2-(2-Nitrophenoxy)phenyl)-1-((2S,5S)-2,5-dimethylpyrrolidin-1-yl)ethanone 
334g 
334g
N
O
O
NO2
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Flash column chromatography (SiO2; 3% EtOAc in toluene) afforded the title 
compound as a yellow solid (54%). Rf (30% EtOAc in toluene): 0.40.  m.p.= 110-112 ºC 
(EtOAc/toluene); [α]D= −22.53 (ethanol, c = 0. 3 g/100ml). IR (neat, cmˉ¹): νmax 1635 
(C=O stretching), 1163 (C-O stretching), 1521, 1356 (N-O stretching); ¹H NMR 
(CDCl3, 300MHz): 0.86 (d, 3H, J= 6.3Hz, CH3), 1.17 (d, 3H, J= 6.3Hz, CH3), 1.42 (q, 
1H, J= 4.5Hz, CH), 1.53 (q, 1H, J= 4.5Hz, CH), 2.01-2.08 (m, 2H, NCH2), 3.48 (d, 1H, 
HA/B, J= 15.6Hz, CHAHBAr), 3.92 (d, 1H, HB/A, J= 15.6Hz, CHBHAAr), 4.07-4.15 (m, 
2H, NCH2),  6.91 (d, 1H, J= 8.0Hz, Ar), 6.97 (d, 1H, J= 8.0Hz, Ar), 7.11 (td, 1H, J= 
1.5Hz, J= 7.5Hz, Ar), 7.18-7.22 (m, 2H, Ar), 7.23-7.43 (m, 2H, Ar), 7.90 (dd, 1H, J= 
1.0Hz, J= 8.0Hz, Ar); ¹³C NMR (CDCl3, 75MHz): δC 18.87, 21.73, (CH3), 29.20, 30.89, 
36.14 (CH2), 53.36, 54.06, 119.40, 122.53, 125.34, 125.51 (CH), 128.47, 128.58, 
132.28, 134.38 (CH), 140.65, 145.76, 151.07,  152.96, 168.72 (C); MS (APCI m/z): 355 
[M+H)
+
, (100%)]; HRMS FAB [M+H]
+
 355.1652, C22H22N2O4+H
+
 requires 355.1652. 
 
1-((2S,5S)-2,5-Bis(methoxymethyl)pyrrolidin-1-yl)-2-(2-(2-
nitrophenoxy)phenyl)ethanone, 334h 
334h
O
N
O
NO2 O
O
 
Flash column chromatography (SiO2; 40% EtOAc in petroleum ether) afforded the title 
compound as a lemon-yellow sticky oil (45%). Rf (60% EtOAc in petroleum ether): 
0.50. [α]D= −51.02 (ethanol, c = 0.2 g/100ml). IR (neat, cmˉ¹): νmax 1639 (C=O 
stretching), 1107 (C-O stretching), 1583, 1350 (N-O stretching); ¹H NMR (CDCl3, 
300MHz): δH 1.83-1.98 (m, 4H, CH2CH2), 2.97 (t, 1H, J= 6.0Hz, NCH), 3.18 (s, 3H, 
OCH3), 3.20-3.41 (m, 6H, includes (s, 3H) @ 3.29, OCH3, NCH, OCH2), 3.64 (d, 1H, 
HA/B, J= 15.0Hz, CHAHBAr), 3.94 (d, 1H, HB/A, J= 15.0Hz, CHBHAAr), 4.08-4.14 (m, 
2H, OCH2), 6.89 (d, 1H, J= 8.0Hz, Ar), 7.02 (d, 1H, J= 8.0Hz, Ar), 7.15-7.26 (m, 3H, 
Ar), 7.37 (dd, 1H, J= 1.0Hz, J= 8.0Hz, Ar), 7.46 (td, 1H, J= 1.0Hz, J= 8.0Hz, Ar), 7.90 
(dd, 1H, J= 1.0Hz, J= 8.0Hz, Ar); ¹³C NMR (CDCl3, 75MHz): δC 25.34, 27.09, 36.54 
(CH2), 57.07, 57.93 (CH3), 58.79, 59.09 (CH), 70.88, 74.20 (CH2), 119.109, 119.67, 
  Experimental 
160 
 
122.71, 125.21, 125.49 (CH), 128.18 (C), 128.52, 132.21, 134.26 (CH), 140.84,  150.82, 
153.21, 169.80 (C); MS (APCI m/z): 415 [M+H)
+
, (100%)]; HRMS FAB 
[M+H]
+
 415.1861, C22H26N2O6+H
+
 requires 415.1864. 
 
2-(2-(2-Nitrophenoxy)phenyl)-N,N-dibenzyl-2-(2-nitrophenyl)acetamide, 335a 
335a
O
O
NO2
O2N
N
Ph Ph
 
Flash column chromatography (SiO2; 20% EtOAc in petroleum ether) afforded the title 
compound as orange crystals (54%). Rf (30% EtOAc in petroleum ether): 0.44; m.p.= 
170-172 
o
C (EtOAc/petroleum ether); IR (neat, cmˉ¹): νmax 1647 (C=O stretching); ¹H 
NMR (CDCl3, 300MHz): δH 4.39 (d, 1H, HA/B, J= 15.0Hz, NCHAHB), 4.52 (d, 1H, HC/D, 
J= 15.0Hz, NCHCHD), 4.64 (d, 1H, HD/C, J= 15.0Hz, NCHDHC), 4.88 (d, 1H, HB/A, J= 
15.0Hz, NCHBHAAr), 6.45 (dd, 1H, J= 3.0Hz, J= 9.0Hz, Ar), 6.15 (s, 1H, CHAr), 6.75 
(dd, 1H, J= 1.0Hz, J= 8.0Hz, Ar), 6.94-6.98 (m, 2H, Ar), 7.11 (td, 1H, J= 3.0Hz, J= 
9.0Hz, Ar), 7.16-7.38 (m, 13H, Ar), 7.50 (d, 2H, J= 6.0Hz, Ar), 7.88 (dt, 2H, J= 3.0Hz, 
J= 9.0Hz, Ar); ¹³C NMR (CDCl3, 75MHz): δC 44.27 (CH), 48.44 50.68 (CH2), 118.59, 
120.21 123.65, 124.84, 124.93, 125.95, 127.45, 127.48, 127.96, 128.59, 128.65, 128.74, 
129.63, 130.95, 132.33, 132.95, 134.10 (CH), 135.73, 136.91, 140.96, 148.89, 149.29, 
153.25, 171.08 (C); MS (APCI m/z): 574 [M+H)
+
, (100%)]; HRMS FAB 
[M+H]
+
 574.1963, C34H27N3O6+H
+
 requires  574.1973. 
 
2-[2-(2-Nitrophenoxy)phenyl]-2-(2-nitrophenyl)-1-pyrrolidin-1-yl-ethanone, 335b 
335b
O
O
NO2
O2N
N
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Flash column chromatography (SiO2; 10% EtOAc in toluene) afforded the title 
compound as a yellow solid (19%). Rf (30% EtOAc in toluene): 0.46; m.p.= 160-162 °C 
(EtOAc/toluene); IR (neat, cmˉ¹): νmax 1638 (C=O stretching), 1187 (C-O stretching), 
1234 (C-N stretching),1518, 1341 (N-O stretching); (¹H NMR (CDCl3, 300MHz): δH 
1.77-1.95 (m, 4H, CH2CH2), 3.18-3.25 (m, 1H, NCH2), 3.35-3.44 (m, 1H, NCH2), 3.49-
3.55 (m, 1H, NCH2), 3.58-3.66 (m, 1H, NCH2), 6.08 (s, 1H, CHAr), 6.55 (dd, 1H, J= 
1.0Hz, J= 8.0Hz, Ar), 6.80 (dd, 1H, J= 1.0Hz, J= 8.0Hz, Ar), 7.06 (td, 1H J= 1.0Hz, J= 
8.0Hz, Ar), 7.14-7.29 (m, 5H, Ar), 7.39-7.46 (m, 2H, Ar), 7.77 (d, 1H, J= 8.0Hz, Ar) 
7.84 (dd, 1H, J= 1.0Hz, J= 8.0Hz, Ar); ¹³C NMR (CDCl3, 75MHz): δC 24.45, 26.81 
(CH2), 45.88 (CH), 46.31, 46.46 (CH2), 118.63, 119.80, 123.47, 124.63, 125.21, 125.95, 
127.81, 129.07, 129.43, 130.53, 132.23, 132.91 (CH), 133.91, 134.10, 140.74, 148.99, 
149.46, 153.27, 168.53 (C); MS (APCI m/z): 448 [M+H)
+
, (100%)]; HRMS FAB 
[M+H]
+
 448.1495, C24H21N3O6+H
+
 requires  448.1503. 
 
2-[2-(2-Nitrophenoxy)phenyl]-2-(2-nitrophenyl)-1-(1-piperidyl)ethanone, 335c 
335c
O
O
NO2
O2N
N
 
Flash column chromatography (SiO2; 10% EtOAc in toluene) afforded the title 
compound as a lemon-yellow oil (24%). Rf (50% EtOAc in toluene): 0.63; IR (neat, 
cmˉ¹): νmax 1639 (C=O stretching), 1094 (C-O stretching), 1521, 1346 (N-O stretching); 
¹H NMR (CDCl3, 300MHz): δH 1.48-1.60 (m, 6H, CH2CH2) 3.29-3.36 (m, 1H, NCH2), 
3.51-3.57 (m, 2H, NCH2), 3.68-3.74 (m, 1H, NCH2), 6.32 (s, 1H, CHAr), 6.60 (d, 1H, 
J= 9.0Hz, Ar), 6.88 (d, 1H, J= 9.0Hz, Ar), 7.09-7.37 (m, 6H, Ar), 7.47 (t, 2H, J= 6.0Hz, 
Ar), 7.85 (d, 1H, J= 9.0Hz, Ar), 7.90 (d, 1H, J= 6.0Hz, Ar). ¹³C NMR (CDCl3, 75MHz): 
δC 24.55, 25.67, 25.86, 43.42, 47.03 (CH2), 44.32, 118.68, 119.89, 123.57, 124.65, 
125.08, 125.95, 127.67 (CH), 128.84 (C), 129.51, 130.86, 132.11, 132.80, 134.08 (CH), 
134.55, 140.69, 148.70, 149.26, 152.82, 168.49 (C); MS (APCI m/z): 462 [M+H)
+
, 
(100%)]; HRMS FAB [M+H]
+
 462.1654, C25H23N3O6+H
+
 requires 462.1660. 
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2-(2-(2-Nitrophenoxy)phenyl)-1-morpholino-2-(2-nitrophenyl)ethanone, 12d 
O
O
NO2
O2N
N
O  
Flash column chromatography (SiO2; 30% EtOAc in toluene) afforded the title 
compound as a sticky orange oil (6%). Rf (50% EtOAc in toluene): 0.48; IR (neat, 
cmˉ¹): νmax 1645 (C=O stretching), 1111 (C-O stretching), 1522, 1347 (N-O stretching); 
¹H NMR (CDCl3, 300MHz): δH 3.35-3.45 (m, 2H, OCH2), 3.62-3.79 (m, 6H, 
OCH2NCH2), 6.31 (s, 1H. CHAr), 6.61 (d, 1H, J= 8.0Hz, Ar), 6.85 (d, 1H, J= 8.0Hz, 
Ar), 7.11-7.18 (m, 2H, Ar), 7.23-7.37 (m, 4H, Ar), 7.45-7.50 (m, 2H, Ar), 7.90 (t, 2H, 
J= 9.0Hz, Ar). ¹³C NMR (CDCl3, 75MHz): δC 42.82 (CH2), 44.44 (CH), 46.47, 66.59, 
66.95 (CH2), 118.38, 120.41, 123.97, 124.93, 125.18, 126.18, 127.98, 129.85, 130.89, 
132.02, 133.06, 134.16 (CH), 134.40, 140.88, 148.93, 149.93, 153.08, 169.43 (C); MS 
(APCI m/z): 464 [M+H)
+
, (100%)]; HRMS FAB [M+H]
+
 464.1455, 
C24H21N3O7+H
+
 requires 464.1452. 
 
[2-[2-(Diethylamino)-1-[2-(2-nitrophenoxy)phenyl]-2-oxo-ethyl]phenyl]azinic acid, 
335e 
335e
O
O
NO2
O2N
N
 
Flash column chromatography (SiO2; 15% EtOAc in toluene) afforded the title 
compound as a lemon-yellow solid (21%). Rf (50% EtOAc in toluene): 0.82; m.p.= 124-
126 °C (EtOAc/toluene); IR (neat, cmˉ¹): νmax 1639 (C=O stretching), 1091 (C-O 
stretching), 1520, 1346 (N-O stretching); ¹H NMR (CDCl3, 300MHz): δH 1.12 (t, 3H, 
J= 7.5Hz, CH3), 1.17 (t, 3H, J= 7.5Hz, CH3), 3.24-3.57 (m, 4H, NCH2), 6.27 (s, 1H, 
CHAr), 6.63 (d, 1H, J= 9.0Hz, Ar), 6.87 (d, 1H, J= 9Hz, Ar), 7.16 (t, 1H, J= 7.5Hz, Ar), 
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7.24-7.37 (m, 5H, Ar), 7.44-7.52 (m, 2H, Ar), 7.86 (d, 1H, J= 9.0Hz, Ar), 7.95 (d, 1H, 
J= 9.0Hz, Ar). ¹³C NMR (CDCl3, 75MHz): δC 12.69, 13.66 (CH3), 40.73, 42.45 (CH2), 
44.44, 118.49, 120.08, 123.65, 124.63, 125.08, 126.04, 127.74, 129.33, 129.51, 130.59, 
132.30, 132.74 (CH), 134.16, 134.40, 140.88, 148.93, 149.93, 153.08, 169.43 (C); MS 
(APCI m/z): 450 [M+H)
+
, (100%)]; HRMS FAB [M+H]
+
 450.1660, C24H23N3O6+H
+
 
requires 450.1654. 
 
2-(2-(2-nitrophenoxy)phenyl)-1-((2S,5S)-2,5-dimethylpyrrolidin-1-yl)-2-(2-
nitrophenyl)ethanone, 335g 
335g
O
N
O
O2N
NO2
 
Flash column chromatography (SiO2; 2% EtOAc in toluene) afforded the title 
compound (as a mixture of two diastereomers) as a yellow solid (5%). Rf (30% EtOAc 
in toluene): 0.58;  m.p.= 90-92 ºC (EtOAc/toluene); [α]D= −36.25 (ethanol, c = 0.14 
g/100ml). IR (neat, cmˉ¹): νmax 1634 (C=O stretching), 1160 (C-O stretching), 1521, 
1348 (N-O stretching); ¹H NMR (CDCl3, 300MHz): δH 0.75-0.81 (m, 1H, CHCH3), 0.92 
(d, 3H, J= 6.6Hz), 1.20 (d, 3H, J= 6.6Hz, CH3), 1.27-1.29 (m, 6H, includes (d, 3H) @ 
1.28, CH3), 1.185-1.55 (m, 4H, CH2CH2), 1.90-1.99 (m, 2H, CH2), 2.08-2.12 (m, 2H, 
CH2), 3.88 (m, 1H, ), 6.13 (s, 1H, CHAr), 6.22 (s, 1H, CHAr), 6.54 (d, 1H, J= 8.4Hz, 
Ar), 6.73 (d, 1H, J= 8.4Hz, Ar), 6.82 (d, 2H, J= 8.4Hz, Ar), 7.18 (d, 1H, J= 8.4Hz, Ar), 
7.21-7.25 (m, 3H, Ar), 7.27-7.34 (m, 7H, Ar), 7.37-7.40 (m, 2H, Ar), 7.47 (d, 1H, J= 
8.0Hz, Ar), 7.72 (d, 1H, J= 1.0Hz, J= 8.0Hz, Ar), 7.90 (d, 1H, J= 1.0Hz, J= 8.0Hz, Ar), 
7.94 (d, 1H, J= 1.0Hz, J= 8.0Hz, Ar); ¹³C NMR (CDCl3, 75MHz): δC 18.83, 21.96 
(CH3), 29.72, 31.74 (CH2), 46.22, 54.32, 54.63, 117.89, 119.72, 120.55, 123.82, 124.71, 
124.99, 126.04 (CH), 127.77 (C), 129.37, 129.59, 130.11 (CH), 130.81 (C), 132.24 
(CH), 132.68, 134.07 (C), 134.31 (CH), 149.50, 153.66, 168.46 (C); MS (APCI m/z): 
476 [M+H)
+
, (100%)]; HRMS FAB [M+H]
+
 476.1811, C26H25N3O6+H
+
 requires 
476.1816. 
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Diagnostic signals corresponding to the major diastereomer are: δH 1.27-1.29 (m, 6H, 
includes (d, 3H) @ 1.28,  CH3), 6.22 (s, 1H, CHAr), 6.73 (d, 1H, J= 8.4Hz, AR), 7.72 
(d, 1H, J= 1.0Hz, J= 8.0Hz, Ar), 7.90 (d, 1H, J= 1.0Hz, J= 8.0Hz, Ar), 7.94 (d, 1H, J= 
1.0Hz, J= 8.0Hz, Ar). 
Diagnostic signals corresponding to the minor diastereomer are: δH 6.13 (s, 1H, 
CHAr), 6.54 (d, 1H, J= 8.4Hz, Ar), 7.47 (d, 1H, J= 8.0Hz, Ar), 7.72 (d, 1H, J= 1.0Hz, 
J= 8.0Hz, Ar), 7.90 (d, 1H, J= 1.0Hz, J= 8.0Hz, Ar). 
 
1-((2S,5S)-2,5-Bis(methoxymethyl)pyrrolidin-1-yl)-2-(2-(2-nitrophenoxy)phenyl)-2-
(2-nitrophenyl)ethanone, 335h 
335h
O
O
NO2
O2N
N
O
O
 
Flash column chromatography (SiO2; 35% EtOAc in petroleum ether) afforded the title 
compound (as a mixture of two diastereomers) as a lemon-yellow sticky oil (10%). Rf 
(60% EtOAc in petroleum ether): 0.65; [α]D= −62.85 (ethanol, c = 0. 24 g/100ml). IR 
(neat, cmˉ¹): νmax 1639 (C=O stretching), 1109 (C-O stretching), 1524, 1348 (N-O 
stretching); ¹H NMR (CDCl3, 300MHz): δH 0.75-0.79 (m, 1 H, CH2), 1.73-1.92 (m, 8H, 
CH2CH2), 2.83 (s, 3H, CH3O), 2.95-3.09 (m, 5H, includes (s, 3H) @ 3.09, CH3O, 
CH2CH), 3.18 (s, 3H,  CH3O), 3.21-3.27 (m, 6H, includes (s, 3H) @ 3.23, CH3O, 
CH2CH3), 3.36 (dd, 1H, J= 9.0Hz, CHN), 3.52 (td, 3H, J= 6.0Hz, J= 9.0Hz, CH2O, 
CHN), 3.71-3.73 (m, 1H, CHN), 4.08-4.15 (m, 1H, CHN), 4.16-4.20 (m, 2H, CH2O), 
6.07 (s, 1H, CHAr), 6.18 (s, 1H CHAr), 6.48 (d, 1H, J= 8.0Hz, Ar), 6.69 (t, 1H, J= 
9.0Hz, Ar), 6.75 (t, 3H, J= 9.0Hz, Ar), 7.00-7.40 (m, 15H, Ar), 7.65 (d, 1H, J= 9.0Hz, 
Ar), 7.81 (dd, 3H, J= 1.0Hz, J= 8.0Hz, Ar); ¹³C NMR (CDCl3, 75MHz): δC 25.49, 25.58, 
27.48, 27.73 (CH2), 45.61, 46.20, 57.82, 57.89 (CH3), 58.59, 58.75, 58.81, 58.90 (CH), 
70.60, 70.71, 73.76,73.79 (CH2), 117.97, 118.88, 119.76, 120.72, 123.32, 123.82, 
124.51, 124.68, 124.75, 125.04, 125.81, 127.78, 128.01, 129.10, 129.25(CH), 129.42 
(C),130.20, 130.40 (CH), 130.66 (C), 132.15,132.57, 132.80,  132.89 (CH), 133.74, 
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133.94 (C), 134.09, 134.27(CH), 140.85, 141.39, 149.05, 149.36, 149.62,  152.98, 
153.75, 168.92, 169.50 (C); MS (APCI m/z): 536 [M+H)
+
, (100%)]; HRMS FAB 
[M+H]
+
 536.2015, C28H29N3O8+H
+
 requires 536.2027. 
 
Diagnostic signals corresponding to the major diastereomer are: δH 2.95-3.09 (m, 5H, 
includes (s, 3H) @ 3.09, CH3O, CH2CH), 3.21-3.27 (m, 6H, includes (s, 3H) @ 3.23, 
CH3O, CH2CH3), 3.36 (dd, 1H, J= 9.0Hz, CHN), 3.71-3.73 (m, 1H, CHN), 4.16-4.20 
(m, 2H, CH2O), 6.18 (s, 1H CHAr), 6.69 (t, 1H, J= 9.0Hz, Ar), 6.75 (t, 3H, J= 9.0Hz, 
Ar), 7.81 (dd, 3H, J= 1.0Hz, J= 8.0Hz, Ar). 
Diagnostic signals corresponding to the minor diastereomer are: δH 2.83 (s, 3H, 
CH3O), 3.18 (s, 3H,  CH3O), 4.08-4.15 (m, 1H, CHN), 6.07 (s, 1H, CHAr), 6.48 (d, 1H, 
J= 8.0Hz, Ar), 7.65 (d, 1H, J= 9.0Hz, Ar). 
 
N,N-Dibenzyl-2-(2-hydroxyphenyl)-2-(2-nitrophenyl)acetamide, 336a 
336a
OH
O
NO2
N
Ph Ph
 
Flash column chromatography (SiO2; 25% EtOAc in petroleum ether) afforded the title 
compound as a colourless solid (37%). Rf (30% EtOAc in petroleum ether): 0.60; m.p.= 
195-197 ºC (EtOAc/petroleum ether); IR (neat, cmˉ¹): νmax 1618 (C=O stretching), 1599, 
1344 (N-O stretching), 3267 (H-O stretching); ¹H NMR (CDCl3, 300MHz): δH 4.21 (d, 
1H, HA/B, J= 15.0Hz, NCHAHB), 4.53 (d, 1H, HC/D, J= 15.0Hz, NCHCHD), 4.73 (d, 1H, 
HD/C, J= 15.0Hz, NCHDHC), 4.88 (d, 1H, HB/A, J= 15.0Hz, NCHBHA), 6.15 (s, 1H, 
CHAr), 6.82 (t, 1H, J= 7.5Hz), 6.94 (m, 3H), 7.01 (d, 1H, J= 6.0Hz), 7.14 (m, 2H), 
7.24-7.31 (m, 8H), 7.44 (t, 1H, J= 7.5Hz), 7.53 (t, 1H, J= 7.5Hz), 7.79 (s, 1H, OH), 8.01 
(d, 1H, J= 6.0Hz). ¹³C NMR (CDCl3, 75MHz): δC 48.35 (CH2), 49.36 (CH), 50.90 
(CH2), 118.21, 121.00 (CH), 121.51, 125.20, 127.63, 127.69, 127.88, 128.35, 128.68, 
128.86, 130.19, 131.48 (CH), 131.82 (C), 133.00 (CH), 133.31, 135.17, 136.30, 148.97, 
155.85, 172.98 (C); MS (APCI m/z): 451 [M-H)
+
, (100%)]; HRMS FAB 
[M+H]
+
 453.1805, C28H24N2O4+H
+
 requires 453.1809. 
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2-(2-Hydroxyphenyl)-2-(2-nitrophenyl)-1-pyrrolidin-1-yl-ethanone, 336b 
336b
OH
O
NO2
N
 
Flash column chromatography (SiO2; 16% EtOAc in toluene) afforded the title 
compound as a colourless solid (33%). Rf (30% EtOAc in toluene): 0.67; m.p.= 189-191 
ºC (EtOAc in toluene); IR (neat, cmˉ¹): νmax 1615 (C=O stretching), 1584, 1345 (N-O 
stretching), 2951 (H-O stretching); ¹H NMR (CDCl3, 300MHz): δH 1.81-1.97 (m, 3H, 
CH2CH2), 2.03-2.10 (m,1H, CH2CH2), 3.38-3.62 (m, 3H, NCH2), 3.87-3.94 (m, 1H, 
NCH2), 5.64 (s, 1H, CHAr), 6.92-6.99 (m, 2H, Ar), 7.15 (t, 2H, J= 7.5Hz, Ar), 7.28 (t, 
1H, J= 7.5Hz, Ar), 7.40-7.50 (m, 2H, Ar), 7.99 (d, 1H, J= 7.5Hz, Ar), 8.74 (s, 1H, OH). 
¹³C NMR (CDCl3, 75MHz): δC 24.44, 26.14, 46.68 (CH), 52.87, 52.90 (CH2), 119.04 
(CH), 120.27 (C), 120.67, 125.22, 128.40, 130.36, 131.21, 132.20 (CH), 132.39 (C), 
133.44 (CH), 148.88, 157.25, 170.60 (C); MS (APCI m/z): 327 [M+H)
+
, (100%)]; 
HRMS FAB [M+H]
+
 327.1343, C18H18N2O4+H
+
 requires 327.1339. 
 
2-(2-Hydroxyphenyl)-2-(2-nitrophenyl)-1-(1-piperidyl)ethanone, 336c 
336c
OH
O
NO2
N
 
Flash column chromatography (SiO2; 10% EtOAc in toluene) afforded the title 
compound as a colourless solid (21%). Rf (50% EtOAc in toluene): 0.81; m.p.= 177-179 
ºC (EtOAc/toluene); IR (neat, cmˉ¹): νmax 1618 (C=O stretching), 1596, 1352 (N-O 
stretching), 3177 (H-O stretching); ¹H NMR (CDCl3, 300MHz): δH 1.44-1.75 (m, 6H, 
CH2CH2), 3.44-3.51 (m, 1H, NCH2), 3.56-3.65 (m, 3H, NCH2), 5.96 (s, 1H, CHAr), 
6.88-6.92 (m, 2H, Ar), 7.11 (d, 1H, J= 7.5Hz, Ar), 7.17 (d, 1H, J= 7.5Hz, Ar), 7.25 (t, 
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1H, J= 7.5Hz, Ar), 7.39 (t, 1H, J= 7.5Hz, Ar),  7.46 (t, 1H, J= 7.5Hz, Ar), 8.00 (d, 1H, 
J= 7.5Hz, Ar), 8.46 (s, 1H, OH). ¹³C NMR (DMSO-d6, 75MHz): δC 24.45, 25.64, 25.73, 
43.86, 47.51 (CH2), 49.45, 118.16, 120.70 (CH), 121.39 (C), 125.06, 128.08, 129.99, 
131.46, 131.51, 133.30, (CH), 133.62, 148.82, 156.24, 170.32 (C); MS (APCI m/z): 341 
[M+H)
+
, (100%)]; HRMS FAB [M+H]
+
 341.1499, C19H20N2O4+H
+
 requires 341.1496 
 
2-(2-Hydroxyphenyl)-1-morpholino-2-(2-nitrophenyl)ethanone, 336d 
335d
OH
O
NO2
N
O
 
Flash column chromatography (SiO2; 10% EtOAc in toluene) afforded the title 
compound as a yellow solid (45%). Rf (50% EtOAc in toluene): 0.22; m.p.= 157-159 ºC 
(EtOAc/toluene); IR (neat, cmˉ¹): νmax 1619 (C=O stretching), 1112 (C-O stretching), 
1515, 1343 (N-O stretching); ¹H NMR (CDCl3, 300MHz): δH 3.08-3.18 (m, 2H, OCH2), 
3.35-3.57 (m, 6H, OCH2NCH2), 5.99 (s, 1H, CHAr), 6.88-6.92 (m, 3H, Ar), 7.04 (d, 1H, 
J= 6.0Hz, Ar), 7.19 (t, 1H, J= 7.5Hz, Ar), 7.46 (t, 1H, J= 7.5Hz, Ar), 7.56 (t, 1H, J= 
7.5Hz, Ar), 7.99 (d, 1H, J = 9.0Hz, Ar), 9.86 (s, 1H, OH); ¹³C NMR (DMSO-d6, 
75MHz): δC 41.95, 45.55, 65.30, 65.88 (CH2), 43.39, 115.42, 119.41 (CH), 122.50 (C), 
124.08, 127.63, 128.83, 128.98, 131.06, 132.83, (CH), 134.50, 148.73, 154.15, 168.78 
(C); MS (APCI m/z): 343 [M+H)
+
, (100%)]; HRMS FAB [M+H]
+
 343.1288, 
C18H18N2O5+H
+
 requires 343.1289. 
 
[2-[2-(Diethylamino)-1-(2-hydroxyphenyl)-2-oxo-ethyl]phenyl]azinic acid, 336e 
336e
OH
O
NO2
N
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Flash column chromatography (SiO2; 15% EtOAc in toluene) afforded the title 
compound as a yellow solid (10%). Rf (50% EtOAc in toluene): 0.62; m.p.= 161-163 °C 
(EtOAc/toluene). IR (neat, cmˉ¹): νmax 1616 (C=O stretching), 1590, 1376 (N-O 
stretching); ¹H NMR (DMSO-d6, 300MHz): δH 0.09-0.17 (m, 6H, CH3), 2.22-2.47 (m, 
4H, NCH2), 5.09 (s, 1H, CHAr), 5.99-6.08 (m, 3H, Ar), 6.15 (d, 1H, J= 6.0Hz, Ar), 6.33 
(t, 1H, J= 7.5Hz, Ar), 6.61 (t, 1H, J= 7.5Hz, Ar), 6.71 (t, 1H, J= 7.5Hz, Ar), 7.09 (d, 1H, 
J= 9.0Hz, Ar), 8.96 (s, 1H, OH). ¹³C NMR (DMSO-d6, 75MHz): 12.30, 13.08 (CH3), 
39.38, 41.09 (CH2), 43.40, 115.22, 119.28 (CH), 123.42, 123.81 (C), 127.43, 128.49, 
128.74, 131.18, 132.47, 134.57 (CH), 149.00, 154.29, 169.04 (C); MS (APCI m/z): 329 
[M+H)
+
, (100%)]; HRMS FAB [M+H]
+
 329.1497, C18H20N2O4+H
+
 requires 329.1496. 
 
2-(2-Hydroxyphenyl)-1-((2S,5S)-2,5-dimethylpyrrolidin-1-yl)-2-(2-
nitrophenyl)ethanone, 336g 
N
O
O2N
OH
336g  
Flash column chromatography (SiO2; 2% EtOAc in toluene) afforded the title 
compound (as a mixture of two diastereomers) (36%) as yellow solid. Rf (30% EtOAc 
in toluene): 0.67;  m.p.= 101-103 ºC (EtOAc/toluene); [α]D= −30.35 (ethanol, c = 0.29 
g/100ml). IR (neat, cmˉ¹): νmax 1615 (C=O stretching), 1113 (C-O stretching), 1554, 
1367 (N-O stretching), 3390 (O-H stretching); ¹H NMR (CDCl3, 300MHz): δH 0.82-
0.89 (m, 2H, CH2), 1.09 (d, 3H, J= 6.3Hz, CH3), 1.15 (d, 3H, J= 6.6Hz, CH3), 1.21 (d, 
3H, J= 6.6Hz, CH3), 1.41 (d, 3H, J= 6.6Hz, CH3), 1.48-1.67 (m, 4H, CH2), 1.98-2.08 
(m, 3H, CH2, CH), 2.10-2.29 (m, 1H, CHN), 4.11-4.18 (m, 1H, CHN), 4.20-2.34 (m, 
1H, CHN), 4.44-4.51 (m, 1H, CHN), 5.70 (s, 1H, CHAr), 5.83 (s, 1H, CHAr), 6.83-6.94 
(m, 3H, Ar), 7.11 (d, 1H, J= 7.5Hz, Ar), 7.15-7.23 (m, 4H, Ar), 7.29 (d, 1H, J= 7.5Hz, 
Ar), 7.32 (dd, 1H, J= 1.5Hz, J= 7.5Hz, Ar), 7.36-7.44 (m, 3H, Ar), 7.46-7.50 (m, 1H, 
Ar),  7.79 (dd, 1H, J= 1.5Hz, J= 7.5Hz, Ar), 7.88 (dd, 1H, J= 1.5Hz, J= 7.5Hz, Ar), 
8.43 (s, 1H, OH); ¹³C NMR (CDCl3, 75MHz): δC 18.30, 18.63, 21.22, 21.93 (CH3), 
29.08, 29.26, 31.04, 31.30 (CH2), 51.39, 54.04, 54.67, 54.97, 55.4 118.67, 119.24, 
120.32, 120.43 (CH), 121.88, 122.23 (C), 124.95, 124.98, 128.18 (CH), 128.32 (C), 
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130.12, 130.21, 130.87, 130.91, 131.74, 132.32, 132.37, 132.45, 133.79 (CH), 133.03, 
149.24, 149.64,  156.37, 157.18, 170.46, 170.99 (C); MS (APCI m/z): 355 [M+H)
+
, 
(100%)]; HRMS FAB [M+H]
+
 355.1652, C20H22N2O4+H
+
 requires 355.1652. 
Diagnostic signals corresponding to the major diastereomer are: δH 1.09 (d, 3H, J= 
6.3Hz, CH3), 1.41 (d, 3H, J= 6.6Hz, CH3), 5.70 (s, 1H, CHAr), 7.88 (dd, 1H, J= 1.5Hz, 
J= 7.5Hz, Ar). 
Diagnostic signals corresponding to the minor diastereomer are: δH 1.15 (d, 3H, J= 
6.6Hz, CH3), 1.21 (d, 3H, J= 6.6Hz, CH3), 5.83 (s, 1H, CHAr), 7.79 (dd, 1H, J= 1.5Hz, 
J= 7.5Hz, Ar). 
 
1-((2S,5S)-2,5-Bis(methoxymethyl)pyrrolidin-1-yl)-2-(2-hydroxyphenyl)-2-(2-
nitrophenyl)ethanone, 336h 
336h
OH
O
NO2
N
O
O
 
Flash column chromatography (SiO2; 35% EtOAc in petroleum ether) afforded the title 
compound (as a mixture of two diastereomers) as a yellow solid (45%). Rf (60% EtOAc 
in petroleum ether): 0.73. m.p.= 126-128 ºC (EtOAc in petroleum ether); [α]D= −75.76 
(ethanol, c = 0.5 g/100ml). IR (neat, cmˉ¹): νmax 1620 (C=O stretching), 1113 (C-O 
stretching), 1524, 1356 (N-O stretching), 3243 (O-H stretching); ¹H NMR (CDCl3, 
300MHz): δH 0.62-0.66 (m, 1H, CH2CH2), 1.58-1.63 (m, 4H, CH2CH2), 1.69-1.76 (m, 
2H, CH2CH2), 1.92-1.98 (m, 1H, CH2CH2), 2.78 (s, 3H, CH3O), 2.93 (d, 1H, J= 3.0Hz, 
CHN), 2.99 (s, 3H, CH3O), 3.02 (s, 3H, CH3O), 3.08 (s, 3H, CH3O), 3.13 (d, 1H, J= 
9.0Hz, CHN), 3.22 (t, 1H, J= 9.0Hz, CHN), 3.39 (td, 2H, J= 2.0Hz, J= 9.0Hz, CH2O), 
3.51-3.59 (m, 2H, CH2O), 3.99-4.06 (m, 2H, CH2O), 5.73 (s, 1H, CHAr), 5.81 (s, 1H, 
CHAr), 6.43 (d, 2H, J= 7.5Hz, Ar), 6.60-6.63 (m, 2H, Ar), 6.85 (d, 1H, J= 7.5Hz, Ar), 
6.88 (m, 3H, Ar), 6.95-7.12 (m, 6H, Ar), 7.60 (d, 1H, J= 7.5Hz, Ar), 7.66 (d, 1H, J= 
7.5Hz, Ar); ¹³C NMR (CDCl3, 75MHz): δC 25.23, 27.04, 27.30 (CH2), 46.90, 47.33, 
57.21, 57.68 (CH3), 58.06, 58.26, 58.47, 58.57 (CH), 70.26, 70.40, 73.11 (CH2), 116.01, 
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116.19, 119.77, 119.95 (CH), 122.86, 122.95 (C), 124.29, 124.32, 127.43, 127.68, 
129.14, 129.24, 129.42, 129.82, 131.68, 131.84, 132.66, 132.75 (CH), 133.85, 133.94, 
148.86, 149.12,  154.75, 154.85, 171.02, 171.25 (C); MS (APCI m/z): 415 [M+H)
+
, 
(100%)]; HRMS FAB [M+H]
+
 415.1861, C22H26N2O6+H
+
 requires 415.1864.  
Diagnostic signals corresponding to the major diastereomer are: δH 2.93 (d, 1H, J= 
3.0Hz, CHN), 3.02 (s, 3H, CH3O), 3.08 (s, 3H, CH3O), 5.81 (s, 1H, CHAr), 7.66 (d, 1H, 
J= 7.5Hz, Ar). 
Diagnostic signals corresponding to the minor diastereomer are: δH 2.78 (s, 3H, 
CH3O), 2.99 (s, 3H, CH3O), 5.73 (s, 1H, CHAr), 7.60 (d, 1H, J= 7.5Hz, Ar). 
 
3-(2-(2-Nitrophenoxy)phenyl)-N,N-dibenzylpropanamide, 338a 
338a
O O
N
NO2
Ph
Ph
 
After aqueous work-up the solvent was evaporated in vacuo to afford the title 
compound as a yellow oil (100%). Rf (10% EtOAc in toluene): 0.46; IR (neat, cmˉ¹): 
νmax 1644 (C=O stretching), 1101 (C-O stretching), 1524, 1347 (N-O stretching); ¹H 
NMR (CDCl3, 300MHz): δH 2.82 (t, 2H, J= 7.5Hz, CH2C=O), 3.06 (t, 2H, J= 7.5Hz, 
CH2Ar), 4.42 (s, 2H, NCH2), 4.57 (s, 2H, NCH2), 6.78 (dd, 1H, J= 1.0Hz, J= 9.0Hz, Ar), 
6.82 (dd, 1H, J= 1.0Hz, J= 9.0Hz, Ar), 7.05 (d, 2H, J= 9.0Hz, Ar), 7.11-7.15 (m, 4H, 
Ar), 7.20 (dd, 1H, J= 1.5Hz, J= 9.0Hz, Ar), 7.23-7.31 (m, 6H, Ar), 7.34-7.39 (m, 2H, 
Ar), 7.91 (dd, 1H, J= 1.5Hz, J= 8.0Hz, Ar); ¹³C NMR (CDCl3, 75MHz): δC 26.95, 33.43, 
48.23, 49.90 (CH2), 119.05, 119.33, 122.74, 125.37, 125.04, 126.51, 127.42, 127.54, 
128.19, 128.27, 128.68, 128.94, 131.83, 132.93 (CH), 134.41, 136.52, 137.38, 140.63, 
150.98, 153.31, 172.92 (C); MS (APCI m/z): 467 [M+H)
+
, (100%)]; HRMS FAB 
[M+H]
+
 467.1973, C29H26N2O4+H
+
 requires 467.1965. 
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3-(2-(2-Nitrophenoxy)phenyl)-1-(pyrrolidin-1-yl)propan-1-one, 338b 
338b
O O
N
NO2
 
Flash column chromatography (SiO2; 100% petroleum ether) afforded the title 
compound as a yellow oil (92%). Rf (30% EtOAc in petroleum ether): 0.32; IR (neat, 
cmˉ¹): νmax1604 (C=O stretching), 1039 (C-N stretching), 1100 (C-O stretching), 1523, 
1344 (N-O stretching); ¹H NMR (CDCl3, 300MHz): δH 1.80 (tt, 2H, J= 6.0Hz, CH2CH2), 
1.88 (tt, 2H, J= 6.0Hz, CH2CH2), 2.65 (t, 2H, J= 9.0Hz, CH2C=O), 2.95 (t, 2H, J= 
7.5Hz, CH2Ar), 3.34 (t, 2H, J= 7.5Hz, NCH2), 3.42 (t, 2H, J= 6.0Hz, NCH2), 6.90 (dd, 
1H, J= 3.0Hz, J= 6.0Hz, Ar), 6.90 (dd, 1H, J= 3.0Hz, J= 6.0Hz, Ar), 7.15 (td, 2H, J= 
1.5Hz, J= 8.0Hz, Ar), 7.12-7.20 (dd, 1H, J= 1.5Hz, J= 8.0Hz, Ar), 7.38 (dd, 1H, J= 
1.5Hz, J= 8.0Hz, Ar), 7.46 (td, 1H, J= 1.5Hz, J= 8.0Hz, Ar), 7.97 (dd, 1H, J= J= 1.5Hz, 
J= 8.0Hz, Ar); ¹³C NMR (CDCl3, 75MHz): δC 24.52, 26.20, 26.49, 35.02, 45.74, 46.56 
(CH2), 118.81, 119.52, 122.65, 125.49, 126.06, 128.14, 131.81, 133.40 (CH), 134.48, 
140.58, 151.16, 153.13, 170.84 (C); MS (APCI m/z): 341 [M+H)
+
, (100%)]; 
HRMS FAB [M+H]
+
 341.1503, C19H20N2O4+H
+
 requires 341.1496. 
 
2-[2-(2-Nitrophenoxy)phenyl]-1-(1-piperidyl)propanone, 338c 
338c
O O
N
NO2
 
After aqueous work-up the solvent was evaporated in vacuo to afford the title 
compound as a yellow oil (87%). Rf (30% EtOAc in petroleum ether): 0.36; IR (neat, 
cmˉ¹): νmax 1631 (C=O stretching), 1098 (C-O stretching), 1583, 1348 (N-O stretching); 
¹H NMR (CDCl3, 300MHz): δH 1.55-1.67 (m, 6H, CH2CH2), 2.77 (t, 2H, J= 7.5Hz, 
CH2C=O), 3.01 (t, 2H, J= 7.5Hz, CH2Ar), 3.42 (t, 2H, J= 6.0Hz, NCH2), 3.60 (t, 2H, J= 
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6.0Hz, NCH2), 6.79 (d, 2H, J= 6.0Hz, Ar), 7.22-7.34 (m, 3H, Ar), 7.45 (d, 1H, J= 6.0Hz, 
Ar), 7.55 (t, 1H, J= 7.5Hz, Ar), 8.04 (d, 1H, J= 6.0Hz, Ar); ¹³C NMR (CDCl3, 75MHz): 
δC 24.39, 25.44, 26.18, 26.76, 33.32, 42.52, 46.42 (CH2), 118.63, 119.17, 122.53, 
125.22, 125.77, 127.94, 131.42 (CH), 132.93 (C), 134.29 (CH), 140.32, 150.75, 152.89, 
170.24 (C); MS (APCI m/z): 355 [M+H)
+
, (100%)]; HRMS FAB [M+H]
+
 355.1646, 
C20H22N2O4+H
+
 requires 355.1652. 
 
2-[2-(2-Nitrophenoxy)phenyl]-1-(1-morpholino)propanone, 338d 
338d
O O
N
NO2
O
 
Flash column chromatography (SiO2; 50% petroleum ether) afforded the title compound 
as a yellow oil (90%). Rf (30% EtOAc in petroleum ether): 0.36; IR (neat, cmˉ¹): νmax 
1639 (C=O stretching), 1023 (C-O stretching), 1582, 1349 (N-O stretching); ¹H NMR 
(CDCl3, 300MHz): δH 2.72 (t, 2H, J= 7.5Hz, CH2C=O), 2.94 (t, 2H, J= 7.5Hz, CH2Ar), 
3.42 (t, 2H, J= 7.5Hz, NCH2), 3.53 (t, 2H, J= 7.5Hz, NCH2), 3.61 (t, 4H, J= 7.5Hz, 
OCH2), 6.89 (dd, 2H, J= 1.5Hz, J= 8.0Hz, Ar), 7.15-7.28 (m, 3H, Ar), 7.36 (dd, 1H, J= 
1.5Hz,  J= 8.0Hz, Ar), 7.47 (t, 1H, J= 8.0Hz, Ar), 7.97 (dd, 1H, J= 1.5Hz,  J= 8.0Hz, 
Ar); ¹³C NMR (CDCl3, 75MHz): δC 26.72, 32.75, 41.73, 45.73, 66.36, 66.58 (CH2), 
118.69, 118.96, 122.66, 125.15, 125.75, 128.06, 131.50 (CH), 132.37 (C), 134.31 (CH), 
140.35, 150.45, 152.90, 170.71, (C); MS (APCI m/z): 357 [M+H)
+
, (100%)]; 
HRMS FAB [M+H]
+
 357.1444, C19H20N2O5+H
+
 requires 357.1445. 
 
N,N-Diethyl-2-[2-(2-nitrophenoxy)phenyl]propanamide, 338e 
338e
O O
N
NO2
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After aqueous work-up the solvent was evaporated in vacuo to afford the title 
compound as a yellow oil (90 %). Rf (30% EtOAc in petroleum ether): 0.37; IR (neat, 
cmˉ¹): νmax 1631 (C=O stretching), 1098 (C-O stretching), 1524, 1349 (N-O stretching); 
¹H NMR (CDCl3, 300MHz): δH 0.95-1.01 (m, 6H, CH3), 2.59 (t, 2H, J= 7.5Hz, 
CH2C=O), 2.87 (t, 2H, J= 7.5Hz, CH2Ar), 3.15 (q, 2H, J= 7.5Hz, NCH2), 3.24 (q, 2H, 
J= 7.5Hz, NCH2), 6.79 (t, 2H, J= 7.5Hz, Ar), 7.02-7.15 (m, 3H, Ar), 7.27 (d, 1H, J= 
6.0Hz, Ar), 7.38 (t, 1H, J= 7.5Hz, Ar), 7.85 (d, 1H, J= 9.0Hz, Ar); ¹³C NMR (CDCl3, 
75MHz): δC 12.92, 14.01 (CH3), 26.69, 33.14, 39.96, 41.75 (CH2), 118.72, 119.05, 
122.54, 125.13, 125.74, 127.89, 131.46 (CH), 132.93 (C), 134.29 (CH), 140.33, 150.74, 
152.95, 171.08 (C); MS (APCI m/z): 343 [M+H)
+
, (100%)]; HRMS FAB 
[M+H]
+
 343.1646, C19H22NO2+H
+
 requires 343.1652. 
 
4.5 Procedure for the synthesis of (2S,5S)-1-((Z)-2-(2-(2-nitrophenoxy)phenyl)-1-
methoxyvinyl)-2,5-bis(methoxymethyl)pyrrolidine, 373 
373
O
NO2
N
O
O
O
 
1-((2S,5S)-2,5-Bis(methoxymethyl)pyrrolidin-1-yl)-2-(2-(2-
nitrophenoxy)phenyl)ethanone, 334h (0.06g, 0.144 mmol) and sodium hydride (5mg, 
0.144 mmol) was dissolved in tetrahydrofuran (2mL, 0.1 M) and stirred at room 
temperature for 15 minutes. Methyl iodide (372) (0.02g, 0.144 mmol) was added and 
the reaction mixture was left stirring for 24 hours. The solvent was evaporated, the 
residue washed with hydrochloric acid solution (3×30mL, 1 M) and extracted with ethyl 
acetate (2×30mL).  The combined organic layers were washed with distilled water 
(2×30mL) and brine (30mL), dried (MgSO4), filtered and the solvent evaporated in 
vacuo to afford the crude residue which was purified by flash column chromatography. 
Flash column chromatography (SiO2; 20% EtOAc in petroleum ether) afforded the title 
compound as lemon-yellow crystalline solid (50%). Rf (30% EtOAc in petroleum 
ether): 0.66; m.p.= 179-181 
○C (DCM). [α]D= −18.74 (ethanol, c = 0.18 g/100ml). IR 
(neat, cmˉ¹): νmax 1104 (C-O stretching), 1520, 1361 (N-O stretching); ¹H NMR (CDCl3, 
300MHz): δH 0.84-0.94 (m, 1H, CH2CH), 1.88-2.19 (m, 4H, CH2CH2), 2.95-3.09 (m, 
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4H, includes (s, 3H) @ 2.99, CH3O, CH2CH), 3.27-3.34 (m, 4H, includes (s, 3H) @ 
3.30, CH3O, CH2O), 3.65-3.74 (m, 4H, includes (s, 3H) @ 3.68, CH3O, CH2O), 4.21-
4.32 (m, 2H, CH2O), 6.03 (s, 1H, CHAr), 6.48 (d, 1H, J= 9.0Hz, Ar), 6.75 (t, 1H, J= 
9.0Hz, Ar), 7.00-7.40 (m, 4H, Ar),7.65 (d, 1H, J= 9.0Hz, Ar), 7.81 (dd, 1H, J= 9.0Hz, 
J= 9.0Hz, Ar); ¹³C NMR (CDCl3, 75MHz): δC 25.27, 27.49 (CH2), 44.82, 55.49, 57.99, 
(CH3), 58.65, 58.88, (CH), 70.61, 73.34, (CH2), 110.64, 120.93, 124.21 (CH), 127.30 
(C), 127.67, 129.05, 129.39, 132.50, 132.78 (CH), 134.63, 149.43, 156.46, 169.74 (C); 
MS (APCI m/z): 429 [M+H)
+
, (100%)]; HRMS FAB [M+H]
+
 429.2013, 
C23H28N2O6+H
+
 requires 429.2020. 
 
4.6 Procedure for the synthesis of methyl 3-[(2S,5S)-2,5-
bis(methoxymethyl)pyrrolidin-1-yl]-2-[2-(2-nitrophenoxy)phenyl]-3-oxo-
propanoate, 381 
381
O
O
OO
NO2
N
O
O
 
1-((2S,5S)-2,5-Bis(methoxymethyl)pyrrolidin-1-yl)-2-(2-(2-
nitrophenoxy)phenyl)ethanone, 334h (0.062g, 1.149 mmol) and sodium hydride (8mg, 
0.223 mmol) was dissolved in tetrahydrofuran (2mL, 0.1 M) and stirred at room 
temperature for 15 minutes. Methyl chloroformate (380) (0.012g, 0.157 mmol) was 
added and the reaction mixture was left stirring for 16 hours. The solvent was 
evaporated, the residue washed with hydrochloric acid solution (3×30mL, 1 M) and 
extracted with ethyl acetate (2×30mL).  The combined organic layers were washed with 
distilled water (2×30mL) and brine (30mL), dried (MgSO4), filtered and the solvent 
evaporated in vacuo to afford the crude residue which was purified by flash column 
chromatography. Flash column chromatography (SiO2; 36% EtOAc in petroleum ether) 
afforded the title compound as a lemon-yellow solid (as a mixture of two diastereomers) 
(57%). Rf (60% EtOAc in petroleum ether): 0.63. m.p.= 191-193 
○
C (EtOAc/petroleum 
ether). [α]D= −40.75 (ethanol, c = 0.16 g/100ml). IR (neat, cmˉ¹): νmax 1766 (C=O 
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stretching, ester), 1646 (C=O stretching), 1113 (C-O stretching), 1521, 1340 (N-O 
stretching); ¹H NMR (CDCl3, 300MHz): δH 1.87-2.08 (m, 3H, CH2CH2), 2.13-2.25 (m, 
1H, CH2CH2), 2.94-3.00 (m, 5H, includes (s, 3H) @ 2.94, CH3O, CH2O), 3.25-3.32 (m, 
4H, includes (s, 3H) @ 3.28, CH3O, CH2O), 3.61-3.76 (m, 4H, includes (s, 3H) @ 3.65, 
CH3O, CH2O), 4.22-4.28 (m, 1H, CHN), 4.31-4.35 (m, 1H, CHN), 5.97 (s, 1H, CHAr), 
7.17 (d, 1H, J= 7.83Hz, Ar), 7.24 (d, 1H, J= 9.0Hz, Ar), 7.30 (d, 1H, J= 9.0Hz, Ar), 
7.37 (t, 2H, J= 9.0Hz, Ar), 7.48 (d, 1H, J= 9.0Hz, Ar), 7.53 (d, 1H, J= 9.0Hz, Ar), 7.90 
(d, 1H, J= 9.0Hz, Ar); ¹³C NMR (CDCl3, 75MHz): δC 25.47, 27.76 (CH2), 45.58, 55.55, 
58.21 (CH3), 58.30, 58.63, 58.88 (CH), 70.58, 73.80, (CH2), 122.71, 124.23, 126.57, 
128.06, 129.11, 130.05 (CH), 131.12 (C), 133.18, 133.26 (CH), 133.96, 148.73, 153.30, 
168.55 (C); MS (APCI m/z): 471 [M-H)
+
, (40%)], 457 [M-CH3)
+
, (100%)]. HRMS FAB 
[M+H]
+
 473.1914, C24H28N2O8+H
+
 requires 473.1918. 
 
4.7 General procedure for the synthesis of the acetylated Baker-Venkataraman 
rearrangement precursors 
To a solution of the phenol derivative (1 eq.) in dichloromethane (0.1 M) was added the 
acid chloride (1.5 eq.). The resulting solution was stirred at 0 
o
C for 10 min, after which 
triethylamine (1.5 eq.) and 4-dimethylaminopyridine (0.1 eq.) were added and the 
reaction mixture allowed to warm up to room temperature and left stirring for 16 hours. 
The mixture was washed with 1 M HCl (3×30mL), and extracted with dichloromethane 
(2×30mL). The combined organic layers were washed with distilled water (2×30mL) 
and brine (30mL), dried (MgSO4), filtered and the solvent evaporated in vacuo to afford 
the pure acylated phenols directly or after flash column chromatography. 
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O
X
Y
O
R2OH
X
Y O
R2 Cl
+
R1
R3 R3
R1
 
 X Y R
1
 R
2
 R
3
 
315a CH2  C=O OCH3 benzoyl H 
389a CH2 C=O NBn2 methyl H 
389b CH2 C=O NBn2 benzoyl H 
389c CH2 C=O NBn2 methoxy H 
389d CH2 C=O pyrrolidyl methyl H 
389e CH2 C=O pyrrolidyl benzoyl H 
389f CH2 C=O pyrrolidyl methoxy H 
392a CH2CH2 C=O NBn2 methyl H 
392b CH2CH2 C=O NBn2 benzoyl H 
392c CH2CH2 C=O NBn2 methoxy H 
392d CH2CH2 C=O pyrrolidyl methyl H 
392e CH2CH2 C=O pyrrolidyl benzoyl H 
392f CH2CH2 C=O pyrrolidyl methoxy H 
396 CH2 C=O pyrrolidyl NEt2 H 
398a C=O CH2 H benzoyl H 
398b C=O CH2 CH3 benzoyl H 
415a C=O CH2 H NEt2 H 
415b C=O CH2 CH3 NEt2 H 
415c C=O CH2 CH3 N(CH3)Ph H 
415d C=O CH2 CH3 morpholino H 
425a C=O CH2 CH3 N(CH3)Ph CH3 
425b C=O CH2 CH3 N(CH3)Ph Br 
425c C=O CH2 acetyl N(CH3)Ph H 
425d C=O CH2 benzoyl N(CH3)Ph H 
425e C=O CH2 CH2C6H5 N(CH3)Ph H 
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2-((Methoxycarbonyl)methyl)phenyl benzoate, 351a 
351a
O
O
O
O
 
After aqueous work-up the solvent was evaporated in vacuo to afford the title 
compound as a lemon-yellow oil (100%). Rf (30% EtOAc in petroleum ether): 0.68. IR 
(neat, cmˉ¹): νmax 1733 (C=O stretching), 1060 (C-O stretching); ¹H NMR (CDCl3, 
300MHz): δ 3.58 (s, 3H, CH3), 3.64 (s, 2H, CH2), 7.25 (t, 2H, J= 6.0Hz, Ar), 7.34-7.38 
(m, 2H, Ar), 7.51 (t, 2H, J= 7.5Hz, Ar), 7.64 (t, 1H, J= 7.5Hz, Ar), 8.20 (d, 2H, J= 
8.0Hz, Ar). ¹³C NMR (CDCl3, 75MHz): δ 36.40 (CH2), 52.17 (CH3), 122.79, 126.33, 
128.73, 129.30, 130.26,131.46, 133.82 (CH), 126.75, 130.67, 149.37, 164.76, 171.24 
(C); MS (APCI m/z): 271 [M+H)
+
, (100%)]. HRMS FAB [M+H]
+
 271.0963, 
C16H14O4+H
+
 requires 271.0963. 
 
[2-[2-(Dibenzylamino)-2-oxo-ethyl]phenyl] acetate, 389a 
389a
O
O
O
N
 
The solvent was evaporated in vacuo to afford the title compound as an off-white solid 
(96%). Rf (30% EtOAc in petroleum ether): 0.63; m.p.= 89-91
○
C (DCM). IR (neat, 
cmˉ¹): νmax 1653 (C=O stretching), 1196 (C-O stretching, ester) 1746 (C=O stretching, 
ester); ¹H NMR (CDCl3, 300MHz): δH 2.08 (s, 3H, CH3), 3,65 (s, 2H, CH2Ar), 4.49 (s, 
2H, NCH2), 4.61 (s, 2H, NCH2), 7.05 (dd, 1H, J= 1.0Hz, J= 9.0Hz, Ar), 7.10 (d, 2H, J= 
9.0Hz, Ar), 7.17-7.22 (m, 3H, Ar), 7.23 (d, 1H, J= 9.0Hz, Ar), 7.27-7.36 (m, 7H, Ar); 
¹³C NMR (CDCl3, 75MHz): δC 20.52 (CH3), 35.39, 48.34, 49.80 (CH2), 122.35, 126.00, 
126.87, 127.16, 127.25, 127.39 (CH), 127.98 (C), 128.13, 128.36, 128.73, 130.41 (CH), 
136.10, 137.03, 148.65, 168.83, 170.44 (C); MS (APCI m/z): 374 [M+H)
+
, 
(100%)]; HRMS FAB [M+H]
+
 374.1751, C24H23NO3+H
+
 requires 374.1751. 
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2-((Dibenzylcarbamoyl)methyl)phenyl benzoate, 389b 
389b
O
O
N
O
 
The solvent was evaporated in vacuo to afford the title compound as an off-white solid 
(100%). Rf (30% EtOAc in petroleum ether): 0.62; m.p.= 140-142 
○
C (DCM). IR (neat, 
cmˉ¹): νmax 1642 (C=O stretching), 1179 (C-O stretching, ester) 1730 (C=O stretching, 
ester); ¹H NMR (CDCl3, 300MHz): δH 3.74 (s, 2H, CH2Ar), 4,38 (s, 2H,  NCH2), 4.60 
(s, 2H, NCH2), 7.02 (dd, 2H, J= 3.0Hz, J= 6.0Hz, Ar), 7.17-7.20 (m, 6H, Ar), 7.21-7.30 
(m, 4H, Ar), 7.34 (dd, 1H, J= 3.0Hz, J= 6.0Hz, Ar), 7.40-7.45 (m, 3H, Ar), 7.63 (dt, 1H, 
J= 3.0Hz, J= 9.0Hz, Ar),  8.05 (dd, 2H, J= 3.0Hz, J= 7.5Hz, Ar); ¹³C NMR (CDCl3, 
75MHz): δC 35.46, 48.51, 50.10 (CH2), 122.70, 126.35, 126.48, 127.56, 127.61 (CH), 
127.67 (C), 128.48, 128.57, 128.69, 128.73, 128.96 (CH), 129.20 (C), 130.31, 130.78, 
133.79 (CH), 136.20, 137.36, 149.13, 164.92, 170.81 (C); MS (APCI m/z): 436 
[M+H)
+
, (100%)]; HRMS FAB [M+H]
+
 436.1901, C29H25NO3+H
+
 requires 436.1907. 
 
2-((Dibenzylcarbamoyl)methyl)phenyl methyl carbonate, 389c 
389c
O
O
O
N
O
 
The solvent was evaporated in vacuo to afford the title compound as a pink oil (99%). 
Rf (30% EtOAc in petroleum ether): 0.50; IR (neat, cmˉ¹): νmax 1651 (C=O stretching), 
1177 (C-O stretching, carbonate) 1761 (C=O stretching, carbonate); ¹H NMR (CDCl3, 
300MHz): δH 3.74 (s, 2H, CH2Ar), 3,79 (s, 3H, CH3), 4.45 (s, 2H, NCH2), 4.62 (s, 2H, 
NCH2), 7.15 (dd, 2H, J= 1.5Hz J= 7.5Hz, Ar), 7.19 (t, 1H, J= 1.0Hz, Ar), 7.21 (dd, 4H, 
J= 1.5Hz, J= 7.5Hz, Ar), 7.23 (d, 2H, J= 7.5Hz, Ar), 7.26 (d, 2H, J= 7.5Hz, Ar), 7.32-
7.34 (m, 2H, Ar), 7.35 (d, 1H, J= 7.5Hz, Ar); ¹³C NMR (CDCl3, 75MHz): δC 35.29, 
48.51, 50.14 (CH2), 55.57 (CH3), 119.74, 122.02, 126.52, 127.34, 127.56 (CH), 127.70 
(C), 128.46 128.57, 128.70, 129.05, 130.86 (CH), 136.40, 137.37, 149.34, 153.96, 
  Experimental 
179 
 
170.68 (C); MS (APCI m/z): 390 [M+H)
+
, (100%)]; HRMS FAB [M+H]
+
 390.1701, 
C24H23NO4+H
+
 requires 390.1700.  
 
[2-(2-Oxo-2-pyrrolidin-1-yl-ethyl)phenyl] acetate, 389d 
389d
O
O
N
O
 
The solvent was evaporated in vacuo to afford the title compound as yellow oil (100%). 
Rf (30% EtOAc in petroleum ether): 0.33; IR (neat, cmˉ¹): νmax 1632 (C=O stretching), 
1169 (C-O stretching, ester) 1759 (C=O stretching, ester); ¹H NMR (CDCl3, 300MHz): 
δH 1.80-1.89 (m, 4H, CH2CH2), 2.32 (s, 3H, CH3), 3.31 (t, 2H, J= 6.0Hz, NCH2), 3.48 
(t, 2H, J= 6.0Hz, NCH2), 3.57 (s, 2H, CH2Ar), 7.06 (d, 1H J= 7.5Hz, Ar), 7.19 (t, 1H, 
J= 7.5Hz, Ar), 7.25-7.32 (m, 2H, Ar). ¹³C NMR (CDCl3, 75MHz): δC 21.10, (CH3), 
24.43, 26.33, 37.51, 46.17, 46.99 (CH2), 122.65, 126.42 (CH), 127.51(C), 128.21, 
130.73 (CH), 149.16, 168.67, 169.46 (C); MS (APCI m/z): 248 [M+H)
+
, 
(100%)]; HRMS FAB [M+H]
+
 248.1284, C14H17NO3+H
+
 requires 248.1281. 
 
[2-(2-Oxo-2-pyrrolidin-1-yl-ethyl)phenyl] benzoate, 389e 
389e
O
O
N
O
 
The solvent was evaporated in vacuo to afford the title compound as pink oil (93%). Rf 
(30% EtOAc in petroleum ether): 0.20; IR (neat, cmˉ¹): νmax 1636 (C=O stretching), 
1196 (C-O stretching, ester), 1731 (C=O stretching, ester); ¹H NMR (CDCl3, 300MHz): 
δH 1.71-1.81 (m, 4H, CH2CH2), 3.28 (t, 2H, J= 7.5Hz, NCH2), 3.43 (t, 2H, J= 7.5Hz, 
NCH2), 3.61 (s, 2H, CH2Ar), 7.21 (td, 1H, J= 1.0Hz, J= 8.0Hz, Ar), 7.25 (dd, 2H, J= 
1.0Hz, J= 8.0Hz, Ar), 7.35 (dd, 1H, J= 1.0Hz, J= 8.0Hz, Ar), 7.38 (dd, 1H, J= 1.0Hz, 
J= 8.0Hz, Ar), 7.52 (td, 2H, J= 1.0Hz, J= 8.0Hz, Ar), 7.66 (td, 1H, J= 1.0Hz, J= 8.0Hz, 
Ar), 8.21 (dd, 1H, J= 1.0Hz, J= 8.0Hz, Ar). ¹³C NMR (CDCl3, 75MHz): δC 24.41, 
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26.81, 36.93, 46.08, 46.97 (CH2), 122.57, 126.51, 127.95, 128.29, 128.78, 129.34, 
130.32 (CH), 130.83, 133.91, 149.27, 164.90, 168.77 (C); MS (APCI m/z): 310 
[M+H)
+
, (100%)]; HRMS FAB [M+H]
+
 310.1437, C19H19NO3+H
+
 requires 310.1438.  
 
Methyl 2-(2-oxo-2-(pyrrolidin-1-yl)ethyl)phenyl carbonate, 389f 
389f
O
O
O
N
O
 
The solvent was evaporated in vacuo to afford the title compound as an orange oil 
(96%). Rf (30% EtOAc in petroleum ether): 0.41; IR (neat, cmˉ¹): νmax 1634 (C=O 
stretching), 1169 (C-O stretching, carbonate), 1759 (C=O stretching, carbonate); ¹H 
NMR (CDCl3, 300MHz): δH 1.79-1.97 (m, 4H, CH2CH2), 3.39 (t, 2H, J= 7.5Hz, NCH2), 
3.48 (t, 2H, J= 7.5Hz, NCH2), 3.62 (s, 2H, CH2Ar), 3.90 (s, 3H, CH3), 7.18 (dd, 1H, J= 
1.5Hz, J= 7.5Hz, Ar), 7.21 (dd, 1H, J= 1.5Hz, J= 7.5Hz, Ar), 7.28 (dd, 1H, J= 1.5Hz, 
J= 7.5Hz, Ar), 7.35 (dd, 1H, J= 1.5Hz, J= 7.5Hz, Ar). ¹³C NMR (CDCl3, 75MHz): δC 
24.51, 26.32, 36.43, 46.12, 46.99 (CH2), 55.59 (CH3), 121.96, 126.61 (CH), 127.38 (C), 
128.26, 130.79 (CH), 149.34, 154.03, 168.57 (C);  MS (APCI m/z): 264 [M+H)
+
, 
(100%)]. HRMS FAB [M+H]
+
 264.1224, C14H17NO4+H
+
 requires 264.1228 
 
[2-[3-(Dibenzylamino)-3-oxo-propyl]phenyl] acetate, 392a 
392a
O
O
N
O
 
The solvent was evaporated in vacuo to afford the title compound as a lemon-yellow 
sticky oil (91%). Rf (50% EtOAc in petroleum ether): 0.34; IR (neat, cmˉ¹): νmax 1643 
(C=O stretching), 1169 (C-O stretching, ester) 1759 (C=O stretching, ester); ¹H NMR 
(CDCl3, 300MHz): δH 2.24 (s, 3H, CH3), 2.67 (t, 2H, J= 7.5Hz, CH2C=O), 2.98 (t, 2H, 
J= 7.5Hz, CH2Ar), 4.38 (s, 2H, NCH2), 4.61 (s, 2H, NCH2), 6.99 (dd, 1H, J= 1.0Hz, J= 
  Experimental 
181 
 
8.0Hz, Ar), 7.10 (d, 2H, J= 8.0Hz, Ar), 7.12 (dd, 1H, J= 1.0Hz, J= 8.0Hz, Ar), 7.16-
7.21 (m, 3H, Ar), 7.22-7.24 (m, 2H, Ar), 7.25-7.29 (m, 4H, Ar), 7.35 (d, 1H, J= 8.0Hz, 
Ar); ¹³C NMR (CDCl3, 75MHz): δC 20.99 (CH3), 26.99, 33.53, 48.43, 49.92 (CH2), 
122.50, 126.35, 126.39, 127.52, 127.58, 127.71, 128.36, 128.69, 129.05, 130.58 (CH), 
133.00, 136.45, 137.29, 149.03, 169.69, 172.75 (C); MS (APCI m/z): 388 [M+H)
+
, 
(100%)]; HRMS FAB [M+H]
+
  388.1908, C25H25NO3+H
+
 requires 388.1907.  
 
[2-[3-(Dibenzylamino)-3-oxo-propyl]phenyl] benzoate, 392b 
392b
O
O
N
O
 
The solvent was evaporated in vacuo to afford the title compound as a lemon-yellow 
sticky oil (100%). Rf (30% EtOAc in petroleum ether): 0.62; IR (neat, cmˉ¹): νmax 1644 
(C=O stretching), 1170 (C-O stretching, ester) 1731 (C=O stretching, ester); ¹H NMR 
(CDCl3, 300MHz): δH 2.72 (t, 2H, J= 7.5Hz, CH2C=O), 3.05 (t, 2H, J= 7.5Hz, CH2Ar), 
4.32 (s, 2H, NCH2), 4.55 (s, 2H, NCH2), 7.03 (t, 2H, J= 7.5Hz, Ar), 7.12 (td, 3H, J= 
1.0Hz, J= 7.5Hz, Ar), 7.19 (td, 2H, J= 1.0Hz, J= 7.5Hz, Ar), 7.25-7.29 (m, 4H, Ar), 
7.32 (dd, 3H, J= 1.0Hz, J= 7.5Hz, Ar), 7.47 (td, 2H, J= 1.0Hz, J= 7.5Hz, Ar), 7.64 (td, 
1H, J= 1.0Hz, J= 7.5Hz, Ar), 8.11 (dd, 2H, J= 1.0Hz, J= 7.5Hz, Ar); ¹³C NMR (CDCl3, 
75MHz): δC 26.45, 33.68, 48.29, 49.90 (CH2), 122.61 (CH), 123.44 (C), 126.45, 127.46, 
127.66, 127.73, 128.29, 128.67, 128.79, 129.00 (CH), 129.31 (C), 130.26, 130.88, 
133.22, 133.81 (CH), 136.38, 137.29, 149.30, 165.29, 172.72 (C);  MS (APCI m/z): 450 
[M+H)
+
, (100%)]; HRMS FAB [M+H]
+
  450.2058, C30H27N1O3+H
+
 requires 450.2064. 
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 [2-[3-(Dibenzylamino)-3-oxo-propyl]phenyl] methyl carbonate, 392c 
392c
O
O
O
N
O
 
The solvent was evaporated in vacuo to afford the title compound as a lemon-yellow 
solid (93%). Rf (30% EtOAc in petroleum ether): 0.58; m.p.= 65-67 
○
C (DCM). IR 
(neat, cmˉ¹): νmax 1643 (C=O stretching), 1169 (C-O stretching, carbonate) 1759 (C=O 
stretching, carbonate); ¹H NMR (CDCl3, 300MHz): δH 2.71 (t, 2H, J= 7.5Hz, CH2C=O), 
3.04 (t, 2H, J= 7.5Hz, CH2Ar), 3.82 (s, 2H, NCH2), 4.39 (s, 2H, NCH2), 4.59 (s, 3H, 
CH3), 7.10 (d, 3H, J= 8.0Hz, Ar), 7.15-7.19 (m, 3H, Ar), 7.21 (d, 1H, J= 8.0Hz, Ar), 
7.24-7.26 (m, 2H, Ar), 7.29-7.31 (m, 4H, Ar), 7.34-7.36 (m, 1H, Ar); ¹³C NMR (CDCl3, 
75MHz): δC 50.52 (CH3), 26.27, 35.65, 48.23, 49.88 (CH2), 121.98, 126.53, 126.61, 
127.51, 127.69, 127.74, 128.41, 128.70, 129.04, 130.78 (CH), 132.95, 136.49, 137.38, 
149.45, 154.36, 172.62 (C); MS (APCI m/z): 404 [M+H)
+
, (100%)]; HRMS FAB 
[M+H]
+
  404.1855, C25H25NO4+H
+
 requires 404.1856. 
 
2-(3-Oxo-3-(pyrrolidin-1-yl)propyl)phenyl acetate, 392d 
392d
O
O
N
O
 
The solvent was evaporated in vacuo to afford the title compound as a lemon-yellow oil 
(100%). Rf (30% EtOAc in petroleum ether): 0.66; IR (neat, cmˉ¹): νmax 1624 (C=O 
stretching), 1169 (C-O stretching, ester), 1756 (C=O stretching, ester); ¹H NMR 
(CDCl3, 300MHz): δH 1.77-1.91 (m, 4H, CH2CH2), 2,33 (s, 3H, CH3), 2.49 (t, 2H, J= 
7.5Hz, CH2C=O), 2.90 (t, 2H, J= 7.5Hz, CH2Ar), 3.26 (t, 2H, J= 6.0Hz, NCH2), 3.45 (t, 
2H, J= 7.5Hz, NCH2), 7.01 (d, 1H, J= 6.0Hz, Ar), 7.16-7.20 (m, 2H, Ar), 7.22-7.30 (m, 
1H, Ar); ¹³C NMR (CDCl3, 75MHz): δC 21.02 (CH3), 24.37, 25.50, 26.02, 35.15, 45.70, 
46.56 (CH2), 122.38, 126.23, 126.40, 130.43 (CH), 133.28, 148.90, 169.78, 170.59 (C); 
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MS (APCI m/z): 262 [M+H)
+
, (100%)]; HRMS FAB [M+H]
+
 262.1437, 
C15H19NO3+H
+
 requires 262.1438. 
 
[2-(3-Oxo-3-pyrrolidin-1-yl-propyl)phenyl] benzoate, 392e 
392e
O
O
N
O
 
The solvent was evaporated in vacuo to afford the title compound as a lemon-yellow 
waxy oil (94%). Rf (50% EtOAc in petroleum ether): 0.37; IR (neat, cmˉ¹): νmax 1643 
(C=O stretching), 1169 (C-O stretching, ester) 1759 (C=O stretching, ester); ¹H NMR 
(CDCl3, 300MHz): δH 1.75-1.80 (m, 4H, CH2CH2), 2.54-2.60 (m, 2H, CH2C=O), 3.00 
(t, 2H, J= 7.5Hz, CH2Ar), 3.20 (br. s, 2H, J= 7.5Hz, NCH2), 3.40 (br. s, 2H, J= 7.5Hz, 
NCH2), 7.15 (dd, 1H, J= 1.0Hz, J= 8.0Hz, Ar), 7.23 (dd, 1H, J= 1.0Hz, J= 8.0Hz, Ar), 
7.35 (d, 1H, J= 8.0Hz, Ar), 7.52 (dd, 1H, J= 1.0Hz, J= 8.0Hz, Ar), 7.55-7.60 (m, 2H, 
Ar), 7.63-7.66 (m, 1H, Ar), 8.21 (dd, 2H, J= 1.0Hz, J= 8.0Hz, Ar); ¹³C NMR (CDCl3, 
75MHz): δC 24.33, 25.80, 25.94, 35.31, 45.80, 46.69 (CH2), 122.48, 126.30, 127.52, 
128.23 (CH), 129.26 (C), 130.17, 130.65 (CH), 133.34 (C), 133.76 (CH), 149.10, 
165.29, 170.79 (C); MS (APCI m/z): 324 [M+H)
+
, (100%)]; HRMS FAB 
[M+H]
+
 324.1592, C20H21NO3+H
+
 requires 324.1594. 
 
Methyl [2-(3-oxo-3-pyrrolidin-1-yl-propyl)phenyl] carbonate, 392f 
392f
O
O
O
N
O
 
The solvent was evaporated in vacuo to afford the title compound as a colourless oil 
(89%). Rf (30% EtOAc in petroleum ether): 0.67; IR (neat, cmˉ¹): νmax 1632 (C=O 
stretching), 1178 (C-O stretching, carbonate) 1759 (C=O stretching, carbonate); ¹H 
NMR (CDCl3, 300MHz): δH 1.77-1.93 (m, 4H, CH2CH2), 2,52 (t, 2H, J= 7.5Hz, 
CH2C=O), 2.95 (t, 2H, J= 7.5Hz, CH2Ar), 3.29 (t, 2H, J= 7.5Hz, NCH2), 3.45 (t, 2H, J= 
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7.5Hz, NCH2), 3.90 (s, 3H, CH3), 7.11 (dd, 1H, J= 1.5Hz, J= 8.0 Hz), 7.21-7.25 (m, 
2H), 7.30 (dd, 1H, J= 1.5Hz J= 8.0Hz); ¹³C NMR (CDCl3, 75MHz): δC 24.48, 25.64, 
26.41, 35.25, 45.75, 46.59 (CH2), 55.63 (CH3), 121.91, 126.57, 127.62, 130.79 (CH), 
133.29, 149.39, 154.40, 170.58 (C); MS (APCI m/z): 278 [M+H)
+
, (100%)]; HRMS 
FAB [M+H]
+
 278.1389, C15H19NO4+H
+
 requires 278.1387. 
 
2-(2-Oxo-2-(pyrrolidin-1-yl)ethyl)phenyl diethylcarbamate, 396 
396
O
N
N
O
O
 
Flash column chromatography (SiO2; 50% EtOAc in petroleum ether) afforded the title 
compound as a colourless oil (57%). Rf (30% EtOAc in petroleum ether): 0.52; IR (neat, 
cmˉ¹): νmax 1610 (C=O stretching), 1192 (C-O stretching, carbamate), 1715 (C=O 
stretching, carbamate); ¹H NMR (CDCl3, 300MHz): δH 1.17-1.25 (m, 2H, CH2CH2), 
1.39 (t, 2H, J= 7.5Hz, CH2CH2), 1.85-1.91 (m, 3H, CH3), 1.97-2.03 (m, 3H, CH3), 2.95 
(q, 2H, J= 7.5Hz, CH2CH3), 3.33-3.40 (m, 2H, CH2CH3), 3.46 (t, 2H, J= 7.5Hz, NCH2), 
3.55-3.66 (m, 2H, NCH2), 3.68 (s, 2H, CH2Ar), 6.80 (t, 1H, J= 7.5Hz, Ar), 6.96-7.03 
(m, 2H, Ar), 7.17 (t, 1H, J= 7.5Hz, Ar). ¹³C NMR (CDCl3, 75MHz): δC 24.50, (CH3), 
26.10, 38.95, 46.32, 47.73 (CH2), 118.34, 119.95 (CH),  121.06 (C), 129.11, 130.55 
(CH), 157.25, 171.55 (C);  MS (APCI m/z): 305 [M+H)
+
, (100%)]. HRMS FAB 
[M+H]
+
 305.1860, C17H24N2O3+H
+
 requires 305.1860. 
 
2-Acetylphenyl benzoate, 398a 
398a
O
O O
 
The solvent was evaporated in vacuo to afford the title compound as colourless crystals 
(100%). Rf (10% EtOAc in petroleum ether): 0.44; m.p.= 88-89 °C (dichloromethane) 
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[(lit. m.p. 87-88 °C)
370
 (ethanol)]; IR (neat, cmˉ¹): ν 1634 (C=O stretching), 1176 (C-O 
stretching, ester), 1759 (C=O stretching, ester); ¹H NMR (CDCl3, 300MHz): δH 2.27 (s, 
3H, CH3), 6.96 (dd, 1H, J= 1.0Hz, J= 8.0Hz, Ar), 7.10 (t, 1H, J= 7.5Hz, Ar), 7.44-7.60 
(m, 4H, Ar), 7.59 (dd, 1H, J= 1.0Hz, J= 8.0Hz, Ar), 7.95 (dd, 2H, J= 1.0Hz, J= 8.0Hz, 
Ar). ¹³C NMR (CDCl3, 75MHz): δC 29.95, (CH3), 124.05, 126.32, 128.84, (CH), 129.33 
(C), 130.43 (CH), 131.36 (C), 133.57, 133.97 (CH), 149.48, 165.30, 197.72 (C); MS 
(APCI m/z): 258 [M+NH4)
+
, (100%)]. 
 
2-Propionylphenyl benzoate, 398b 
398b
O
O O
 
Flash column chromatography (SiO2; 5% EtOAc in petroleum ether) afforded the title 
compound as colourless solid (61%). Rf (10% EtOAc in petroleum ether): 0.43; m.p.= 
58-60 °C (EtOAc/petroleum ether) [(lit. m.p.= 58-59 °C)
371
 (petroleum ether)]; IR (neat, 
cmˉ¹): ν 1684 (C=O stretching), 1194 (C-O stretching, ester), 1726 (C=O stretching, 
ester); ¹H NMR (CDCl3, 300MHz): δ 1.16 (t, 3H, J= 7.5Hz, CH3), 2.96 (q, 2H, J= 
7.5Hz, CH2), 7.29 (d, 1H, J= 7.5Hz, Ar), 7.40 (t, 1H, J= 7.5Hz, Ar), 7.49-7.60 (m, 1H, 
Ar), 7.64-7.72 (m, 1H, Ar), 7.86 (dd, 1H, J= 1.0Hz, J= 8.0Hz, Ar), 8.15 (dd, 2H, J= 
1.0Hz, J= 8.0Hz, Ar), 8.24 (dd, 2H, J= 1.0Hz, J= 8.0Hz, Ar). ¹³C NMR (CDCl3, 
75MHz): δ 8.33 (CH3), 35.08 (CH2), 123.97, 126.42, 128.60 (CH), 128.80 (C), 129.86, 
130.31 (CH), 130.42 (C), 133.09, 133.94 (CH), 149.13, 165.30, 172.47 (C); MS (APCI 
m/z): 272 [M+NH4)
+
, (100%)]. 
  
2-Acetylphenyl diethylcarbamate, 415a 
415a
O ON
O
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Flash column chromatography (SiO2; 17% EtOAc in petroleum ether) afforded the title 
compound as a colourless oil (27%). Rf (30% EtOAc in petroleum ether): 0.55; IR (neat, 
cmˉ¹): νmax 1686 (C=O stretching), 1150 (C-O stretching, carbamate), 1713 (C=O 
stretching, carbamate); ¹H NMR (CDCl3, 300MHz): δH 1.21 (t, 3H, J= 7.5Hz, CH3CH2), 
1.29 (t, 3H, J= 7.5Hz, CH3CH2), 2.55 (s, 3H, CH3), 3.38 (q, 4H, J= 6.0Hz, CH2CH3), 
3.49 (q, 2H, J= 7.5Hz, CH2CH3), 7.12 (d, 1H, J= 9.0Hz, Ar), 7.25 (t, 1H, J= 7.5Hz, Ar), 
7.9 (td, 1H, J= 7.5Hz, Ar), 7.74 (dd, 1H, J= 9.0Hz, Ar). ¹³C NMR (CDCl3, 75MHz): δC 
13.48, 14.30, 29.72 (CH3), 42.08, 42.44 (CH2), 123.93, 125.42, 129.78 (CH), 132.06 
(C), 133.13 (CH), 149.95, 153.85, 198.43 (C);  MS (APCI m/z): 236 [M+H)
+
, 
(100%)].
372
 
 
2-Propionylphenyl diethylcarbamate, 415b 
415b
O ON
O
 
Flash column chromatography (SiO2; 8% EtOAc in petroleum ether) afforded the title 
compound as a colourless oil (32%). Rf (10% EtOAc in petroleum ether): 0.52; IR (neat, 
cmˉ¹): νmax 1603 (C=O stretching), 1152 (C-O stretching, carbamate), 1714 (C=O 
stretching, carbamate); ¹H NMR (CDCl3, 300MHz): δH 1.17-134 (m, 6H, CH3CH2N), 
1.31 (t, 3H, J= 7.5Hz, CH3CH2C=O), 2.94 (q, 2H, J= 7.5Hz, CH2CH3C=O), 3.40 (q, 
4H, J= 6.0Hz, CH2CH3N), 3.51 (q, 2H, J= 6.0Hz, CH2CH3N), 7.15 (d, 1H, J= 9.0Hz, 
Ar), 7.30 (t, 1H, J= 4.5Hz, Ar), 7.50 (t, 1H, J= 7.5Hz, Ar), 7.71 (d, 1H, J= 6.0Hz, Ar).  
¹³C NMR (CDCl3, 75MHz): δC 8.32, 13.49, 14.32 (CH3), 34.99, 42.14, 42.47 (CH2), 
123.75, 125.33, 129.08, 132.47 (CH), 132.54, 149.50, 153.86, 201.85 (C); MS (APCI 
m/z): 250 [M+H)
+
, (100%)].
372
  
 
 
 
 
 
 
  Experimental 
187 
 
2-Propionylphenyl methylphenylcarbamate, 415c 
415c
O ON
O
 
Flash column chromatography (SiO2; 10% EtOAc in petroleum ether) afforded the title 
compound as a colourless oil (76%). Rf (20% EtOAc in petroleum ether): 0.48; IR (neat, 
cmˉ¹): νmax 1689 (C=O stretching), 1134 (C-O stretching, carbamate), 1721 (C=O 
stretching, carbamate); ¹H NMR (CDCl3, 300MHz): δH 0.96 (t, 3H, J= 6.0Hz, CH3CH2), 
2.63 (br. s, 2H, CH2CH3), 3.26 (s, 3H, CH3N), 6.99 (d, 1H, J= 8.0Hz, Ar), 7.08 (t, 3H, 
J= 7.5Hz, Ar), 7.11-7.33 (m, 4H, Ar), 7.53 (d, 1H, J= 8.0Hz, Ar). ¹³C NMR (DMSO-d6, 
400MHz at 60 
○
C): δC 7.47 (CH3), 34.04 (CH2), 37.68 (CH3), 122.89, 125.40, 125.73, 
128.37, 128.68, 128.75 (CH),  131.56 (C), 132.23 (CH), 142.45, 148.36, 152.32, 201.57 
(C); MS (APCI m/z): 284 [M+H)
+
, (100%)]. HRMS FAB [M+H]
+
 284.1281, 
C17H17NO3+H
+
 requires 284.1281.  
 
2-Propionylphenyl morpholine-4-carboxylate, 415d 
415d
O O
O
N
O
 
Flash column chromatography (SiO2; 40% EtOAc in petroleum ether) afforded the title 
compound as colourless solid (94%). Rf (30% EtOAc in petroleum ether): 0.44; m.p.= 
102-104 °C (EtOAc/petroleum ether). IR (neat, cmˉ¹): νmax 1686 (C=O stretching), 1718 
(C=O stretching, carbamate), 1053 (C-O stretching); ¹H NMR (CDCl3, 300MHz): δH 
1.17 (t, 3H, J= 7.5Hz, CH3CH2), 2.88 (q, 2H, J= 7.5Hz, CH2CH3), 3.55 (br. s, 2H, 
OCH2), 3.66-3.78 (m, 6H, OCH2NCH2), 7.13 (d, 1H, J= 7.5Hz, Ar), 7.25 (t, 1H, J= 
7.5Hz, Ar), 7.47 (td, 1H, J= 1.5Hz, J= 7.5Hz, Ar), 7.79 (dd, 1H, J= 1.5Hz, J= 8.0Hz, 
Ar). ¹³C NMR (CDCl3, 75MHz): δC 8.18, (CH3), 34.44, 44.23, 45.06, 66.52 (CH2), 
123.76, 125.51, 129.26, 131.45 (CH), 132.69, 149.22, 153.26, 200.99 (C); MS (APCI 
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m/z): 264 [M+H)
+
, (100%)]; HRMS FAB [M+H]
+
 264.1230, C14H17NO4+H
+
 requires 
264.1230. 
 
4-Methyl-2-propionylphenyl methylphenylcarbamate, 425a 
425a
ON
O
O
 
Flash column chromatography (SiO2; 15% EtOAc in petroleum ether) afforded the title 
compound as a colourless solid (63%). Rf (30% EtOAc/petroleum ether): 0.57; m.p.= 
67-69 
○C (methanol). IR (neat, cmˉ¹): νmax 1679 (C=O stretching), 1135 (C-O stretching, 
ester), 1711 (C=O stretching, ester); ¹H NMR (CDCl3, 300MHz): δ 1.11 (br. t, 3H, J= 
6.0Hz, CH3CH2), 2.35 (s, 3H, CH3Ar), 2.77 (br. s, 2H, CH2CH3), 3.41 (br. s, 3H, 
CH3N),  7.02 (d, 1H, J= 7.5Hz, Ar), 7.26 (br. t, 2H, J= 3.0Hz, Ar),  7.36-7.42 (m, 4H, 
Ar), 7.48 (br. s, 1H, Ar). ¹³C NMR (DMSO-d6, 400MHz at 60 
○
C): δH 7.48, 19.92 
(CH3), 33.99 (CH2), 37.53 (CH3), 122.62, 125.38, 125.71, 128.33, 128.94 (CH), 131.22 
(C), 132.66 (CH), 134.52, 142.50, 146.22, 152.47, 200.79 (C); MS (APCI m/z): 298 
[M+H)
+
, (100%)]. HRMS FAB [M+H]
+
 298.1433, C18H19NO3+H
+
 requires 298.1438. 
 
4-Bromo-2-propionylphenyl methylphenylcarbamate, 425b 
425b
OO
O
N
Br
 
The solvent was evaporated in vacuo to afford the title compound as a colourless solid 
(96%). Rf (30% EtOAc in petroleum ether): 0.87. Mp= 77-79 
○
C (dichloromethane). IR 
(neat, cmˉ¹): νmax 1694 (C=O stretching), 1138 (C-O stretching, carbamate), 1720 (C=O 
stretching, carbamate); ¹H NMR (DMSO d6, 300MHz): δH 0.98 (br. s, 3H, J= 6.3Hz, 
CH3CH2), 2.82 (br. s, 2H, CH2CH3), 3.39 (br. s, 3H, CH3N),  7.21 (d, 1H, J= 7.89Hz, 
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Ar), 7.28 (t, 1H, J= 6.3Hz, Ar),  7.39-7.44 (m, 4H, Ar), 7.74 (d, 1H, J= 7.89Hz, Ar), 
7.93 (br. s, 1H, Ar). ¹³C NMR (DMSO-d6, 400MHz at 60 
○
C): δC 7.26 (CH3), 7.65 
(CH2), 34.16 (CH3), 117.31 (C), 125.19, 125.41, 125.75, 128.41, 128.79 (CH), 130.92 
(C), 133.53 (CH), 142.23, 147.48, 151.93, 199.65 (C); MS (APCI m/z): 362 (
79
Br), 364 
(
81
Br) [M+H)
+
, (100%)]. HRMS FAB [M+H]
+
 362.0383, C17H16BrNO3+H
+
 requires 
362.0386. 
 
[2-[(Z)-3-Hydroxybut-2-enoyl]phenyl] N-methyl-N-phenyl-carbamate, 425c 
425c
ON
O
O OH
 
Flash column chromatography (SiO2; 17% EtOAc in petroleum ether) afforded the title 
compound as a colourless solid (50%). Rf (30% EtOAc in petroleum ether): 0.58; m.p.= 
75-77 
○C (EtOAc/Petrol). IR (neat, cmˉ¹): νmax 1722 (C=O stretching, ester), 1129 (C-O 
stretching) ; ¹H NMR (CDCl3, 300MHz): δH 1.97 (s, 3H, CH3), 3.29 (s, 3H, CH3N), 
5.71 (s, 1H, CH), 7.04 (d, 1H, J= 7.5Hz, Ar), 7.13 (m, 3H, Ar), 7.24-7.35 (m, 4H, Ar), 
7.55 (dd, 1H, J= 1.5Hz, J= 7.5Hz, Ar), 15.85 (s, 1H, OH). ¹³C NMR (CDCl3, 75MHz): 
δC 25.69, 38.47 (CH3), 100.52, 123.80, 125.74, 129.16, 129.42, 132.29 (CH), 149.28, 
193.14 (C); MS (APCI m/z): 310 [M-H)
+
, (100%)]. HRMS FAB [M+H]
+
 312.1232, 
C18H17NO4+H
+
 requires 312.1230. 
 
2-((Z)-3-Hydroxy-3-phenylacryloyl)phenyl methylphenylcarbamate, 425d 
425d
ON
O
O OH
 
Flash column chromatography (SiO2; 15% EtOAc in petroleum ether) afforded the title 
compound as a colourless solid (91%). Rf (20% EtOAc in petroleum ether): 0.52; m.p.= 
70-72 
○
C (DCM). IR (neat, cmˉ¹): νmax 1128 (C-O stretching, carbamate), 1721 (C=O 
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stretching, carbamate); ¹H NMR (CDCl3, 300MHz): δH 3.38 (s, 3H, CH3N), 6.55 (s, 1H, 
CH), 7.19-7.24 (m, 2H, Ar), 7.29-7.35 (m, 5H, Ar), 7.44-7.49 (m, 3H, Ar), 7.53-7.58 
(m, 1H, Ar), 7.75 (d, 1H, J= 7.5Hz, Ar), 7.81 (d, 2H, J= 7.5Hz, Ar). ¹³C NMR (DMSO-
d6, 400MHz at 60 
○
C): δC 37.61 (CH3), 96.73, 123.35, 123.73, 125.11, 125.49, 125.83, 
126.28, 126.70, 128.42, 128.75 (CH), 129.08 (C), 132.54 (CH), 134.05, 142.33, 148.76, 
152.27, 183.87, 185.36 (C); MS (APCI m/z): 374 [M+H)
+
, (100%)]. HRMS FAB 
[M+H]
+
 374.1381, C23H19NO4+H
+
 requires 374.1387. 
 
2-(3-Phenylpropanoyl)phenyl methylphenylcarbamate, 425e 
425e
ON
O
O
 
Flash column chromatography (SiO2; 10% EtOAc in petroleum ether) afforded the title 
compound as a colourless oil (99%). Rf (20% EtOAc/petroleum ether): 0.57; m.p. = 56-
58 
○C (dichloromethane). IR (neat, cmˉ¹): νmax 1686 (C=O stretching), 1131 (C-O 
stretching, carbamate), 1721 (C=O stretching, carbamate); ¹H NMR (CDCl3, 300MHz): 
δH 2.99 (br. s, 2H, CH2C=O), 3.01 (br. s, 2H, CH2Ar), 3.38 (s, 3H, CH3N), 7.14-7.36 
(m, 12H, Ar), 7.48 (t, 1H, J= 7.5Hz, Ar),  7.72 (d, 1H, J= 7.5Hz, Ar). ¹³C NMR 
(DMSO-d6, 400MHz at 60 
○
C): δC 29.10 (CH2), 37.70 (CH3), 42.36 (CH2), 123.06, 
123.48, 125.32, 125.70, 127.63, 128.07, 128.34, 128.73, 128.88 (CH), 131.36 (C), 
132.49 (CH), 140.66, 142.36, 148.56, 152.33, 199.07 (C); MS (APCI m/z): 360 
[M+H)
+
, (100%)]. HRMS FAB [M+H]
+
 360.1590, C23H21NO3+H
+
 requires 360.1594. 
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4.8 General procedure for the Baker-Venkataraman rearrangement reactions 
O O
O
R2 OH O
R1
O
R2
R1
R3 R3
399a, 416a,c, 426a,e, 430398a, 415a,c, 425a,e  
 R
1
 R
2
 R
3
 
399a H C6H5 H 
416a H NEt2 H 
416c CH3 N(CH3)C6H5 H 
426a CH3 N(CH3)C6H5 CH3 
426e CH2C6H5 N(CH3)C6H5 H 
430 H N(CH3)C6H5 H 
To a solution of the O-acylated phenols (1 eq.) in anhydrous tetrahydrofuran (0.2 M) 
was added sodium hydride (2.5 eq.) and the resulting solution was heated at reflux for 
1-2 hours. After which, the mixture was cooled down and acidified with hydrochloric 
acid solution (1 M, 30mL). The product was extracted with ethyl acetate (2×30mL) and 
the combined organic layers were washed with distilled water (2×20mL), brine (10mL), 
dried (MgSO4), filtered and the solvent evaporated in vacuo to afford the crude residue 
which was purified by flash column chromatography. 
 
(Z)-3-Hydroxy-1-(2-hydroxyphenyl)-3-phenylprop-2-en-1-on, 399a 
OH O OH
399a  
Flash column chromatography (SiO2; 4% EtOAc in petroleum ether) afforded the title 
compound as white solid (96%). Rf (10% EtOAc in petroleum ether): 0.56; m.p.= 130-
132 °C (EtOAc/petroleum ether). IR (neat, cmˉ¹): νmax 1601 (C=O stretching), 1087 (C-
O stretching), 3045 (OH stretching); ¹H NMR (CDCl3, 300MHz): δH 6.85 (s, 1H, CH), 
6.93 (t, 1H, J= 7.5Hz, Ar), 7.01 (d, 1H, J= 9.0Hz, Ar), 7.44-7.60 (m, 4H, Ar), 7.79 (d, 
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1H, J= 9.0Hz, Ar), 7.94 (d, 2H, J= 9.0Hz, Ar), 12.11 (s, 1H, ArOH), 15.55 (s, 1H, OH). 
¹³C NMR (CDCl3, 75MHz): δC 92.41, 118.95, 119.09 (CH), 119.23 (C), 126.95, 128.65, 
128.93, 132.57, 135.99 (CH), 133.72, 162.60, 177.61, 195.81 (C); MS (APCI m/z): 241 
[M+H)
+
, (100%)].
373
 
 
N,N-Diethyl-3-(2-hydroxyphenyl)-3-oxopropanamide, 416a 
416a
OH O
N
O
 
Flash column chromatography (SiO2; 45% EtOAc in petroleum ether) afforded the title 
compound as an orange solid (74%). Rf (30% EtOAc in petroleum ether): 0.43; m.p.= 
86-88 °C (EtOAc/petroleum ether) [(lit. m.p.= 85 °C)
99
 (EtOAc/hexane)]; IR (neat, 
cmˉ¹): νmax 1624 (C=O stretching), 2967 (OH stretching), 1096 (C-O stretching); ¹H 
NMR (CDCl3, 300MHz): δH 1.17-1.26 (m, 6H, CH3), 3.32-3.44 (m, 4H, CH2CH3), 4.07 
(s, 2H, CH2C=O), 6.88-6.96 (m, 2H, Ar), 7.47 (t, 1H, J= 8.0Hz, Ar), 7.79 (d, 1H, J= 
7.5Hz, Ar), 11.96 (s, 1H, OH). ¹³C NMR (CDCl3, 75MHz): δC 12.98, 14.35 (CH3), 
40.48, 42.91, 45.50 (CH2), 118.59, 119.39, 119.44 (C), 130.98, 137.02 (CH), 162.71, 
165.64, 200.30 (C); MS (APCI m/z): 236 [M+H)
+
, (100%)]. 
 
 3-(2-Hydroxyphenyl)-N,2-dimethyl-3-oxo-N-phenylpropanamide, 416c 
416c
OH O
N
O
 
Flash column chromatography (SiO2; 6% acetone in toluene) afforded the title 
compound as a lemon-yellow solid (48%). Rf (20% acetone in toluene): 0.50; m.p.= 89-
91 
○C (acetone/toluene). IR (neat, cmˉ¹): νmax 1659 (C=O stretching, amide), 1611 (C=O 
stretching, ketone), 3060 (OH stretching); ¹H NMR (CDCl3, 300MHz): δH 1.44 (d, 3H, 
J= 6.0Hz, CH3CH), 3.31 (s, 3H, CH3N), 4.32 (q, 3H, J= 6.0Hz, CH), 6.68 (t, 1H, J= 
7.5Hz, Ar), 6.89 (d, 1H, J= 9.0Hz, Ar), 7.12-7.18 (m, 5H, Ar), 7.23-7.29 (m, 1H, Ar), 
7.37 (t, 1H, J= 7.5Hz, Ar), 11.96 (s, 1H, OH). ¹³C NMR (CDCl3, 75MHz): δC 15.60, 
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37.94 (CH3), 46.64, 117.96, 118.68 (CH), 128.09 (C), 128.35, 128.46, 129.17, 130.07, 
136.55 (CH), 142.79, 162.91, 169.76, 203.86 (C); MS (APCI m/z): 284 [M+H)
+
, 
(100%)]. HRMS FAB [M+H]
+
 284.1282, C17H17NO3+H
+
 requires 284.1281. 
 
4-Hydroxy-3-methyl-2H-chromen-2-one, 417 
417
O O
OH
 
Flash column chromatography (SiO2; 30% acetone in toluene) afforded the title 
compound as white solid (44%). Rf (20% acetone in toluene): 0.45; m.p.= 230-232 
○
C 
(acetone/toluene) [(lit. m.p.= 227-228 °C)
374
 (ethanol)]; IR (neat, cmˉ¹): νmax 1662 (C=O 
stretching), 1083 (C-O stretching), 3151 (OH stretching); ¹H NMR (DMSO- d6, 
300MHz): δH 1.99 (s, 3H, CH3), 7.31-7.36 (m, 2H, Ar), 7.58 (td, 1H, J= 1.0Hz, J= 
8.0Hz, Ar), 7.89 (d, 1H, J= 8.0Hz, Ar), 11.30 (s, 1H, OH). ¹³C NMR (CDCl3, 75MHz): 
δC 9.78 (CH3), 100.23 (C), 116.06 (CH), 116.26 (C), 122.97, 123.84, 131.46, (CH), 
151.64, 159.75, 163.16 (C); MS (APCI m/z): 175 [M-H)
+
, (100%)].  
 
3-(2-Hydroxy-5-methylphenyl)-N,2-dimethyl-3-oxo-N-phenylpropanamide, 426a  
426a
OH O
N
O
 
Flash column chromatography (SiO2; 15% EtOAc in petroleum ether) afforded the title 
compound as a lemon-yellow solid (22%). Rf (30% EtOAc in petroleum ether): 0.53; 
m.p.= 91-93 
○C (EtOAc/petroleum ether). IR (neat, cmˉ¹): νmax 1657 (C=O stretching, 
amide), 1613 (C=O stretching, ketone), 2923 (O-H stretching); ¹H NMR (CDCl3, 
300MHz): δH 1.44 (d, 3H, J= 7.0Hz, CH3CH), 2.17 (s, 3H, CH3Ar), 3.31 (s, 3H, CH3N), 
4.33 (q, 1H, J= 7.0Hz, CH), 6.80 (d, 2H, J= 8.0Hz, Ar), 7.14-7.20 (m, 4H, Ar), 7.21-
7.31 (m, 2H, Ar), 11.81 (s, 1H, OH). ¹³C NMR (CDCl3, 75MHz): δC 15.64, 20.51, 37.99 
(CH3), 46.19 (CH), 117.69 (C), 118.40 (CH), 127.69 (C), 128.31, 128.44, 128.77 (CH), 
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130.19 (C), 137.68 (CH), 160.87, 169.87 (C); MS (APCI m/z): 298 [M+H)+, (100%)]. 
HRMS FAB [M+H]
+
 298.1438, C18H19NO3+H
+
 requires 298.1438. 
 
2-Benzyl-3-(2-hydroxyphenyl)-N-methyl-3-oxo-N-phenyl-propanamide, 426e 
426e
OH O
NO
 
Flash column chromatography (SiO2; 6% EtOAc in petroleum ether) afforded the title 
compound as a lemon-yellow crystalline solid (58%). Rf (30% EtOAc in petroleum 
ether): 0.68. m.p.= 117-119 
○C (EtOAc in petroleum ether). IR (neat, cmˉ¹): νmax 1656 
(C=O stretching, amide), 1634 (C=O stretching, ketone), 3169 (O-H stretching); ¹H 
NMR (CDCl3, 300MHz): δH 3.10 (dd, 1H, J= 6.15Hz, J= 13.77Hz, CH2Ar), 3.27 (s, 3H, 
CH3N), 3.47 (dd, 1H, J= 7.72Hz, J= 13.77Hz, CH2Ar), 4.6 (dd, 1H, J= 6.35Hz, J= 
7.5Hz, CH), 6.7 (td, 2H, J= 1.0Hz, J= 8.0Hz, Ar), 6.82-6.87 (m, 4H, Ar), 6.89-6.93 (m, 
2H, Ar), 7.09-7.24 (m, 5H, Ar), 7.34 (td, 1H, J= 1.0Hz, J= 8.0Hz, Ar), 12.03 (s, 1H, 
OH). ¹³C NMR (CDCl3, 75MHz): δC 36.52 (CH2), 38.09 (CH3), 53.57, 118.48 (CH), 
118.60 (C), 126.80, 128.08, 128.51, 128.65, 129.04, 129.37, 130.09, 136.59 (CH), 
138.81, 142.79, 162.99, 167.88, 201.96 (C); MS (APCI m/z): 360 [M+H)
+
, (100%)]. 
HRMS FAB [M+H]
+
 360.1592, C23H21NO3+H
+
 requires 360.1594. 
 
3-(2-Hydroxyphenyl)-N-methyl-3-oxo-N-phenylpropanamide, 430 
430
OH
N
O O
 
Flash column chromatography (SiO2; 12% EtOAc in toluene) afforded the title 
compound as a colourless sticky oil (33%). Rf (30% EtOAc in toluene): 0.53. IR (neat, 
cmˉ¹): νmax 1632 (C=O stretching), 1118 (C-O stretching), 2932 (O-H stretching); ¹H 
NMR (CDCl3, 300MHz): δH 3.34 (s, 3H, CH3), 3.87 (s, 2H, CH2), 6.81 (t, 1H, J= 8.0Hz, 
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Ar), 6.92 (d, 1H, J= 8.0Hz, Ar), 7.24 (d, 2H, J= 8.0Hz, Ar), 7.24 (d, 1H, J= 8.0Hz, Ar), 
7.37-7.45 (m, 4H, Ar), 11.88 (s, 1H, OH). ¹³C NMR (CDCl3, 75MHz): δC 37.59 (CH3), 
45.32 (CH2), 118.54, 119.119, 127.23, 128.54, 130.12, 130.25, 136.81 (CH), 143.43, 
162.50, 166.55, 200.17 (C); MS (APCI m/z): 270 [M+H)
+
, (100%)]. HRMS FAB 
[M+H]
+
 270.1125, C16H15NO3+H
+
 requires 270.1125. 
 
4.9 General procedure for the Baker-Venkataraman-retro-Claisen cascade 
reactions 
OH
OH
OO O
O
N
O
N
+
R1
R3 R3
R1
R2
R4
R2
R4
403 404d, 427415a,c
425a,d,e  
 R
3
  R
1
 R
2
 R
4
 
403 H 404d H CH3 C6H5 
403a CH3 427e CH2C6H5 CH3 C6H5 
403b Br 
To a solution of the acylated phenols 415a,c or 425a,d,e (1 eq.) in tetrahydrofuran (0.2 
M) was added sodium hydride (2.5 eq.) and the resulting solution was heated at reflux 
for 24 hours. After which, the mixture was allowed to cool, and acidified with 
hydrochloric acid solution (1 M, 30mL). The product was extracted with ethyl acetate 
(2×30mL) and the combined organic layers were washed with distilled water (2×20mL), 
brine (10mL), dried (MgSO4), filtered and the solvent evaporated in vacuo to afford the 
crude residue which was purified by flash column chromatography. 
 
2-Hydroxybenzoic acid, salicylic acid, 403 
403
OH
OH
O
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Flash column chromatography (SiO2; 10% EtOAc in petroleum ether) afforded the title 
compound as a colourless crystals (50%). Rf (30% EtOAc in petroleum ether): 0.65; 
m.p.= 157-159 
○
C (EtOAc/Petrol) [(lit. m.p.= 158-161 °C)
375
 (EtOAc)]. IR (neat, cmˉ¹): 
νmax 1689 (C=O stretching), 1134 (C-O stretching), 3151 (OH stretching); ¹H NMR 
(CDCl3, 300MHz): δH 6.94 (t, 1H, J= 7.5Hz, Ar), 7.00 (d, 1H, J= 7.5Hz, Ar), 7.53 (td, 
1H, J= 1.5Hz, J= 7.5Hz, Ar), 7.92 (dd, 1H, J= 1.5Hz, J= 7.5Hz, Ar), 10.36 (s, 1H, OH). 
¹³C NMR (CDCl3, 75MHz): δC 111.36, 117.99, 119.76, 131.10 (CH), 137.19, 162.31, 
174.86 (C); MS (APCI m/z): 137 [M-H)
+
, (100%)]. 
 
2-Hydroxy-5-methylbenzoic acid, 403a 
 
403a
OH O
OH
 
Flash column chromatography (SiO2; 20% EtOAc in petroleum ether) afforded the title 
compound as a lemon-yellow solid (25%). Rf (10% EtOAc in petroleum ether): 0.54.  
m.p.= 150-152 °C (EtOAc/petroleum) [(lit. m.p.= 148-150 °C)
376
 (ethanol/water)]; IR 
(neat, cmˉ¹): νmax 1655 (C=O stretching), 1198 (C-O stretching), 2922 (OH stretching); 
¹H NMR (CDCl3, 300MHz): δH 2.31 (s, 3H, CH3), 6.91 (d, 1H, J= 8.0Hz, Ar), 7.34 (dd, 
1H, J= 1.5Hz, J= 8.0Hz, Ar), 7.71 (d, 1H, J= 8.0Hz, Ar), 10.21 (s, 1H, OH). ¹³C NMR 
(CDCl3, 75MHz): δC 20.50 (CH3), 110.94 (C), 117.73 (CH), 128.97 (C), 130.63, 138.20 
(CH), 160.26, 174.90 (C); MS (APCI m/z): 151 [M-H)+, (100%)]. 
 
5-Bromo-2-hydroxybenzoic acid, 403b 
403a
OH
Br
O
OH
 
Flash column chromatography (SiO2; 15% EtOAc in petroleum ether) afforded the title 
compound as a lemon-yellow crystalline solid (43%). Rf (30% EtOAc in petroleum 
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ether): 0.58; m.p.= 63-65 °C (EtOAc/petroleum) [(lit. m.p.= 60-62 °C)
377
  (solvent not 
quoted)]; IR (neat, cmˉ¹): νmax 1739 (C=O stretching), 3023 (OH stretching), 1124 (C-O 
stretching); ¹H NMR (CDCl3, 300MHz):  δH 6.91 (d, 1H, J= 8.0Hz, Ar), 7.59 (dd, 1H, 
J= 1.5Hz, J= 8.0Hz, Ar), 8.02 (s, 1H, Ar), 10.34 (s, 1H, OH). ¹³C NMR (CDCl3, 
75MHz): δC 111.27 (C), 119.93, 133.18, 139.67 (CH), 161.26 (C); MS (APCI m/z): 215 
(
79
Br), 217 (
81
Br) [M
+
, (100%)].  
 
N-Methyl-N-phenylpropanamide, 404d 
404d
N
O
 
Flash column chromatography (SiO2; 14% EtOAc in petroleum ether) afforded the title 
compound as a yellow oil (50%). Rf (20% EtOAc in petroleum ether): 0.39; IR (neat, 
cmˉ¹): νmax 1640 (C=O stretching); ¹H NMR (CDCl3, 300MHz): δH 1.04 (t, 3H, J= 
7.5Hz, CH3CH2), 2.07 (q, 2H, J= 7.5Hz, CH2CH3), 3.25 (s, 3H, CH3N), 7.17 (d, 2H, J= 
7.5Hz, Ar), 7.35 (t, 1H, J= 7.5Hz, Ar), 7.40 (t, 2H, J= 7.5Hz, Ar).  ¹³C NMR (CDCl3, 
75MHz): δC 9.87, 37.51 (CH3), 27.64 (CH2), 127.38, 127.85, 129.86 (CH), 144.25, 
174.33 (C); MS (APCI m/z): 164 [M+H)
+
, (100%)].
378
  
 
N-Methyl-N,3-diphenylpropanamide, 427e 
427e
N
O
 
Flash column chromatography (SiO2; 14% EtOAc in petroleum ether) afforded the title 
compound as a lemon-yellow oil (42%). Rf (20% EtOAc in petroleum ether): 0.47. IR 
(neat, cmˉ¹): νmax 1650 (C=O stretching), 1119 (C-O stretching); ¹H NMR (CDCl3, 
300MHz): δH 2.41 (t, 2H, J= 7.5Hz, CH2C=O), 2.94 (t, 2H, J= 7.5Hz, CH2Ar), 3.28 (s, 
3H, CH3N), 7.03-7.10 (m, 4H, Ar), 7.17-7.28 (m, 3H, Ar), 7.31-7.42 (m, 3H, Ar). ¹³C 
NMR (CDCl3, 75MHz): δC 31.83, 36.04 (CH2), 37.45 (CH3), 126.07, 127.31, 127.86, 
  Experimental 
198 
 
128.39, 128.47, 129.79 (CH), 141.23, 143.92, 172.42 (C); MS (APCI m/z): 240 
[M+H)
+
, (100%)].
378
 
 
4.10 Miscellaneous procedures 
4.10.1 Procedure for the synthesis of 2-benzyloxyphenyl acetic acid, 279 
277 278 279
OH
O
OH
Br
+
reflux 95 oC, 16h
O
O
OH
ethanol, 6.5 M NaOH
 
2-Hydroxyphenyl acetic acid (277) (0.25g, 16.44 mmol) was solubilised in a mixture of 
sodium hydroxide solution (6.5 M, 10mL) and ethanol (20mL) and heated at reflux for 
30 minutes.  Benzyl bromide (278) (6mL, 49.34 mmol) was added and the resulting 
mixture was heated at reflux for 16 hours. The solvent was concentrated and the mixture 
acidified with hydrochloric acid solution (1 M, pH ca 1-2). The crude extract was 
washed with ethyl acetate (3×30mL), dried (MgSO4), filtered and the solvent 
evaporated in vacuo to afford the crude residue. Flash column chromatography (SiO2; 
10% EtOAc in petroleum ether) afforded the title compound as colourless crystals 
(3.4g, 85%). Rf (60% EOAc in Petrol): 0.88. m.p.= 91-93 °C (EtOAc/petroleum ether) 
[(lit. m.p.= 94 °C)
379
 (benzene)]; IR (neat, cmˉ¹): ν 1706 (C=O stretching), 2920 (OH 
stretching), 1294 (C-O stretching), 1079 (ether C-O stretching); ¹H NMR (CDCl3, 
300MHz): δ 3.72 (s, 2H, CH2C=O), 5.08 (s, 2H, CH2O), 6.95 (t, 2H, J= 9.0Hz, Ar), 
7.23 (dd, 1H, J= 9.0Hz, Ar), 7.28-7.41 (m, 6H, Ar). ¹³C NMR (CDCl3, 75MHz): δ 
36.16, 70.14 (CH2), 111.95, 121.05, 122.82, 127.19, 127.98, 128.68, 129.01 (CH), 
131.95, 136.95, 156.64, 177.33: MS (APCI m/z): 241 [M-H)
+
, (100%)]. 
 
4.10.2 Procedure for the synthesis of 1-(2-(2 nitrophenoxy)phenyl)propan-1-
one, 263 
263
O
NO2
O
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2-(2-(2-Nitrophenoxy)phenyl)-2-ethyl-1,3-dioxolane (319) (315 mg, 1.0 mmol) and 
para-toluenesulfonic acid (190 mg, 1.0 mmol) were dissolved in acetone:water (8mL: 
2mL) and the reaction heated at 75 °C for 2.5 h. The reaction was allowed to cool and 
the acetone removed in vacuo. EtOAc (10mL) was added and the mixture washed with 
sat. aq. NaHCO3 (2×10mL). The combined aqueous layers were extracted with EtOAc 
(10 mL) and the combined organic layers washed with brine (10mL), dried (MgSO4) 
and the solvent removed in vacuo to yield the title compound as a pure pale yellow oil 
(98%). Rf (20% ethyl acetate in petroleum ether, eluted twice); 0.62; IR (neat, cmˉ¹): 
νmax 1682 (C=O), 1240 (Ar-O-Ar); 
1
H NMR (300 MHz; CDCl3): δH 1.15 (t, 3H, J= 
7.0Hz, CH3), 3.03 (q, 2H, J= 7.0Hz, CH2), 6.89 (d, 1H, J= 8.8Hz, Ar), 6.99 (d, 1H, J= 
8.8Hz, Ar), 7.28-7.24 (m, 2H, Ar), 7.45 (t, 1H, J= 8.0Hz, Ar), 7.54 (t, 1H, J= 8.0Hz, 
Ar), 7.82 (d, 1H, J=7.5Hz, Ar), 8.01 (d, 1H, J= 8.0Hz, Ar); ¹³C NMR (CDCl3, 75MHz): 
δC 8.1 (CH3), 36.5 (CH2), 119.0, 120.5, 123.8, 124.7, 125.9, 130.5 (CH), 130.8 (C), 
133.3, 134.5 (CH), 141.2 149.7, 154.1, 201.7 (C); MS (APCI m/z): 272 [M+H)
+
, 
(100%)]; HRMS FAB [M+H]
+ 
272.0911, C15H13NO4 (M+H
+
) requires 272.0923.
31
 
 
4.10.3 Procedure for the synthesis of 2-(2-ethyl-1,3-dioxolan-2-yl)phenol, 318 
318
HO
OO
 
2’-Hydroxypropiophenone (261) (10g, 66.6 mmol), para-toluenesulfonic acid 
monohydrate (1.27g, 6.66 mmol) and ethylene glycol (4.39mL, 79.9 mmol) were 
suspended in toluene (250mL) and heated to reflux under Dean-Stark conditions for 18 
h, upon cooling the reaction was washed with brine (2×100mL) and the brine layer 
extracted with EtOAc (100mL). The combined organic layers were dried (MgSO4) and 
the solvents removed in vacuo. The crude product flash chromatographed (SiO2; 2% 
EtOAc in petroleum ether) to give the title compound as a partially purified colourless 
oil before being taken onto the next step. Diagnostic signals in the 
1
H NMR (300 MHz; 
CDCl3): δH 1.00 (t, 3H, J= 7.5Hz, CH3), 2.02 (q, 2H, J= 7.5Hz, CH2CH3), 3.95 (t, 2H, 
J= 7.5Hz, CH2O), 4.15 (t, 2H, J= 7.5Hz, CH2O), 6.88-6.84 (m, 2H, Ar), 7.20 (td, 1H, J 
= 1.5Hz, 7.5 Hz, Ar), 7.25 (dd, 1H, J = 1.5Hz, 8.0Hz, Ar), 8.29 (s, 1H, OH).
31
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4.10.4 Procedure for the synthesis of 2-(2-(2-nitrophenoxy)phenyl)-2-ethyl-1,3-
dioxolane, 319 
319
O
OO
NO2
 
2-(2-Ethyl-1,3-dioxolan-2-yl)phenol (318) (1.58g, 8.1 mmol) and 1-fluoro-2-
nitrobenzene (60) (0.86mL, 8.1 mmol) were dissolved in dimethyl sulfoxide (80mL). 
Potassium carbonate (2.8g, 20.3 mmol) was added and the reaction stirred at room 
temperature for 17 h. Upon consumption of the starting material (TLC) water (75mL) 
and EtOAc (75mL) were added. The layers were separated and the aqueous layer was 
extracted with EtOAc (2×50mL). The combined organic layers were washed with water 
(2×50mL) and brine (50mL), dried (MgSO4) and the solvent removed in vacuo. The 
crude product was purified by column chromatography on silica gel (10% EtOAc in 
petroleum ether) to give the title compound as a pale yellow solid (85%). Rf (10% 
EtOAc in petroleum ether: 0.24; m.p.= 72-74 °C (EtOAc/petroleum ether); IR (neat, 
cmˉ¹): νmax 1246 (Ar-O-Ar); 
1
H NMR (300 MHz; CDCl3): δH 0.86 (t, 3H, J= 7.5Hz, 
CH3), 2.16 (q, 2H, J= 7.6Hz, CH2CH3), 3.76-3.68 (m, 2H, CH2O), 3.96-3.88 (m, 2H, 
CH2O), 6.78 (d, 1H, J= 8.0Hz, Ar), 6.96 (d, 1H, J= 8.0Hz, Ar), 7.10 (t, 1H, J= 7.5 Hz, 
Ar), 7.20 (t, 1H, J= 7.5 Hz, Ar), 7.33 (t, 1H, J= 7.5Hz, Ar), 7.42 (t, 1H, J= 8.0 Hz, Ar), 
7.61 (d, 1H, J= 8.0 Hz, Ar), 7.97 (d, 1H, J= 8.0 Hz, Ar); ¹³C NMR (CDCl3, 75MHz): δC 
7.84 (CH3), 31.4 (CH2), 64.7, 110.2 (C), 118.6, 121.6, 121.8, 124.8, 125.7, 128.6, 129.6, 
133.7, (CH), 134.1 140.4, 152.1, 152.3, (C); MS (APCI m/z): 316 [M+H)
+
, (100%)]. 
HRMS FAB [M+H]
+
 316.1173, C17H17NO5+H
+
 requires 316.1185.
31
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4.10.5 Procedure for the synthesis of 2-(2-(2-nitrophenoxy)phenyl)acetic acid, 
440 
O
OH
O
NO2
440  
2-(2-(2-Nitrophenoxy)phenyl)acetate methyl ester (455) (0.1g, 0.34 mmol) was stirred 
in 5mL of a basic THF solution 50% (1 M NaOH: THF) for 16 hours at room 
temperature. The solvent was evaporated, the residue acidified with conc. HCl (1mL) 
and extracted with dichloromethane (2×30mL).  The combined organic layers were 
washed with distilled water (2×30mL) and brine (30mL), dried (MgSO4), filtered and 
the solvent evaporated in vacuo to afford the title compound as a yellow solid (0.095g, 
100%). m.p.= 158-160 °C (DCM) [(lit. m.p.= 156-157 °C)
380
 (solvent not quoted)]; IR 
(neat, cmˉ¹): νmax 1704 (C=O stretching), 1525 (C-O stretching), 1582, 1340 (N-O 
stretching); ¹H NMR (CDCl3, 300MHz): δH 3.76 (s, 2H, CH2), 6.88 (d, 1H, J= 9.0Hz, 
Ar), 7.00 (d, 1H, J= 6.0Hz, Ar), 7.14-7.21 (m, 2H, Ar), 7.27 (d, 1H, J= 6.0Hz, Ar), 7.33 
(t, 1H, J= 7.5Hz, Ar), 7.47 (td, 1H, J= 7.5Hz, Ar), 7.93 (dd, 1H, J= 9.0Hz, Ar). ¹³C 
NMR (CDCl3, 75MHz): δC 35.44 (CH2), 118.70, 120.38, 123.41, 124.96, 125.46, 
129.32, 132.07, 134.36 (CH), 125.86, 134.38, 150.39, 154.09, 171.20 (C); MS (APCI 
m/z): 272 [M-H)
+
, (100%)]. 
 
4.10.6 Procedure for the synthesis of N,N-dibenzyl-2-(2-
methoxyphenyl)acetamide, 356 
O
N
O
356  
To a solution of 2-methoxyphenyl acetic acid (353) (0.5g, 3.0 mmol) in 
dichloromethane (20mL, containing two drops of N,N-dimethylformamide) was added 
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oxalyl chloride (588μL, 4.51 mmol). The resulted solution was stirred at room 
temperature for 1 hour, after which the solvent was evaporated to give a crude residue. 
The residue and dibenzylamine (1156μL, 6.0 mmol) were dissolved in toluene (30mL, 
0.1 M) and the resulting solution stirred at room temperature for 4 hours and at 40
○
C for 
20 hours. The solution was allowed to cool, washed with 1 M HCl (3×30mL), and 
extracted with ethyl acetate (2×30mL). The combined organic layers were washed with 
distilled brine (30mL) and water (30mL), dried (MgSO4), filtered and the solvent 
evaporated in vacuo to yield the title compound as a lemon-yellow solid (1.01g, 98%). 
Rf (30% EtOAc in petroleum ether): 0.71. m.p.= 65-67
○C (EtOAc). IR (neat, cmˉ¹): ν 
1645 (C=O stretching), 1079 (C-O stretching); ¹H NMR (CDCl3, 300MHz): δ 3.73 (s, 
3H, CH3), 3.76 (s, 2H, CH2C=O), 4.48 (s, 2H, CH2N), 4.58 (s, 2H, CH2N), 6.81 (d, 1H, 
J= 6.0Hz, Ar), 6.91 (t, 1H, J= 7.5Hz, Ar), 7.14 (d, 2H, J= 9.0Hz, Ar), 7.31-741 (m, 10H, 
Ar). ¹³C NMR (CDCl3, 75MHz): δ 34.89, 48.17, 50.20 (CH2), 55.36 (CH3), 110.37, 
120.81, 126.71, 127.42, 127.59, 128.33, 128.50, 128.61, 128.91, 130.66 (CH), 124.05, 
136.85, 137.64, 156.90, 172.20 (C); MS (ESI
+
, APCI m/z): 346 (100%). HRMS FAB 
[M+H]
+
  346.1799, C23H23NO2+H
+
 requires 346.1802. 
 
4.10.7 Procedure for the synthesis of 2-(dibenzylamino)-1-(2-
hydroxyphenyl)ethanone, 357a 
357a
OH
N
O
Ph
Ph
 
To a solution of dibenzylamine (246) (448μL, 0.23 mmol) in dichloromethane (5mL, 
0.1 M) was added triethylamine (65μL, 0.46 mmol) and the resulting solution was 
stirred at room temperature for 30 minutes. Bromo-2-hydroxyacetophenone (0.05g, 0.23 
mmol) was added and the reaction stirred for 2 hours at room temperature. After which, 
the mixture was washed with hydrochloric acid solution (1 M, 2×10mL). The product 
was extracted with dichloromethane (2×10mL) and the combined organic layers were 
washed with distilled water (2×10mL), brine (10mL), dried (MgSO4), filtered and the 
solvent evaporated in vacuo to afford the title compound as a yellow solid (0.04g, 52%). 
Rf (20% EtOAc in petroleum ether): 0.60. ¹H NMR (CDCl3, 300MHz): δH 3.86 (s, 2H, 
CH2C=O), 4.63 (s, 4H, CH2N), 7.07-7.15 (m, 4H, Ar), 7.32-7.39 (m, 4H, Ar), 7.51 (dd, 
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2H, J= 1.5Hz, J= 8.0Hz, Ar), 7.63 (td, 2H, J= 1.2Hz, J= 7.2Hz, Ar), 7.26-7.41 (d, 2H, 
J= 7.5Hz, Ar), 10.23 (s, 1H, OH).  
 
4.10.8 Procedure for the synthesis of methyl 2-(2-(2,6-
dichlorophenylamino)phenyl)acetate (452), and 1-(2,6-Dichlorophenyl)indolin-
2-one (453) 
NH
ONa
O
Cl
Cl
NH
O
O
Cl
Cl
445 452
N
Cl
Cl
MeOH, reflux
conc. H2SO4
+
453
O
 
Diclofenac sodium (445) was heated at reflux in methanol (plus two drops of conc. 
H2SO4) for 2 hours. The solvent was evaporated, the residue washed with saturated 
sodium bicarbonate solution (3×30mL) and extracted with ethyl acetate (2×30mL).  The 
combined organic layers were washed with distilled water (2×30mL) and brine (30mL), 
dried (MgSO4), filtered and the solvent evaporated in vacuo to afford the crude residue 
which was purified by flash column chromatography. 
 
Methyl 2-(2-(2,6-dichlorophenylamino)phenyl)acetate, 452 
NH
O
O
Cl
Cl
452  
Flash column chromatography (SiO2; 15% EtOAc in petroleum ether) afforded the title 
compound as white crystalline solid (0.42g, 88 %). Rf (30% EtOAc in petroleum ether): 
0.85. m.p.= 90-92 °C (ethyl acetate/petroleum ether) [(lit. m.p.= 87 °C)
291
 (methanol)]; 
IR (neat, cmˉ¹): ν 1715 (C=O stretching), 1576 (C-O stretching), 3303 (O-H stretching); 
¹H NMR (CDCl3, 300MHz): δ 3.75 (s, 3H, CH3), 3.82 (s, 2H, CH2), 6.93-7.01 (m, 3H, 
Ar), 7.13 (t, 1H, J= 7.5Hz, Ar), 7.23 (d, 1H, J= 6.0Hz, Ar), 7.34 (d, 2H, J= 9.0Hz, Ar). 
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¹³C NMR (CDCl3, 75MHz): δc 38.65 (CH2), 52.60 (CH3), 118.21, 122.06, 124.06, 
128.13, 129.01, 131.02 (CH), 124.18, 129.62, 137.85, 142.77, 172.78 (C); MS (APCI 
m/z): 310 [M+H)
+
, (100%)]. 
 
1-(2,6-Dichlorophenyl)indolin-2-one, 453 
N
Cl
Cl
453
O
 
Flash column chromatography (SiO2; 15% EtOAc in petroleum ether) afforded the title 
compound as an orange crystalline solid (0.05g, 12%). Rf (30% EtOAc in petroleum 
ether): 0.63. m.p.= 118-120 °C (ethyl acetate/petroleum ether) [(lit. m.p.= 124-125 
○
C)
323
 (methanol)]; IR (neat, cmˉ¹): ν 1611 (C=O stretching); ¹H NMR (CDCl3, 
300MHz): δ 3.78 (s, 2H, CH2), 6.40 (d, 1H, J= 6.0Hz, Ar), 7.09 (t, 1H, J= 7.5Hz, Ar), 
7.20 (t, 1H, J= 7.5Hz, Ar), 7.33-7.40 (m, 2H, Ar) 7.51 (d, 2H, J= 9.0Hz, Ar). ¹³C NMR 
(CDCl3, 75MHz): δ 35.85 (CH2), 109.25, 123.18, 124.92, 128.03, 129.15, 130.59 (CH), 
124.39, 130.51, 135.59, 143.38, 173.77 (C); MS (APCI m/z): 278 [M+H)
+
, (100%)].  
 
4.10.9 Procedure for the synthesis of methyl 2-(2-hydroxyphenyl)acetate, 454  
454
OH
O
O
 
2-Hydroxyphenylacetic acid (277) (5.0g, 32.9 mmol) was heated at reflux in 50mL of 
methanol (plus ~1mL of conc. H2SO4) for 16 hours. The solvent was evaporated, the 
residue washed with saturated sodium bicarbonate solution (3×25mL) and extracted 
with ethyl acetate (2×25mL). The combined organic layers were washed with distilled 
water (2×25mL) and brine (2×25mL), dried (MgSO4), filtered and the solvent 
evaporated in vacuo to afford the title compound as a white solid (5.46g, 100%), Rf 
(30% EtOAc in petroleum ether): 0.68. m.p.= 61-63
○
C (ethyl acetate) [(lit. m.p.= 61-62 
°C)
381
 (ethyl acetate)]. IR (neat, cmˉ¹): ν 1717 (C=O stretching), 1098 (C-O stretching), 
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3420 (O-H stretching); ¹H NMR (CDCl3, 300MHz): δ 3.69 (s, 2H, CH2), 3.75 (s, 3H, 
CH3), 6.88 (t, 1H, J= 8.0Hz, Ar), 6.94 (d, 1H, J= 8.0Hz, Ar), 7.10 (d, 1H, J= 8.0Hz, 
Ar), 7.20 (d, 1H, J= 8.0Hz, Ar), 7.39 (s, 1H, OH). ¹³C NMR (CDCl3, 75MHz): δ 37.82 
(CH2), 52.94 (CH3), 117.76, 120.65, 129.37, 131.13 (CH), 121.05, 155.23, 174.49 (C); 
MS (APCI m/z): 167 [M+H)
+
, (100%)]. 
 
4.10.10 Procedure for the synthesis of methyl 2-(2-(2-
nitrophenoxy)phenyl)acetate, 455 
O
O
O
NO2
455  
To a solution of the methyl2-(2-hydroxyphenyl)acetate (454) (0.2g, 1.20 mmol) in 
dimethyl sulfoxide (12mL, 0.1 M) was added potassium carbonate (0.16g, 1,20 mmol) 
and the resulting solution was stirred at room temperature for 30 minutes. 1-Fluoro-2-
nitrobenzene (134μL, 1.23 mmol) was added and the reaction stirred for 24 hours at 
room temperature. After which, the mixture was acidified with hydrochloric acid 
solution (1 M, 30mL). The product was extracted with ethyl acetate (2×30mL) and the 
combined organic layers were washed with distilled water (2×20mL), brine (10mL), 
dried (MgSO4), filtered and the solvent evaporated in vacuo. Flash column 
chromatography (SiO2; 20% EtOAc in toluene) afforded the title compound as an 
orange oil (0.1g, 30%). Rf (10% EOAc in toluene): 0.62. IR (neat, cmˉ¹): ν 1735 (C=O 
stretching), 1604 (C-O stretching), 1583, 1346 (N-O stretching); ¹H NMR (CDCl3, 
300MHz): δ 3.60 (s, 3H, CH3), 3.71 (s, 2H, CH2), 6.90 (d, 1H, J= 8.0Hz, Ar), 6.98 (d, 
1H, J= 8.0Hz, Ar), 7.17 (t, 2H, J= 8.0Hz, Ar), 7.29 (dd, 1H, J= 1.2Hz, J= 8.0Hz, Ar), 
7.35 (d, 1H, J= 8.0Hz, Ar), 7.48 (td, 1H, J= 1.2Hz,  J= 8.0Hz, Ar), 7.94 (dd, 1H, J= 
1.2Hz, J= 8.0Hz, Ar). ¹³C NMR (CDCl3, 75MHz): δ 35.70 (CH3), 52.12 (CH2), 119.08, 
119.84, 123.10, 125.08, 126.29, 129.07, 132.06, 134.24 (CH), 125.81, 141.02, 150.60, 
153.76, 171.52 (C); MS (APCI m/z): 288 [M+H)
+
, (100%)]. HRMS FAB 
[M+H]
+
 288.0868, C15H13NO5+H
+
 requires 288.0866. 
4.11 General procedure for the COX inhibitor screening assay  
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1. 100% initial activity wells: added 150 μl of assay buffer, 10 μl of heme, 10 μl of 
ADHP (10-acetyl-3,7-dihyroxyphenoxazepine), 10 μl of enzyme (either COX I or 
COX II), and 10 μl of DMSO. 
2. Background wells: added 160 μl of assay buffer, 10 μl of heme, 10 μl of ADPH, and 
10 μl of DMSO. 
3. Inhibitor wells: added 150 μl of assay buffer, 10 μl of heme, 10 μl of ADPH, 10 μl 
of enzyme (either COX I or COX II), and 10 μl of inhibitors*. 
4. The reactions were initiated by quickly adding 10 μl of arachidonic acid solution to 
all the wells being used. 
5. The wells were incubated for two minutes at room temperature. 
6. The plate was read using an excitation wavelength between 530-540 nm and an 
emission wavelength between 585-595 nm.  
7. The average fluorescence of each sample was determined. 
8. The fluorescence of the background wells was subtracted from the fluorescence of 
the 100% initial activity and the inhibitor wells. 
9. The percent inhibition was determined for each sample by subtracting each inhibitor 
sample value from the 100% initial activity sample value, the result divide by the 
100% initial activity value and then multiplied by 100 to give the percent inhibition. 
*Inhibitor (diclofenac sodium 445, diclofenac methyl ester 452, diarylether pyrrolidyl-
acetamide 334b and diaryl acetic acid 440) solutions were prepared in concentration of 
20, 200 and 2000 nm using DMSO as a solvent. 
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CHAPTER FIVE - CONCLUSIONS AND FUTURE WORK 
5.1 Conclusion 
In a preliminary effort to produce the first example of an asymmetric Truce-Smiles 
rearrangement—a new and potentially mild method to produce enantiomerically 
enriched α-aryl carbonyl compounds—modest success in the application of the 
rearrangement to novel amide substrates has been demonstrated. It has also been 
demonstrated, for the first time, that amide precursors that proceed through a five-
membered spirocyclic transition state rearrange, whereas those proceeding through a 
six-membered transition state don’t, but stop at the diarylether stage. In the case of the 
enantiopure rearrangement substrates bearing a chiral auxilliary, it has been shown that 
initial efforts only gave modest diastereoselectivies (dr= max. 1.7:1), but it was also 
demonstrated that potential exists in this rearrangement to develop it further, as was 
evidenced by the high d.e. observed in the synthesis of the 1,3-dicarbonyl compound 
381. 
Similarly, to further try and investigate the scope of the mechanistically-related Baker-
Venkataraman rearrangement reaction, the same amide substrates, including both 
acetamides, and propanamides were employed with a range of acylating agents, but 
because of facile, competing hydrolysis, no rearranged products were obtained with 
ester or carbonate substrates. Nevertheless, a series of carbamoyl ketone based 
substrates were also studied, in the hope of applying an established literature method to 
the synthesis of 1,3-dicarbonyl compounds. During this study, a novel Baker-
Venkataraman-retro-Claisen cascade was developed, in which the Baker-Venkataraman 
rearrangement precursors acted as an alkyl donor and the carbamoyl chloride partner as 
an alkyl acceptor, to afford salicylic acid derivatives and (novel) amides. The results 
obtained proved the utility of the hypothesised Baker-Venkataraman-retro-Claisen 
cascade in the synthesis of amides.  
This work also included the partial eradication of cyclooxygenase activity using the 
diarylether of one of the acetamide-based precursors (334b), which showed good to 
modest activity against both COX  I and COX II. 
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5.2 Future work 
Whilst attempts have been made to optimise the method developed, with respect to α-
alkylation of the substrates prior to, and after, the Truce-Smiles rearrangement step, 
limited success was achieved. If further optimisation, was to take place better 
diastereoselectivities may be achieved through the use of α-alkylated 2-coumaranone  
prior to the rearrangement step. In order to find better substrates which give enriched α-
arylated compounds, ketone based substrates could be further explored with C2-
symmetrical chiral pyrrolidine-based auxiliaries. In addition, alternative chiral 
auxiliaries can also be included into ketone-based (starting from 460) or amide-based 
substrates (starting from 281) and attempt to force a better diaseteroselectivity, Scheme 
160. 
R1
R1
OH
R1
OO OOH O
X
OOH
established 
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HN HN
MeO
MeO
chiral pyrrolidines
already attempted
amines
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R
O
Yamada
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N
Myers
NH
S
O
O
Oppolzer
X= Cl, Br, F
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O
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NO2
R2
NO2
NO2
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R2
(R1)
 
  Scheme 160. Proposed future work on the enantioselective Truce-Smiles 
rearrangement. 
In respect to the Baker-Venkataraman-retro-Claisen cascade it is also possibly worth 
incorporating suitable chiral auxiliaries to attempt to prepare an asymmetric variant, in 
order to explore the enantioselectivities obtained through both the acyl migration and 
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the retro-Claisen steps, in the hope of offering enantiopure 1,3-dicarbonyl compounds 
and novel chiral amides, respectively. 
Since better selectivity was observed with 1,3-dicarbonyl compounds (e.g. 381, 83% 
de), a domino rearrangement reaction could be set up by performing the Baker-
Venkataraman rearrangement first, followed by the Truce-Smiles rearrangement or vice 
versa, to afford enantioenriched products e.g. 464, Scheme 161. 
X= Cl, Br, F
R1-R4= arbitrary group
R1
OOH
O R2
466
F
NO2
OOH O
R2
464
R1
O2N
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OOH
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NO2 R
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OOH O
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O2N
381
O
O
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NO2
N
O
O
R3 R
3
R3
R3R3
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O
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R4
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R4
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Scheme 161. The proposed domino rearrangement reaction. For different R groups see 
Scheme 160; T-S= Truce-Smiles rearrangement; B-V= Baker-Venkataraman 
rearrangement. 
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Table 1. Crystal data and structure refinement. 
 Identification code  2013ncs0352 / DA1.81(38-45)   
Empirical formula  C28H24N2O4 
Formula weight  452.49 
Temperature  100(2) K 
Wavelength  1.54178 Å 
Crystal system  Monoclinic 
Space group  P21/n  
Unit cell dimensions a = 7.3807(14) Å  = 90° 
 b = 13.547(3) Å  = 90.834(10)° 
 c = 22.864(5) Å   = 90° 
Volume 2285.8(8) Å
3
 
Z 4 
Density (calculated) 1.315 Mg / m
3
 
Absorption coefficient 0.717 mm
1
 
F(000) 952 
Crystal Blade; Orange 
Crystal size 0.250  0.120  0.080 mm3 
 range for data collection 3.793  68.242° 
Index ranges 8  h  8, 16  k  15, 27  l  27 
Reflections collected 19910 
Independent reflections 4140 [Rint = 0.0397] 
Completeness to  = 67.687° 99.2 %  
Absorption correction Semiempirical from equivalents 
Max. and min. transmission 1.000 and 0.843 
Refinement method Full-matrix least-squares on F
2
 
Data / restraints / parameters 4140 / 0 / 308 
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Goodness-of-fit on F
2
 1.049 
Final R indices [F
2
 > 2(F2)] R1 = 0.0471, wR2 = 0.1287 
R indices (all data) R1 = 0.0487, wR2 = 0.1309 
Extinction coefficient n/a 
Largest diff. peak and hole 0.294 and 0.207 e Å3 
 
Diffractometer: Rigaku AFC11 quarter chi goniometer equipped with an enhanced 
sensitivity (HG) Saturn944+ detector mounted at the window of 007 HF copper rotating 
anode generator with Varimax optics. 
Cell determination and data collection: CrystalClear-SM Expert 3.1 b26 (Rigaku, 
2012).  
Data reduction, cell refinement and absorption correction: CrystalClear-SM Expert 
3.1 b26 (Rigaku, 2012). 
Structure solution: SHELXS97 (Sheldrick, G.M. (2008). Acta Cryst. A64, 112-122).  
Structure refinement: SHELXL-2012 (G Sheldrick, G.M. (2008). Acta Cryst. A64, 112-
122.). 
Graphics: ORTEP3 for Windows (L. J. Farrugia, J. Appl. Crystallogr. 1997, 30, 565 
 
Special details:  
Table 2. Atomic coordinates [ 104], equivalent isotropic displacement parameters [Å2  
10
3
] and site occupancy factors. Ueq is defined as one third of the trace of the 
orthogonalized U
ij
 tensor. 
Atom  x y z Ueq S.o.f. 
C1 3998(2) 2203(1) 869(1) 26(1) 1 
C2 5299(2) 2757(1) 466(1) 26(1) 1 
C3 4232(2) 3473(1) 82(1) 28(1) 1 
C4 3214(2) 4265(1) 301(1) 30(1) 1 
C5 2284(2) 4923(1) 58(1) 37(1) 1 
C6 2314(2) 4804(1) 655(1) 41(1) 1 
C7 3282(2) 4032(1) 887(1) 41(1) 1 
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C8 4224(2) 3385(1) 524(1) 34(1) 1 
C9 6412(2) 2012(1) 127(1) 27(1) 1 
C10 8306(2) 2076(1) 127(1) 29(1) 1 
C11 9322(2) 1382(1) 178(1) 34(1) 1 
C12 8474(2) 629(1) 479(1) 35(1) 1 
C13 6608(2) 557(1) 482(1) 34(1) 1 
C14 5596(2) 1243(1) 182(1) 30(1) 1 
C15 6464(2) 1943(1) 1609(1) 32(1) 1 
C16 7380(2) 991(1) 1788(1) 34(1) 1 
C17 8183(2) 912(1) 2338(1) 47(1) 1 
C18 9080(3) 54(2) 2503(1) 57(1) 1 
C19 9149(2) 732(2) 2129(1) 53(1) 1 
C20 8348(2) 667(1) 1578(1) 49(1) 1 
C21 7496(2) 199(1) 1407(1) 41(1) 1 
C22 3345(2) 1279(1) 1751(1) 33(1) 1 
C23 2657(2) 1936(1) 2236(1) 38(1) 1 
C24 3095(2) 1730(1) 2816(1) 48(1) 1 
C25 2412(3) 2329(2) 3261(1) 60(1) 1 
C26 1297(3) 3111(2) 3128(1) 60(1) 1 
C27 853(3) 3318(1) 2555(1) 54(1) 1 
C28 1532(2) 2737(1) 2109(1) 44(1) 1 
N1 4637(2) 1786(1) 1364(1) 29(1) 1 
N2 3078(2) 4451(1) 932(1) 37(1) 1 
O1 2390(1) 2106(1) 717(1) 32(1) 1 
O2 9107(1) 2822(1) 433(1) 34(1) 1 
O3 4156(1) 4071(1) 1270(1) 39(1) 1 
O4 1863(2) 4992(1) 1099(1) 73(1) 1 
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Table 3. Bond lengths [Å] and angles [°]. 
 
C1O1 1.2384(17) 
C1N1 1.3450(18) 
C1C2 1.5364(18) 
C2C3 1.5210(18) 
C2C9 1.5201(18) 
C2H2 1.0000 
C3C8 1.390(2) 
C3C4 1.4061(19) 
C4C5 1.386(2) 
C4N2 1.4694(19) 
C5C6 1.377(2) 
C5H5 0.9500 
C6C7 1.377(2) 
C6H6 0.9500 
C7C8 1.387(2) 
C7H7 0.9500 
C8H8 0.9500 
C9C14 1.3906(19) 
C9C10 1.4007(19) 
C10O2 1.3594(17) 
C10C11 1.395(2) 
C11C12 1.376(2) 
C11H11 0.9500 
C12C13 1.381(2) 
C12H12 0.9500 
C13C14 1.383(2) 
C13H13 0.9500 
C14H14 0.9500 
C15N1 1.4682(18) 
C15C16 1.510(2) 
C15H15A 0.9900 
C15H15B 0.9900 
C16C21 1.385(2) 
C16C17 1.387(2) 
C17C18 1.387(3) 
C17H17 0.9500 
C18C19 1.367(3) 
C18H18 0.9500 
C19C20 1.386(3) 
C19H19 0.9500 
C20C21 1.386(2) 
C20H20 0.9500 
C21H21 0.9500 
C22N1 1.4782(17) 
C22C23 1.516(2) 
C22H22A 0.9900 
C22H22B 0.9900 
C23C24 1.389(2) 
C23C28 1.394(2) 
C24C25 1.401(3) 
C24H24 0.9500 
C25C26 1.373(3) 
C25H25 0.9500 
C26C27 1.375(3) 
C26H26 0.9500 
C27C28 1.388(2) 
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C27H27 0.9500 
C28H28 0.9500 
N2O3 1.2161(17) 
N2O4 1.2231(17) 
O2H2A 0.8400 
 
O1C1N1 120.95(12) 
O1C1C2 119.24(11) 
N1C1C2 119.72(11) 
C3C2C9 114.11(11) 
C3C2C1 109.58(10) 
C9C2C1 109.17(11) 
C3C2H2 107.9 
C9C2H2 107.9 
C1C2H2 107.9 
C8C3C4 115.25(13) 
C8C3C2 120.98(12) 
C4C3C2 123.76(12) 
C5C4C3 122.83(14) 
C5C4N2 115.47(13) 
C3C4N2 121.70(12) 
C6C5C4 119.83(14) 
C6C5H5 120.1 
C4C5H5 120.1 
C5C6C7 119.07(14) 
C5C6H6 120.5 
C7C6H6 120.5 
C6C7C8 120.58(14) 
C6C7H7 119.7 
C8C7H7 119.7 
C7C8C3 122.43(14) 
C7C8H8 118.8 
C3C8H8 118.8 
C14C9C10 118.11(12) 
C14C9C2 121.47(12) 
C10C9C2 120.41(12) 
O2C10C11 121.68(12) 
O2C10C9 118.15(12) 
C11C10C9 120.16(13) 
C12C11C10 120.35(13) 
C12C11H11 119.8 
C10C11H11 119.8 
C11C12C13 120.12(13) 
C11C12H12 119.9 
C13C12H12 119.9 
C12C13C14 119.72(13) 
C12C13H13 120.1 
C14C13H13 120.1 
C13C14C9 121.54(13) 
C13C14H14 119.2 
C9C14H14 119.2 
N1C15C16 112.61(12) 
N1C15H15A 109.1 
C16C15H15A 109.1 
N1C15H15B 109.1 
C16C15H15B 109.1 
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H15AC15H15B 107.8 
C21C16C17 118.75(15) 
C21C16C15 121.51(13) 
C17C16C15 119.70(15) 
C16C17C18 120.49(18) 
C16C17H17 119.8 
C18C17H17 119.8 
C19C18C17 120.29(17) 
C19C18H18 119.9 
C17C18H18 119.9 
C18C19C20 119.99(16) 
C18C19H19 120.0 
C20C19H19 120.0 
C21C20C19 119.73(17) 
C21C20H20 120.1 
C19C20H20 120.1 
C16C21C20 120.71(15) 
C16C21H21 119.6 
C20C21H21 119.6 
N1C22C23 112.99(12) 
N1C22H22A 109.0 
C23C22H22A 109.0 
N1C22H22B 109.0 
C23C22H22B 109.0 
H22AC22H22B 107.8 
C24C23C28 119.00(15) 
C24C23C22 120.34(15) 
C28C23C22 120.63(14) 
C23C24C25 119.73(18) 
C23C24H24 120.1 
C25C24H24 120.1 
C26C25C24 120.44(18) 
C26C25H25 119.8 
C24C25H25 119.8 
C25C26C27 120.18(17) 
C25C26H26 119.9 
C27C26H26 119.9 
C26C27C28 120.04(19) 
C26C27H27 120.0 
C28C27H27 120.0 
C27C28C23 120.60(17) 
C27C28H28 119.7 
C23C28H28 119.7 
C1N1C15 124.66(12) 
C1N1C22 118.51(11) 
C15N1C22 115.88(11) 
O3N2O4 122.06(13) 
O3N2C4 119.89(12) 
O4N2C4 118.06(13) 
C10O2H2A 109.5 
 Symmetry transformations used to generate equivalent atoms:  
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Table 4. Anisotropic displacement parameters [Å
2 103]. The anisotropic displacement 
factor exponent takes the form: 2 2[h2a*2U11 + ... + 2 h k a* b* U12 ]. 
Atom U
11
 U
22
 U
33
 U
23
 U
13
 U
12 
C1 25(1)  27(1) 27(1)  2(1) 1(1)  4(1) 
C2 24(1)  29(1) 26(1)  2(1) 1(1)  1(1) 
C3 25(1)  28(1) 31(1)  0(1) 1(1)  1(1) 
C4 26(1)  30(1) 36(1)  1(1) 0(1)  1(1) 
C5 27(1)  30(1) 53(1)  3(1) 2(1)  1(1) 
C6 36(1)  36(1) 50(1)  11(1) 11(1)  2(1) 
C7 47(1)  43(1) 33(1)  6(1) 9(1)  3(1) 
C8 37(1)  34(1) 31(1)  0(1) 1(1)  1(1) 
C9 28(1)  28(1) 26(1)  2(1) 2(1)  3(1) 
C10 28(1)  29(1) 29(1)  2(1) 1(1)  2(1) 
C11 28(1)  37(1) 37(1)  0(1) 2(1)  7(1) 
C12 38(1)  34(1) 35(1)  2(1) 5(1)  7(1) 
C13 39(1)  30(1) 32(1)  4(1) 2(1)  1(1) 
C14 29(1)  33(1) 30(1)  1(1) 2(1)  1(1) 
C15 30(1)  39(1) 28(1)  1(1) 4(1)  0(1) 
C16 29(1)  44(1) 31(1)  7(1) 1(1)  2(1) 
C17 51(1)  58(1) 33(1)  10(1) 6(1)  2(1) 
C18 57(1)  70(1) 45(1)  22(1) 6(1)  11(1) 
C19 43(1)  59(1) 59(1)  27(1) 12(1)  16(1) 
C20 45(1)  47(1) 55(1)  6(1) 15(1)  11(1) 
C21 37(1)  48(1) 36(1)  3(1) 2(1)  8(1) 
C22 34(1)  35(1) 31(1)  2(1) 6(1)  2(1) 
C23 39(1)  41(1) 33(1)  2(1) 9(1)  6(1) 
C24 50(1)  60(1) 34(1)  2(1) 7(1)  7(1) 
C25 64(1)  85(2) 32(1)  4(1) 12(1)  15(1) 
C26 68(1)  64(1) 48(1)  19(1) 24(1)  12(1) 
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C27 57(1)  48(1) 59(1)  9(1) 23(1)  2(1) 
C28 45(1)  45(1) 42(1)  3(1) 12(1)  2(1) 
N1 27(1)  34(1) 26(1)  1(1) 2(1)  2(1) 
N2 32(1)  37(1) 41(1)  8(1) 2(1)  4(1) 
O1 24(1)  37(1) 35(1)  1(1) 0(1)  2(1) 
O2 25(1)  34(1) 45(1)  7(1) 4(1)  2(1) 
O3 42(1)  39(1) 36(1)  6(1) 1(1)  4(1) 
O4 67(1)  95(1) 58(1)  22(1) 2(1)  47(1) 
  
Table 5. Hydrogen coordinates [ 104] and isotropic displacement parameters [Å2  103]. 
Atom  x y z Ueq S.o.f.
 
H2 6150 3150 718 32 1 
H5 1628 5454 109 44 1 
H6 1675 5249 905 49 1 
H7 3305 3942 1299 49 1 
H8 4889 2862 696 41 1 
H11 10606 1430 177 41 1 
H12 9174 158 685 42 1 
H13 6022 37 690 40 1 
H14 4312 1189 186 37 1 
H15A 6386 2381 1954 39 1 
H15B 7213 2280 1314 39 1 
H17 8118 1450 2604 57 1 
H18 9649 13 2878 69 1 
H19 9746 1322 2247 64 1 
H20 8383 1215 1319 59 1 
H21 6986 251 1025 49 1 
H22A 3946 694 1926 40 1 
H22B 2301 1043 1513 40 1 
H24 3854 1185 2911 57 1 
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H25 2723 2193 3658 72 1 
H26 832 3510 3433 72 1 
H27 80 3859 2465 65 1 
H28 1228 2886 1714 53 1 
H2A 10205 2688 492 51 1 
  
Table 6. Torsion angles [°]. 
 O1C1C2C3 25.20(16) 
N1C1C2C3 158.31(12) 
O1C1C2C9 100.44(14) 
N1C1C2C9 76.05(15) 
C9C2C3C8 3.94(18) 
C1C2C3C8 118.82(13) 
C9C2C3C4 175.35(12) 
C1C2C3C4 61.90(16) 
C8C3C4C5 0.8(2) 
C2C3C4C5 178.52(13) 
C8C3C4N2 179.52(12) 
C2C3C4N2 1.2(2) 
C3C4C5C6 1.0(2) 
N2C4C5C6 179.34(13) 
C4C5C6C7 0.3(2) 
C5C6C7C8 0.4(2) 
C6C7C8C3 0.5(2) 
C4C3C8C7 0.1(2) 
C2C3C8C7 179.28(13) 
C3C2C9C14 71.63(16) 
C1C2C9C14 51.35(16) 
C3C2C9C10 109.42(14) 
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C1C2C9C10 127.60(13) 
C14C9C10O2 179.43(12) 
C2C9C10O2 0.45(18) 
C14C9C10C11 0.1(2) 
C2C9C10C11 179.06(12) 
O2C10C11C12 179.36(13) 
C9C10C11C12 0.1(2) 
C10C11C12C13 0.1(2) 
C11C12C13C14 0.0(2) 
C12C13C14C9 0.0(2) 
C10C9C14C13 0.0(2) 
C2C9C14C13 178.98(12) 
N1C15C16C21 51.70(18) 
N1C15C16C17 130.61(15) 
C21C16C17C18 0.2(2) 
C15C16C17C18 177.93(15) 
C16C17C18C19 1.4(3) 
C17C18C19C20 1.1(3) 
C18C19C20C21 0.7(3) 
C17C16C21C20 2.0(2) 
C15C16C21C20 179.73(14) 
C19C20C21C16 2.3(2) 
N1C22C23C24 114.06(16) 
N1C22C23C28 67.94(18) 
C28C23C24C25 0.3(3) 
C22C23C24C25 178.39(15) 
C23C24C25C26 0.7(3) 
C24C25C26C27 0.5(3) 
C25C26C27C28 0.1(3) 
C26C27C28C23 0.5(3) 
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C24C23C28C27 0.2(2) 
C22C23C28C27 177.79(15) 
O1C1N1C15 173.48(12) 
C2C1N1C15 10.09(19) 
O1C1N1C22 5.09(19) 
C2C1N1C22 178.49(11) 
C16C15N1C1 133.07(13) 
C16C15N1C22 58.27(16) 
C23C22N1C1 94.72(15) 
C23C22N1C15 74.68(16) 
C5C4N2O3 162.92(13) 
C3C4N2O3 16.8(2) 
C5C4N2O4 17.1(2) 
C3C4N2O4 163.18(15) 
 Symmetry transformations used to generate equivalent atoms:  
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